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ABSTRACT 
Oestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both 
their clinical behaviour and response to therapy. The ER and Progesterone (PgR) are 
currently the best predictors of response to the anti-oestrogen tamoxifen, yet up to 
40% of ER+ breast cancer will relapse despite tamoxifen treatment. New prognostic 
biomarkers and further biological understanding of tamoxifen resistance (TR) are 
required. There has been an explosion of greater understanding since the arrival of 
cutting-edge gene and genomic profiling technology. The two major aims of this 
research are to develop stable gene signatures that are effective at distinguishing 
„prognostic‟ groups and, when tested directly for response to tamoxifen, a set of 
„predictive‟ markers.  
 
In order to establish cellular pathways responsible for TR, tissue at relapse while on 
tamoxifen is preferred. However, in practice, this is difficult to obtain. Hence, in this 
study, I have established TR derivatives of breast cancer cell lines, T47D and ZR75-
1, and analysed their gene-expression by microarray. MAGEA2 and EGLN3 were 4.0 
and 3.8 fold upregulated respectively in TR cell lines. For MAGEA2- and EGLN3-
overexpressing lines, the proliferation and growth rates in tamoxifen-containing 
media were significantly higher (p-value <0.001 and p<0.05, respectively) than for 
control cells. I have investigated possible downstream targets for each protein which 
may contribute to the mechanism of resistance. Immunohistochemistry validation 
was performed on a cohort of 196 tamoxifen-treated primary breast tumour tissues: 
MAGEA2 and EGLN3 were found to be valuable predictive (Positive predictive 
value of 89%, and 85%, with high sensitivity 38% and 42% respectively) biomarkers 
for TR in primary breast tumours.  
 
In the human breast tumour arm of this study, 25 frozen samples with known 
response to tamoxifen were analysed on both SNP6.0 and expression EXON arrays. 
The integrated analysis suggested that 5 genes (OPCML, OR10G7, SNF1LK2, PALM 
and ZBTB-16) are good predictors of TR, with high negative predictor values (68%, 
71%, 59% and 73% respectively for the last 4 genes). Significant regions of copy 
number variation (CNV) were identified at chromosomes 8q24, 17q21-22 and 
11q23-25. The application of this high-resolution approach should lead to a better 
understanding of the roles of complex genetic alterations in TR. 
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M   Molar (moles/litre) 
mM   Millimolar (millimoles/litre) 
µM   Micromolar (micromoles/litre) 
nM  Nanomolar (nanomoles/litre) 
pM   Picomolar (picomoles/litre) 
 
UNITS OF LENGTH, AREA, VOLUME, MASS, TIME 
 
m   Metre 
cm   Centimetre 
mm   Millimetre 
µm   Micrometre 
nm   Nanometre 
ml   Millilitre 
µl   microlitre 
gr   Gram 
µg   Microgram 
kg   Kilogram 
h   Hour 
min   Minute 
s   Second 
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1.    Introduction 
1.1. Breast Cancer 
Breast cancer is the most common cause of cancer in women and the second most 
common cause of cancer death in women in the United Kingdom. While the majority 
of new breast cancers are diagnosed as a result of an abnormality seen on a 
mammogram, a lump or change in consistency of the breast tissue can also be a 
warning sign of the disease. Heightened awareness of breast cancer risk in the past 
decades has led to an increase in the number of women undergoing mammography 
for screening, leading to detection of cancers at earlier stages and a resultant 
improvement in survival rates. Still, breast cancer is the most common cause of death 
in women between the ages of 45 and 55 and a woman has a 1 in 9 lifetime risk to be 
afflicted by breast cancer. Although breast cancer in women is a common form of 
cancer, male breast cancer does occur and accounts for about 1% of all cancer deaths 
in men. 
Research has yielded much information about the causes of breast cancer, and it is 
now believed that genetic and/or hormonal factors are the primary risk factors for 
this disease (Hemminki et al., 2008). Staging systems have been developed to allow 
doctors to characterize the extent to which a particular cancer has spread and to make 
decisions concerning treatment options. Breast cancer treatment depends upon many 
factors, including the type of cancer and the extent to which it has spread. Treatment 
options for breast cancer may involve surgery (removal of the cancer alone or, in 
some cases, mastectomy), radiation therapy, hormonal therapy, and chemotherapy 
(Moulder and Hortobagyi, 2008). 
With advances in screening, diagnosis, and treatment, the death rate for breast cancer 
has declined by about 20% over the past decade, and research is ongoing to develop 
even more effective screening and treatment programs. 
The exact cause of breast cancer is unknown. Science cannot explain why one 
woman develops breast cancer and another does not. Research has shown that 
women with certain risk factors are more likely than others to develop this disease.  
Studies have found the following risk factors for breast cancer: 
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1) The chance of getting breast cancer increases as a woman gets older. The 
average age breast cancer occur in women is 60. This disease is not common 
before menopause (Scalliet and Kirkove, 2007). 
2) A woman who had breast cancer in one breast has an increased risk of getting 
cancer in her other breast (Meteoglu et al., 2005). 
3) A woman's risk of breast cancer is higher if her mother, sister, or daughter 
had breast cancer. The risk is higher if her family member got breast cancer 
before age 40. Having other relatives with breast cancer (in either her 
mother's or father's family) may also increase a woman's risk (Draper et al, 
2006). 
4) Some women have cells in the breast that look abnormal under a microscope. 
Having certain types of abnormal cells (atypical hyperplasia and lobular 
carcinoma in situ [LCIS] increases the risk of breast cancer (Afonso and 
Bouwman, 2008). 
5) Changes in certain genes increase the risk of breast cancer. These genes 
include BRCA1, BRCA2, and others (Tikhomirova et al., 2007), (Domchek 
et al.), (Troudi et al., 2008). Tests can sometimes show the presence of 
specific gene changes in families with many women who have had breast 
cancer. Health care providers may suggest ways to try to reduce the risk of 
breast cancer, or to improve the detection of this disease in women who have 
these changes in their genes. 
6) Reproductive and menstrual history: 
o If a woman has their first child after 35 years or older, the greater her 
chance of breast cancer (Afonso and Bouwman, 2008). 
o Women who have early menarche before age 12 are at an increased 
risk of breast cancer (Merki-Feld et al, 2008). 
 25 
o Women who have late menopause (after age 55) are at an increased 
risk of breast cancer (Harvey et al., 2008), (Johansson et al., 2008). 
o Women who never had children are at an increased risk of breast 
cancer (Harvey et al., 2008), (Henderson et al., 2008), (Harvey et al., 
2008). 
o Women who take menopausal hormone therapy with oestrogen plus 
progestin after menopause also appear to have an increased risk of 
breast cancer (Barnett et al., 2008). 
o Large, well-designed studies have shown no link between abortion or 
miscarriage and breast cancer (Brind et al, 2008). 
7) Breast cancer is diagnosed more often in white women than Latina, Asian, or 
African American women (Markman et al., 2008). 
8) Women who had been exposed to radiation therapy to the chest (including 
breasts) before age 30 are at an increased risk of breast cancer. Studies show 
that the younger a woman was when she received radiation treatment, the 
higher her risk of breast cancer later in life. 
9) Breast tissue may be dense or fatty. Older women whose mammograms 
(Harvey et al., 2008) show more dense tissue are at increased risk of breast 
cancer. 
10) Taking Diethylstilbestrol (DES) increases the risk of breast cancer. It was 
given to some pregnant women in the United States between about 1940 and 
1971. Women who took DES during pregnancy may have a slightly increased 
risk of breast cancer (Titus-Ernstoff et al., 2008).  
11) The chance of getting breast cancer after menopause is higher in women who 
are overweight or obese (Rapp et al., 2008). 
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12) Women who are physically inactive throughout life may have an increased 
risk of breast cancer. Being active may help reduce risk by preventing weight 
gain and obesity (Emaus et al, 2008, 2009). 
13) Studies suggest that the more alcohol a woman drinks, the greater her risk of 
breast cancer (Berstad et al., 2008; Suzuki et al., 2008). 
Other possible risk factors are under study. Researchers are studying the effect of 
diet, physical activity, and genetics on breast cancer risk. They are also examining 
whether certain substances in the environment can increase the risk of breast cancer. 
Many risk factors can be avoided. Others, such as family history, cannot be avoided. 
Women can help protect themselves by staying away from known risk factors 
whenever possible, but it is also important to keep in mind that most women who 
have known risk factors do not get breast cancer. Also, most women with breast 
cancer do not have a family history of the disease. In fact, apart from growing older, 
most women with breast cancer have no apparent risk to develop this disease. 
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1.2. Staging of Breast Cancer Research  
Breast cancer prognosis and treatment options are generally based on tumour-node-
metastasis staging (Greene FL et al, 2002). Hormone receptor status, histologic 
grade, lymphovascular spread, comorbidities, patient menopausal status and age are 
also important factors in deciding treatment options for an individual patient. 
The TMN Staging is routinely used in the United Kingdom. Table 1.1 illustrates the 
typical treatment options offered to breast cancer patients based on their staging. 
Stage 0 is known as carcinoma in-situ. Lobular carcinoma in-situ is usually an 
incidental finding of abnormal tissue growth in the lobules of the breast. It does not 
progress but increases the risk of subsequent breast cancer by approximately 7% 
(Chuba PJ et al, 2005). Local or systemic treatment is not required but patients 
should be counseled to self-examine the breasts frequently, and annual mammogram 
plus 6 monthly examinations by a physician. Chemopreventative endocrine treatment 
(such as selective oestrogen receptor modulator, SERM, like tamoxifen) should be 
discussed with the patient. 
In contrast, ductal carcinoma in situ (DCIS) can progress to invasive breast cancer. 
The standard treatment for DCIS is breast-conserving surgery (unless in multiple 
sites, when mastectomy is indicated). Lymph node clearance is usually not 
performed, as nodal metastsis is rare. Although there are conflicting views, 
tamoxifen is generally not offered for DCIS. 
Stage 1 and 2:  
Known as early breast cancer, these are tumours less than 5 cm in size and with no 
metastasis to the lymph nodes. Treatment option include breast-conserving surgery 
followed by radiation, this improves cancer-specific survival rate to equivalence with 
those with mastectomy (Clarke M et al, 2005). Women with stage 1 and II may opt 
for mastectomy if there is high-risk of local recurrence (Kurtz JM et al, 1990), 
contraindications to radiation or personal preference. 
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Stage 3:  
Locally advanced breast cancer (LABC) includes tumours of 5cm and larger, with 
lymph node involvement, or with chest wall and skin involvement, considered 
inoperable but without distant metastases, and also inflammatory breast cancer. 
Induction chemotherapy followed by local therapy (surgery, radiation, or both) is 
becoming standard treatment. Patients have a 55% survival at 5-years (excluding the 
inflammatory cases) (Giordano SH et al, 2003). The most important prognostic 
factors are response to induction chemotherapy and lymph node status. 
Stage 4: 
Many patients who relapsed after early breast cancer treatment, will present with 
metastatic disease. The 5-year survival is only 23% (Horner MJ et al, 2009), it is 
therefore important to understand the patients‟ treatment goals. The option of 
treatment includes radiation (palliating pain), endocrine therapy or chemotherapy, 
including targeted monoclonal therapy, like Trastuzumab (Herceptin). Endocrine 
therapy is generally more tolerable, but chemotherapy is likely to be used for a 
timely response. Tailored individual therapy depending on patient tumour type, 
whether it is ERBB2-positive or EGFR-positive, and patients‟ preference comes into 
play as treatment is now aimed to help palliate symptoms rather than be curative. 
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Table 1.1 A table simplifying typical treatment options for Breast Cancer 
by Stage. 
 
ALN = axillary lymph node, SLN = sentinal lymph node, Rx = Treatment, Sx = 
Surgery, DXT = Radiotherapy, recp = Receptor, op = Operation, bx = Biopsy 
*- SLN biopsy if clinically negative nodes; otherwise, ALN dissection is 
recommended. 
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1.3. Treatment of Breast Cancer 
Women with breast cancer have many treatment options. These include surgery, 
radiation therapy, chemotherapy, hormone therapy, and biological therapy. Many 
women receive more than one type of treatment. 
The choice of treatment depends mainly on the stage of the disease. Treatment 
options by stage are described below. 
Cancer treatment is either local therapy or systemic therapy: 
 Local therapy: Surgery and radiation therapy are local treatments. They 
remove or destroy cancer in the breast. When breast cancer has spread to 
other parts of the body, local therapy may be used to control the disease in 
those specific areas. 
 Systemic therapy: Chemotherapy, hormone therapy, and biological therapy 
are systemic treatments. They enter the bloodstream and destroy or control 
cancer throughout the body. Some women with breast cancer have systemic 
therapy to shrink the tumour before surgery or radiation. Others have 
systemic therapy after surgery and/or radiation to prevent the cancer from 
coming back. Systemic treatments also are used for cancer that has spread. 
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1.3 Oestrogen Positive Breast Cancer 
1.3.1. Oestrogen  
1.3.1.1. Breast cancer and Oestrogen  
At staging, all breast cancer pathological specimens, i.e. Fine Needle Aspirate (FNA) 
or tissue biopsy will have their Oestrogen, Progesterone and ErbB2 receptor status 
confirmed. Breast cancer with ER and PgR positive has 70% chance of responding to 
Tamoxifen whereas in ER positive and PgR negative or vice versa, only have a 33% 
chance of responding to Tamoxifen. Sixty five to 70% of all breast cancers are ER 
positive. Hence it is important to understand the physiological role of oestrogen. 
Figure 1.1 illustrates the hormone dependant physiological breast development. 
Figure 1.2 shows the biochemical pathways involved in the synthesis of endogenous 
steroids.  
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Figure 1.1  Mammary gland development Embryogenesis: A small placode in 
the ectoderm develops into a bud. At the base of the bud, rapid epithelial 
proliferation forms a single duct that grows towards a fat pad. Finally, mesenchyme 
derived structures form the nipple. Puberty: Cyclical ovarian production of oestrogen 
& progesterone accelerates epithelial duct outgrowth. Terminal end buds (TEB), 
consisting of an outer layer of cap cells (myoepithelial progenitors) & an inner layer 
of body cells (luminal progenitors) proliferate rapidly and facilitate ductal outgrowth. 
In the mature gland, ductal side branches form and disappear with each oestrogen 
cycle. Pregnancy: Placental lactogens, prolactin, and progesterone stimulate cell 
proliferation, alveolar bud (AB) formation and alveolar expansion. Lactation: During 
lactation, luminal cells of mature alveoli synthesise milk, which is transported 
through the ducts to the nipple. Regression: On cessation of feeding, apoptosis 
occurs in the secretory epithelium, the surrounding stroma is remodelled to replace 
apoptosed cells. Finally, cyclical production of ovarian oestrogen and progesterone 
returns. This illustrates the steps involved in converting cholesterol to oestradiol. 
Androstenedione, a key intermediary in the pathway is either converted to 
testosterone, which undergoes aromatisation to oestradiol, or to oestrone and 
converted to oestradiol by 17βhydroxysteroid reductase. In pre-menopausal women, 
ovarian granulosa cells produce the majority of oestradiol, with smaller amounts 
synthesized in the adrenal glands.  
Peripherally, precursor hormones such as testosterone are converted by aromatisation 
to oestradiol; adipose tissue actively converts precursors to oestradiol, this continues 
post-menopausally. Oestradiol is also produced in the brain and arterial endothelium.  
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Figure 1.2  Metabolism pathway of steroids. One hypothesis to explain the 
possibility that oestrogens promote breast cancer through the action of its 
metabolites, (such as chatecholoestrogens and catechol-quinones) which cause the 
formation of DNA adducts in experimental models.  
 
There is evidence that polymorphisms of the enzymes involved in the formation of 
oestrogen metabolites such as chatecholoestrogens and catechol-quinones, modulate 
the risk of breast cancer (Cheng et al., 2005), (Hu et al., 1998), (Lin and Scanlan, 
2005), (Lavigne et al., 1997).  
There is also evidence to support the theory that oestrogen causes breast cancer via 
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its pro-proliferative effects on breast tissue; though only 15-25% of normal breast 
epithelial cells express ER receptors, over 65% of breast cancers are ER-positive and 
depend on oestrogen for growth. Furthermore, ER expression is higher in the normal 
breast tissue of women with breast cancer than in women without the disease (Avisar 
et al., 1998), (Bhandare et al., 2005).  
As early as 1896, Beatson demonstrated that depriving breast cancer of endogenous 
oestrogen, through oopherectomy resulted in control of metastatic disease in ~30% of 
patients (1986). Today, various pharmacological strategies are used to reduce 
oestrogen and control the disease, as follows:  
i) GnRH analogues, (e.g. goserelin) and GnRH antagonists (eg Cetrorelix) are used 
in pre-menopausal women to reduce ovarian production of oestrogen.  
ii) Aromatase inhibitors prevent the synthesis of oestrogen in breast cancer cells, the 
ovaries and peripheral tissues; for example: exemestane is a suicide substrate while 
anastrazole is a competitive inhibitor of aromatase. Aromatase, also known as 
CYP19 is depicted in the steroidogenesis pathway catalysing the conversion of 
androstenedione to estrone and the conversion of testosterone to oestradiol (Figure 
1.2).  
 
iii) ER antagonists are also widely used; these can be divided into pure anti-
oestrogens such as: Faslodex (ICI 182,780) and Selective Estrogen Receptor 
Modulators, (SERMs) such as tamoxifen and raloxifene.  
Tamoxifen and Anastrazole have proven to be effective in the treatment and 
prevention of breast cancer; they are both widely used in these contexts. (Buzdar et 
al, 2005); (Baum et al, 2002).  
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1.3.1.2. The Oestrogen Receptor (ER)  
The effects of oestrogen are mediated through the oestrogen receptor ER, which 
exists in two forms: ERα and ERβ, encoded by separate genes. Oestrogen receptors 
belong to the nuclear hormone receptor superfamily, a large family of ligand-
regulated, zinc finger-containing transcription factors, which share a characteristic 
structure. ERα and ERβ have distinct tissue expression patterns: (ERα is found in the 
endometrium, breast, ovaries and pituitary while ERβ occurs in kidney, bone, brain, 
heart, lungs, intestinal mucosa, prostate and endothelial cells) (Saji et al., 2000); 
(Paech et al, 1997); (Katzenellenbogen et al., 2000a), (Katzenellenbogen and 
Katzenellenbogen, 2000; Katzenellenbogen et al., 2000b).  
1.3.1.3. ER: Mechanisms of action  
 
ERα has been extensively studied and plays a dominant role in the promotion and 
progression of breast cancer; it is over-expressed in 65-77% of primary breast 
cancers. By contrast, ERβ may have a tumour suppressor role; expression is reduced 
in malignancies of the breast, ovary, prostate and colon, and overexpression of ERβ 
inhibits proliferation and invasion of breast and prostate cancers (Duong et al, 2006). 
Oestrogen is thought to act via several different mechanisms, as follows and 
summarised in Figure 1.3: 
i) In the “classical” model of ligand dependant ER activation; upon 
oestrogen binding, the receptor undergoes a conformational change, 
dissociates from chaperone proteins (such as hsp90) it dimerises, and 
is targeted to the nucleus. In the nucleus, the oestrogen-bound ERα 
dimer binds DNA at an oestrogen response element (ERE), a 
palindromic consensus sequence present in the gene regulatory 
regions of ER-responsive genes, (5‟-GGTCAnnnTGACC-3‟). 
Transcription of oestrogen responsive genes is activated through 
interaction with the basal transcription machinery and recruitment of 
co-regulatory proteins: co-activators or co-repressors  (See Figure 1.4 
for summary). 
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ii) The ligand-bound ER can also interact at “non-classical” sites on 
DNA by direct protein-protein interaction with other transcription 
factors (such as AP-1, Sp1, NF-kB) and activate transcription of their 
target genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Oestrogen action at the molecular level.  
(a) The ligand-bound oestrogen receptor (ER) activates gene expression by direct 
dimeric binding to its “classical” DNA response element (ERE), or at “non-
classical” sites by interaction with other transcription factors (e.g. AP-1; Sp1), in 
complexes that include co-activators (CoAs) and histone acetyl transferasae 
(HATs). (b) Receptor tyrosine kinase (RTK) signalling can lead to ligand-
independent ER activation via phosphorylation. (c) Signalling may also be 
mediated through “non-genomic” signalling by ER that is localised at the cell 
membrane or in the cytoplasm. Two recently described pathways are illustrated: 
(d) ligand induced methylation (M) of ER and formation of an ER complex with 
focal adhesion kinase (FAK) that activates the Akt pathway, and (e) activation of 
Erk signalling by an ER-Src-PELP1 complex. Diagram taken from (Musgrove & 
Sutherland, 2009). 
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iii) Ligand-independent activation of ER can occur in the cytoplasm via 
cross talk with other signalling pathways (e.g. receptor tyrosine 
kinases such as. EGFR, ErbB2, IGFR). Activation leads to ER 
phosphorylation at key amino acid residues in the AF-1 activation 
domain by MAPK/ERK or PI3K/AKT altering the level of activation 
of ER, resulting in dimerisation and transcription of ER responsive 
genes (Leo et al., 2005); (Kato et al, 2001). Phosphorylation of co-
regulator proteins can also occur, altering their activity and thus 
modulating the transcriptional activity of ER.  
iii) More recently a non genomic pathway has been proposed where 
cytoplasmic ER becomes activated at the cell membrane leading to 
increased signalling through alternative pathways that do not result in 
the binding of ER to the DNA – hence the term “non-genomic”. 
 
Figure 1.4  ER co-activator recruitment. Upon binding ER ligands, (ER 
agonists, antagonists, or SERMs) the receptor undergoes a conformational change, 
which regulates the recruitment of co-regulatory proteins. Co-activators such as 
SRC1 bind to the active (agonist bound) receptor and activate transcription, while co-
repressors interact with the antagonist-bound receptor, inhibiting transcription. 
Depending on the cell and promoter context, unique and overlapping sets of genes 
are regulated by the different ligands. (Deroo et al, 2006)  
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1.3.1.4. Use of tamoxifen and other hormonal 
therapies  
Early clinical trials with tamoxifen established its value in advanced breast cancer 
(Ward et al, 1973; Ward et al, 1978; Cole et al, 1971; Jordan et al, 1988). Originally, 
tamoxifen was given to all patients with breast cancer, however it‟s current use is 
restricted to hormone receptor positive tumours. For decades, tamoxifen has been the 
gold standard treatment for ER positive disease in both metastatic and adjuvant 
settings.  
Tamoxifen‟s safety and efficacy has been established in randomised controlled trials 
(RCT) involving approximately 30,000 women. Adjuvant treatment with tamoxifen 
for women with ER positive disease results in a 51% reduction in recurrence rate and 
28% reduction in death, standard treatment is for 5 years (Gray et al, 1993; Lewis et 
al, 2007). Tamoxifen is cost effective and safe. It has been shown to lower serum 
cholesterol levels and lower the risk of osteoporotic fracture in post-menopausal 
women, (Mikuls et al., 2005); (Jakesz et al., 2005); (Love et al., 1990). Its less 
desirable side effects include: hot flushes, an increased risk of uterine cancers, 
(endometrial carcinoma and uterine sarcoma), thromboembolism and elevated 
triglycerides (Cuzick et al., 2002); EBCTCG, 1998; (Fisher et al., 2005).  
The observation that tamoxifen reduced the incidence of cancer in the contralateral 
breast by 54% after 5 years prompted further investigation for its use as a 
chemopreventative. Placebo controlled trials in over 25,000 women showed that 
tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by 
about 32%, IBIS-1, (International Breast Cancer Intervention Study-1), Royal 
Marsden Hospital Chemoprevention trial, Italian tamoxifen prevention study and 
NSABP-P1 (National Surgical Adjuvant Breast and Bowel Project P-1) trials.  
The Study of Tamoxifen and Raloxifene, (STAR) and NSABP P2 directly compared 
tamoxifen with raloxifene for chemoprevention. Both studies showed similar risk 
reduction for invasive breast cancer and osteoporotic fractures with less toxicity for 
raloxifene. Intriguingly, both trials suggested that tamoxifen had greater activity in 
the prevention of noninvasive breast cancer (carcinoma in situ – DCIS and LCIS) 
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(Vogel VG, 2007). The IBIS-1 and Marsden trials/studies has confirmed that the 
chemoprotective effects for prevention of invasive breast cancer continue long after 
the end of treatment, while the side effects resolve more quickly, suggesting an 
increase in the risk benefit profile after the end of active treatment. (Forbes et al., 
2008); (Powles et al., 2007).  
Over the past 5-10 years, a growing body of evidence has accumulated establishing 
the clinical superiority of more modern agents, aromatase inhibitors (AIs) in the 
treatment of hormone responsive breast cancer in postmenopausal women. Meta-
analysis of data from 25 trials in the metastatic setting (comprising 8504 patients) 
demonstrated a significant overall survival advantage for aromatase inhibitors 
compared with tamoxifen (11% RH reduction, 95% CI = 1% to 19%; P = .03), 
(Mauri et al., 2006).  
However, at the 2008 San Antonio Breast Cancer Symposium, a meta-analysis of 
Aromatase Inhibitor (AI) trials (Ingle et al, 2008; Jakesz et al, 2008; Mouridsen et al, 
2008) showed that it may be premature for oncologists to discard tamoxifen. A meta-
analysis of eight large trials using AI alone or with a switch between AI and 
tamoxifen after 2-3 years, or an extension (defined by 5 years of tamoxifen, followed 
by 2-3 years of AI) has shown that while patients receiving an AI showed a clear 
disease-free survival (DFS) advantage, the groups with significant overall survival 
(OS) were those switched over groups that received tamoxifen first (see Table 1.1). 
No OS difference, in fact not even a suggested trend towards an improved survival 
advantage, has been seen in patients receiving an AI alone (Hughes-Davies, et al, 
2009). Two possible explanations have been offered for the lack of OS benefit: i) 
longer followed up is needed; ii) about two-thirds of the patients were node negative, 
which made it harder to demonstrate a significant absolute mortality difference. The 
largest AI alone trial (BIG I-98) also shows no statistical difference between 
letrozole alone and tamoxifen alone (p=0.08). This trial has two cross-over arms but 
the results of these have not yet been reported. So to date, it is recommended by most 
hospital trusts to use AI after 2-3 years of tamoxifen to achieve an OS advantage 
unless there are contraindications to tamoxifen use. 
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Table 1.1 A summary of the AI trials that have been reported to date. 
Abbreviations; sub=substitution, sw=switching. Ext=extension, A=Anastrazole, 
L=Letrozole, E=Exemestane, AG=Aminogluthemide. Those trials that have a 
statistically significant mortality benefit are highlighted in pink. This table clearly 
shows that only the switching trials have been able to show a mortality benefit from 
the AIs. Refs: 1=ATAC Trialists, 2008; 2=Mouridsen et al, 2008; 3=Coombes et al, 
2007; 4=Jakesz et al, 2008; 5=Kaufmann et al, 2007; 6=Boccardo et al, 2007; 
7=Mamounas et al, 2008; 8=Ingle et al, 2008. All these analyses are intention to treat 
(ITT) with no adjustment for crossover and patients are kept in their originally 
assigned groups even if they crossover from the control arm to the investigational 
arm. However, for the ATAC and IES data presented in this table, the ER-unknown 
or ER-negative patients were excluded from analysis. For MA17, a 2005 report 
showed an OS advantage in the node-positive subgroup; this was not seen in most 
recent results, probably because of high crossover rate. For ATAC, the figure in the 
table is for ER-positive subgroup. Reproduced from (Hughes-Davies, et al, 2009). 
 
 
As for their relative side effect profiles: women taking anastrozole experienced more 
sexual dysfunction, myalgia and an increased risk of osteoporotic fractures, while 
tamoxifen was associated with an increased risk of thrombosis and endometrial 
cancer (Forbes et al., 2008); (Howell et al., 2005); (Baum, 2002); (Buzdar, 2005).  
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At present, tamoxifen remains in widespread use for numerous reasons: aromatase 
inhibitors are contraindicated in pre-menopausal women; arguably, clinicians are 
intrinsically reluctant to change their practice. In the UK, current guidance from the 
National Institute of Clinical Excellence (NICE) allows patients and their clinicians 
to choose the appropriate adjuvant hormone therapy from an AI or tamoxifen. No 
recommendation has been made for one AI over another {National Institute for 
Health and Clinical Excellence, 2006}. The American Society of Clinical Oncology, 
ASCO has recommended the use of an AI “at some point” in their treatment for all 
postmenopausal women with ER positive breast cancer. There are differences in their 
side effect profile, which means that some women tolerate one or other class of drug 
more easily. Tamoxifen is still established as an effective treatment for metastatic 
disease and if patients are given adjuvant AIs, if they relapse they may be given 
tamoxifen at this point. Therefore one can expect tamoxifen to continue to be in 
widespread use for some time to come.  
However, in the metastatic disease setting, ~50% of patients exhibit de novo 
resistance to tamoxifen, and eventually all patients develop tamoxifen resistance and 
this clearly limits the use of this drug (Tonetti and Jordan, 1995); (Ali and Coombes, 
2002).  
1.4. Tamoxifen resistance  
 
The complexity of ER activation and tamoxifen‟s interaction with ER provides 
multiple mechanisms by which tamoxifen resistance may occur. Two-thirds of breast 
cancers express oestrogen receptor-, which drives breast cancer cell growth. 
Endocrine therapies are designed to block oestrogen action, but many tumours still 
exhibit de novo or acquired therapeutic resistance. The primary mechanism of de 
novo resistance to tamoxifen is lack of expression of ER. However, recently a 
second intrinsic mechanism has been highlighted, involving the inactivation of 
cytochrome P450 2D6 (CYP2D6), causing a failure of conversion of tamoxifen to its 
active metabolite, endoxifen, and consequently reduced response (Hoskin et al, 
2009). 
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In contrast, a number of mechanisms have been proposed to account for acquired 
resistance. Most of these have been published using results derived from ER-
positive breast cancer cell lines exposed to long term tamoxifen or withdrawal of 
oestrogen (in vitro). Although these studies reflect the range of tamoxifen resistance 
mechanisms in vitro, they are unlikely to describe totally how patients become 
resistant. This is due to fact that there are relatively few ER+ cell lines which do not 
represent all in vivo phenotypes (see section 1.6) but also because cells in culture 
cannot reflect the epithelial-stromal or the tumour-host interaction which will 
modulate resistance in vivo. 
 
Here, I will discuss the known mechanisms for endocrine-resistant in breast cancer in 
two broad classes; a) deregulation of various aspects of oestrogen (ER) signalling, 
and b) un-related signalling (cross talk) pathways with alternative proliferative and 
survival stimuli that confer resistance by activating the ER by alternative 
mechanisms (Table 1.2). 
 
Deregulation of ER signalling: 
 
1)  Loss of ERα expression: Since the effects of tamoxifen are mediated through 
ER, and ERα expression predicts response to tamoxifen, it is logical that loss of ERα 
expression confers resistance to therapy. However, IHC studies looking at paired 
tamoxifen sensitive and resistant tumours show that although ERα expression may be 
lost in some patients who develop tamoxifen resistance, 60-80% continue to express 
ERα on disease progression (Gutierrez et al., 2005); (Johnston et al., 1995). In 
addition, ~20% of patients demonstrate a response to further hormone therapy 
following failure of tamoxifen, suggesting that the ER continues to regulate growth 
in many tamoxifen-resistant patients (Osborne et al., 2001); (Howell et al, 2001). 
Cell line models of tamoxifen resistance, such as the ones used in this project 
continue to respond to β-oestrodiol.  
Mutations of the ERα gene may lead to a non-functioning receptor without loss of 
expression. However, although ERα mutations altering the effects of bound ligand 
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can be generated in vitro and detected in some resistant cell lines, they are thought to 
be relatively uncommon clinically (Roodi et al., 1995); (Karnik et al., 1994).  
Epigenetic changes may also reduce expression of ER or oestrogen target genes. In a 
study of DNA methylation status of 148 primary breast tumors, it was found that 
hypermethylation of the ERα gene, (ESR1) outperformed hormone receptor status as 
a predictor of clinical response in tamoxifen treated patients. Interesting addition, 
promoter methylation of CYP1B1, which encodes a tamoxifen and oestradiol-
metabolizing cytochrome p450, was also a highly significant predictor of tamoxifen 
response between tamoxifen-treated and non tamoxifen-treated patients 
(Widschwendter et al., 2004).  
2)  Median ERβ mRNA levels measured by RT-PCR were 2-fold higher than 
ERα in tamoxifen-resistant tumours compared with tamoxifen-sensitive tumours 
(Speirs et al., 1999) suggesting that aberrations in ERβ levels may contribute to 
resistance.  
3)  A common mechanism of drug resistance is through reduced intracellular 
concentrations of drug as a result of decreased metabolism or increased absorption 
(pharmacological tolerance). A study analyzing serum and intra-tumoural tamoxifen 
levels suggested that acquired resistance is associated with reduced intra-tumoural 
tamoxifen concentrations in the presence of maintained serum levels (Johnston et al., 
1993).  
Decreased metabolism of tamoxifen to active, agonist metabolites is another 
potential mechanism of resistance (Osborne et al., 1991). Recent studies have 
demonstrated the importance of endoxifen, (4-OHN-desmethyltamoxifen) a potent 
tamoxifen metabolite produced by the action of the cytochrome P450 enzyme, (CYP) 
2D6 (Johnson et al., 2004). Polymorphisms in the (CYP) 2D6 gene affect the plasma 
concentration of endoxifen and clinical outcome of women given hormone therapy. 
In the NCCTG 89-30-52 study, a retrospective analysis of 256 tamoxifen-treated 
patients, CYP2D6 genotypes were determined from paraffin-embedded blocks. 
Women with the CYP2D6 *4/*4 genotype (the less active phenotype comprising 
~7% of the European population) had a higher risk of disease relapse and a lower 
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incidence of hot flashes than women with the wildtype allele (Goetz et al., 2005).  
 
Table 1.2 Summary of selected pathways associated with tamoxifen 
resistance. (Adapted from Musgrove and Sutherland, 2009) 
 
 
Growth factor receptor and cytoplasmic signalling: 
 
4)  Alterations in co-regulatory proteins:  SRC-3 (AIB1) is an ER co-activator 
overexpressed in >50% of breast tumours (Anzick et al., 1997); (Osborne K et al, 
2003). In cell line studies, SRC-3, also called AIB1, RAC3, ACTR, and p/CIP, is an 
ER coactivator that enhances the agonist activity of tamoxifen in resistant cells (Feng 
et al., 2001). This is particularly seen in tumours expressing epidermal growth factor 
(EGF) receptor family members leading to activation of MAPKs (Font de Mora et 
al, 2000). In patients samples (n=316) from those not given adjuvant tamoxifen, high 
SRC-3 levels were associated with good prognosis, while in tamoxifen-treated 
patients, high SRC-3 expression was associated with a worse disease free survival 
(Osborne et al., 2003). 
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Experimental data suggest that overexpression of other co-activators eg SRC-1 may 
also enhance the agonist activity of 4-OH tamoxifen (Smith et al., 1997); 
(Tzukerman et al., 1994). An IHC study examining levels of SRC1 expression in 70 
primary breast tumours of known HER2 status (HER2 positive, n = 35) and normal 
breast tissue found over-expression of SRC-1 was significantly associated with 
disease recurrence in HER2 positive patients treated with tamoxifen (Meng et al., 
2004).  
5)  Kinase / signal transduction pathways: ERK1/2 expression and activity is 
increased in several breast cancer cell-line models of endocrine resistance (Lee et al., 
2000 ) (Coutts and Murphy, 1998). Increased ERK 1/2 activity (assessed by 
phosphorylated MAPK immunostaining) correlated with shorter duration of response 
to endocrine therapy in clinical breast cancer (Gee et al., 2001). pERK1/ERK2 did 
not play a role in the phosphorylation of ER Ser118 (Martin L-A et al, 2005). 
Two cell-line studies have addressed the possible involvement of the PI3K cell 
survival pathway with tamoxifen resistance. Transfection of MCF-7 cells with AKT 
reduced the inhibition of cell growth by tamoxifen, suggesting overexpression of 
AKT may contribute to tamoxifen resistance (Campbell et al., 2001). PI3KCA 
mutations have been reported in approximately one third of breast cancers (Bachman 
et al, 2004). These are reported to effect the downstream signalling (Kang et al, 
2005). Clark et al. measured tamoxifen-induced apoptosis with and without the PI3K 
pathway inhibitor LY294002. Addition of LY294002 significantly increased the pro-
apoptotic effects of tamoxifen, particularly in the cell line with the highest 
endogenous levels of AKT activity (Clark et al., 2002). Stress-activated protein 
kinase/c-junNH2 terminal kinase (SAPK/JNK). ER can interact with the SAPK/JNK 
pathway either via binding AP-1 or by direct activation of ER and co-regulators by 
p38 MAPK.  
Activation of the p38 MAPK pathway occurs in response to a number of 
extracellular stimuli including growth factors, cytokines, physical and chemical 
stress (Chen et al., 1998). The downstream targets of p38 MAPK include further 
protein kinases and transcription factors. In cell lines expressing ER; 4-OH 
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tamoxifen has been shown to activate the p38 MAPK pathway and induce apoptosis. 
Under these circumstances, inhibition of the p38 signalling pathway greatly reduces 
the ability of tamoxifen to induce apoptosis. In paired biopsy samples taken pre-
treatment and on relapse from patients treated with adjuvant tamoxifen, report 
(Martin et al, 2005) that elevated ERK1/ERK2/oestrogen receptor cross-talk 
enhances oestrogen mediated signalling during long-term oestrogen deprivation. 
Moreover, patients with ER-positive and ErbB2 positive at relapse showed uniformly 
high expression of p38 MAPK, suggesting that in this subset of patients, activation of 
ER may have occurred by this route (Dowsett and Ellis, 2003).  
In tamoxifen resistant cells, erbB3/erbB2 and erbB3/EGFR heterodimerisation, 
promoted ERK1/2 and AKT pathway activation and increased cell proliferation and 
invasion (Hutcheson, 2003; Hutcheson, 2007). 
 
6) Loss of PTEN was found to engage ErbB3 and IGF-IR signalling to promote anti-
oestrogen resistance in breast cancer (Miller TW et al, 2009). Tamoxifen treatment 
inhibited oestrodiol-induced ER transcriptional activity is all shPTEN cell lines but 
did not abrogate the increased cell proliferation induced by PTEN knockdown. 
PTEN knockdown increased basal and ligand-induced activation of the IGF-I and 
ErbB3 receptor tyrosine kinases, and prolonged the association of the p85 PI3K 
subunit with the IGF-I effector IRS-I with ErbB3, implicating PTEN in the 
modulation of signalling upstream from PI3K. 
 
7) The most widely studied mechanisms of tamoxifen resistance has been upregulation of 
ERBB2 expression and activity. ER+ luminal tumours with elevated ERBB2 levels have 
the poorest prognosis (Kun Y et al, 2003), and about half of ERBB2-positive tumours are 
also positive for ER (Piccart-Gebhart et al, 2005). Up-regulation of ERBB2 expression is 
strongly associated with gene amplification, however transcriptional affects have also 
been documented. In particular, ligand bound ER has been found to repress ERBB2 
expression, which is reversed in tamoxifen-containing media in vitro (Bates & Hurst, 
1997). A number of transcription factors have been suggested to repress ERBB2 
expression, including GATA4 (Hua et al, 2009) and FOXP3 (Zuo et al, 2007) but these 
have not been directly associated with ER or tamoxifen resistance. In contrast, the PAX2 
factor and the ER co-activator SRC-3 have been shown to compete for binding and 
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regulation of ERBB2 transcription. Increased PAX2 expression (and hence repression of 
ERBB2) was associated with a better outcome on tamoxifen (Hurtado et al, 2008). 
 
8) Other growth factor receptor families may also contribute to tamoxifen resistance. 
Increased expression of Fibroblast growth factor receptor 4 (FGFR4) predicted 
failure on tamoxifen therapy in patients with recurrent breast cancer (Meijer et al, 
2008). Although not yet investigated in terms of therapy response, a recent genome-
wide association study identified single nucleotide polymorphisms (SNPs) within the 
second intron of FGFR2 as being associated with a small but highly significant 
increase in cancer risk in ER+ breast cancer (Easton D et al, 2007).  
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1.5. Gene expression profiling  
One of the conceptually most important discoveries of the past 10 years was the 
realization that invasive breast cancer is not a single disease with different degrees of 
ER and HER2 expression and variable histologic features but a collection of several 
molecularly rather distinct diseases (Bertucci et al., 2004; Dorssers et al., 2001; Rody 
et al., 2006).  Transcriptional profiling revealed large-scale gene expression 
differences between ER-positive and ER-negative cancers that go far beyond the 
expression of ER itself.  It is plausible that ER-positive and -negative cancers 
originate from different epithelial precursors, luminal and basal ductal epithelial 
cells, respectively.  Furthermore, among the ER-positive cancers, two distinct 
subtypes can also be distinguished that show different sensitivities to therapy and 
have different prognosis.  Currently, four different molecular classes of breast 
cancers can be identified consistently through gene expression profiling.  Using the 
original terminology proposed by Perou et al. these include: (i) “Basal-like” breast 
cancers that correspond mostly to ER-and HER2-negative, high histologic grade 
cancers, (ii) “Luminal-A” cancers that are mostly ER-positive and lower grade 
cancers, (iii) “Luminal-B” cancers that are also mostly ER-positive but often higher 
grade, and (iv) “HER2-positive” cancers that include most of the HER2 gene 
amplified cases (Sorlie et al., 2001; Perou et al. 1999).  It is important to recognize 
that up to 25-30% breast cancers do not fall into any one of the above robust 
molecular categories.  
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Figure 1.5 Gene Expression patterns of breast carcinoma distinguish tumour 
subclasses with clinical implications. Perou et al first published this landmark paper 
in 2002, which showed 5 distinct molecular type of breast cancer, which is associated 
with histological grade. „Luminal Subtype A‟ has the best prognosis while „basal-
like‟ has the worst prognosis. 
 
The four molecular classes of breast cancer correspond closely, but not perfectly, to 
well-established clinical phenotypes of breast cancer.  This correspondence is 
reassuring and provides a molecular framework to understand clinical phenotype.  It 
is important to consider that while histological grade can not be targeted with 
therapies; better understanding of the molecular abnormalities that cause high grade 
morphologic features may lead to new therapeutic targets.  On the other hand, the 
diagnostic relevance of molecular classification is limited by its close association 
with ER- and HER2-status and histological grade.  Basal-like cancers are almost 
exclusively ER- and HER2-negative and high grade cancers therefore it is expected 
that they will have poor prognosis in the absence of adjuvant systemic therapy. This 
group have higher sensitivity to chemotherapy in general and do not benefit from 
endocrine treatment.  Conversely, Luminal-A cancers that are mostly ER-positive, 
HER-2 normal and have lower grade will have the highest endocrine sensitivity (but 
lowest chemotherapy sensitivity) and best prognosis (Hu et al., 2006).  To what 
extent molecular classification provides clinical value beyond routine histopathology 
parameters remains unknown.  However, molecular classification provides a simple 
summary measure of complex clinical-pathological variables.  This is an important 
potential advantage because considerable variation exists in the assessment of routine 
histopathological features (i.e. grade and even ER-status) of the same cancer by 
different pathologists. 
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1.6. Gene Expression Signatures and Other 
Markers to Predict Prognosis 
Two alternative predictor development strategies exist; the first referred to as the 
“supervised” marker discovery strategy.  This relies on comparing gene expression 
data from cohorts of cases with known outcome to identify genes that are associated 
with prognosis or response to therapy and than combine these informative genes into 
a multivariate prediction model.  The second strategy may be called the “hypothesis 
testing” approach.  This starts with defining a hypothesis that particular genes or 
molecular pathways may influence a clinical outcome of interest and these genes are 
used to construct a multi-gene predictive signature.  Candidate genes may be selected 
based on existing biological knowledge or can be identified through experiments in 
vitro.  
Regardless of which development strategy is utilized, genomic outcome predictors 
(i.e. “gene signatures”) are conceptually similar to multivariate clinical prognostic 
prediction models.  These prediction tools apply the mathematical principle that 
individually weak predictive variables, that are at least partly independent of each 
other, can be combined into prediction models that are more accurate than any single 
variable alone. The main difference is that genomic predictors combine molecular 
rather than clinico-pathological variables into a prediction model.  
 
1.7. Prognostic gene signatures 
 Three distinct gene expression profiling-based prognostic tests were recently 
developed.  One of these, MammaPrint (Agendia Inc., Amsterdam, Netherlands), 
was recently cleared by the U.S. Food and Drug Administration (FDA) to aid 
prognostic prediction in node-negative breast cancer.  This assay measures the 
expression of 70 genes and calculates a prognostic score that can be used to 
categorize patients into “good” or “poor” prognostic risk groups.  This test was 
subsequently evaluated on two separate cohorts of patients that received no systemic 
adjuvant therapy.  The first cohort included 295 patients and showed that those with 
the good prognosis gene signature had 95% (standard error ±2%) and 85% (±4%) 
distant metastasis-free survival at 5 and 10 years, respectively.  In contrast, the poor 
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prognostic group had 60% (±4%) and 50% (±4.5%) distant metastasis-free survival 
at 5 and 10 years, respectively (van de Vijver et al., 2002).  A second validation 
study (n=307) confirmed these findings and showed that patients with the good 
prognosis signature had 90% (95% confidence interval, 85-96%) distant metastasis-
free survival at 10 years, whereas it was 71% (65-78%) in the poor prognosis group 
(Buyse et al, 2006).  Importantly, the MammaPrint signature could re-stratify 
patients within clinical risk categories defined by the Adjuvant Online (a program 
used widely for stratifying risk available to the public on the website).  Some of the 
clinically low-risk patients were correctly re-categorized as high-risk based on their 
gene signature, and some clinically high-risk patients were correctly predicted to be 
low-risk by the genomic test.  However, a recent report also highlighted an important 
limitation of this test, almost all ER-negative cancers (>90%) are classified as high-
risk by † MammaPrint after adjustment for tumor grade, size, and ER status that 
confirms least partly independent added prognostic value. *MINDACT (Microarray 
in Node Negative Disease May Avoid Chemotherapy) trial is currently ongoing in 
Europe to accrual for a prospective study on the predictive value of this gene chip. 
 
A second prognostic signature utilized the “hypothesis testing” discovery strategy.  
Investigators set out to define the gene expression differences between low and high-
histological-grade cancers and assumed that these genes would be able to improve 
prognostic predictions for morphologically intermediate-grade cancers.  Using this 
approach, a 97-gene genomic grade signature was identified that discriminated 
between low and high-grade tumours and separated intermediate-grade tumors into 
two distinct subgroups of lower and higher genomic grade cancers with different 
prognosis (Sotiriou and Desmedt, 2006).  These results were observed across 
multiple independent data sets generated on different microarray platforms.  Not 
surprisingly, the genomic grade gene index is dominated by genes involved in cell 
cycle regulation and proliferation (Desmedt and Sotiriou, 2006).  
 
It is important to point out that the various prognostic signatures have very few genes 
in common.  This may seem surprising at first, but it is a common feature of high-
dimensional data that contain large numbers of highly correlated variables.  Gene 
expression values are highly correlated with each other and therefore, if the 
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expression of a particular gene is associated with a particular clinical outcome, all 
other genes whose expression are closely correlated with that index gene will also 
correlate with the same clinical outcome.  However, the strength of association 
between any given gene and the clinical outcome varies from training set to training 
set and therefore, the rank order of the informative genes is unstable when they are 
ranked by strength of association.  Nevertheless, all of these co-expressed genes 
carry similar information about the outcome of interest and therefore many different 
statistically equally good predictors can be discovered from the same data set (Ein-
Dor et al, 2005).  A corollary of this is that different predictors that use information 
from different genes can predict equally well on a given data set. 
 
A limitation of the current microarray-based prognostic assays is that they only 
provide moderately precise estimates of risk of recurrence.  Also, almost all ER-
negative cancers are assigned to high prognostic risk category by the currently 
available assays.  On the other hand, the genomic predictors seem to complement 
tumour size- and grade-based prognostic models.  This is probably driven by the 
improved ability of the genomic tests to categorize clinically intermediate risk groups 
(i.e. intermediate grade cancers) into low or high prognostic categories.  What 
constitutes a low enough risk to forgo systemic adjuvant chemotherapy is influenced 
not only by the absolute risk of relapse but also by the risk of adverse events, the 
probability of benefit from therapy, and personal preferences.  Many patients are 
willing to accept adjuvant chemotherapy for rather small gains in survival (Ravdin et 
al, 1998).  Molecular prognostic markers may provide little clinical value for these 
individuals because no predictive test is accurate enough to completely rule out risk 
of relapse or some potential benefit from adjuvant therapy.  However, many other 
patients are reluctant to accept the toxicities, inconvenience, and costs of 
chemotherapy for a small and uncertain benefit.  For these individuals, more precise 
prediction of risk of recurrence and sensitivity to adjuvant therapy with genomic tests 
can assist in making a more informed decision. 
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1.8. Molecular Predictors of Response to 
Endocrine Therapy 
 
1.9.1   Oncotype DX assay and other genomic predictors 
One of the most important questions for patients with ER-positive breast cancer is 
whether they should receive adjuvant endocrine therapy alone or also take 
chemotherapy.  Oncotype DX (Genomic Health, Inc., Redwood City, CA), 
represents a novel and commercially available molecular assay in the United States 
to assist decision making in this clinical setting.  This RT-PCR-based assay 
represents an important conceptual advance in the diagnosis of ER-positive breast 
cancers.  It measures the expression of 21 genes including ER and HER2 as well as 
several ER-regulated transcripts and proliferation related-genes including Ki-67.  
Several of these genes were already known to be associated with outcome and can be 
assessed with more conventional methods as well.  However, an important value of 
Oncotype DX is that it combines these results into a simple and easily interpretable 
“recurrence score” (RS).  The RS could be used as a continuous variable to estimate 
the probability of recurrence at 10-years or can be grouped into low-, intermediate- 
or high-risk categories.  Correlation between RS and distant relapse was examined in 
668 patients with ER-positive, node-negative cancers treated with tamoxifen who 
were enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
B14 clinical trial.  The 10-year distant recurrence rates were 7% (4-10%), 14% (8-
20%), and 30% (24-37%) for the low-, intermediate-, and high-risk categories 
(p<0.001) (Paik et al., 2004).  These results suggested that ER-positive patients with 
high RS may not be treated optimally with 5 years of tamoxifen.  Similar results 
were observed for a community-based patient population (Habel LA, ASCO annual 
meeting proceeding 2005).  The value of the recurrence score for predicting benefit 
from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF or MF) 
chemotherapy in ER-positive, node-negative breast cancers was also examined.  A 
study that included 651 patients who were enrolled in the NSABP B20 randomized 
clinical trial, which compared adjuvant tamoxifen with tamoxifen plus CMF (or MF) 
adjuvant chemotherapy, showed that a higher RS was associated with greater benefit 
from adjuvant chemotherapy (Paik et al., 2004).  The absolute improvement in 10-
 54 
year distant recurrence free survival was 28% (60% vs 88%) for patients with RS 
>31, while there was no benefit for patients with RS <18 (test for interaction 
p=0.038).  The hazard ratio for distant recurrence after chemotherapy was 1.31 (0.46-
3.78) for patients with RS <18 and 0.26 (0.13-0.53) for patients with scores >31.  
These data indicate that a RS identifies a subset of women with ER-positive and 
node-negative breast cancers who are at high risk of recurrence despite 5 years of 
tamoxifen therapy and that this risk can be reduced with adjuvant chemotherapy.   
 
In aggregate, the available data suggests that Oncotype DX can be useful when the 
decision regarding adjuvant chemotherapy is not straightforward based on routine 
clinical variables.  However, some important caveats must be noted.  Oncotype DX 
is not appropriate for ER-negative patients because they are all categorized as high 
risk (Badve and Nakshatri, 2009).  The predictive performance of this test in patients 
who receive adjuvant aromatase inhibitor therapy or third generation anthracycline 
and taxane combination adjuvant chemotherapy remains to be studied.  In particular, 
the magnitude of benefit that patients with low or medium recurrence scores 
experience when treated with a third-generation adjuvant chemotherapy regimen is 
unknown.  Also, the limited available data suggests that patients with lymph node-
positive, ER-positive, low recurrence score disease continue to remain at substantial 
risk of recurrence if treated with 5 years of tamoxifen therapy only.  One study 
suggested that these patients may have up to 40% risk of local or distant recurrence 
at 10 years (Albain K, Br C Res Treat 2007; vol 106, abs 10).  In contrast, the risk of 
distant recurrence of patients with the same risk score and lymph node-negative 
disease was 7%. Oncotype DX is routinely used in the States, and this predictive chip 
is being formally assessed in Europe by the prospective † TAILORX (Trail 
Assigning Individual Option for Treatment) trial, which opened in 2007 for accrual. 
Several other efforts were made to develop predictors of response to endocrine 
therapies among ER-positive patients.  One group reported that the ratio of HOXB13 
and IL17BR genes was predictive of disease-free survival in patients with early-
stage, ER-positive, breast cancer, who received treatment with tamoxifen (Ma et al, 
2004).  Unfortunately, subsequent studies tested this 2-gene ratio in heterogeneously 
treated patient populations and often used different assay thresholds and 
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normalization methods; therefore the true prognostic or predictive values of this 
assay remain uncertain.  
1.9. Gene Profiling Platforms 
The microarray platforms that were used to develop the current clinical outcome 
predictors have a clear limitation; they confine their interrogation to the “mRNA 
world” as it was known 10-15 years ago.  In the past few years, our knowledge of the 
RNA world has evolved rapidly.  It is now apparent that a previously unrecognized 
complex world of small regulatory RNA species exists including microRNA, siRNA, 
snoRNA and vast regions of non-coding DNA, pseudo-genes and antisense DNA 
strands are also frequently transcribed.  Alternative splice forms of mRNAs are 
commonly generated from the same gene and can lead to distinct transcripts with 
different functions.  It is almost certain that this extended RNA world contains 
complementary information not fully captured by measuring the expression of 
previously know genes.  The next generation of DNA arrays (e.g tiling arrays, 
miRNA arrays) will enable investigators to study the clinical and diagnostic potential 
of these new RNA species. 
 
By performing our study on concurrent high-throughput genome wide analysis using 
SNP6.0 from Affymetrix. Copy number variation (CNV) data analysis by the side of 
EXON gene-level, and „splice variant‟ analysis; we aim to overcome some of the 
limitation listed above. These two new platforms is the result of advancement in 
array technology with increasingly smaller feature size. The point to appreciate is 
that with feature densities increasing, more transcribed genome is covered. In fact 
rather than just measuring the gene or the genome expression, the array measures the 
abundance of RNA or the DNA fragments (exon or more SNP regions) in that 
region, respectively for EXON and SNP6.0 array. 
 
Current molecular models of breast cancer biology are based on interactions between 
a few hundred molecules.  However, gene expression data indicates that at least 5 -10 
thousand different mRNA transcripts are expressed in every cancer and most of these 
have no known function in cancer biology.  Many of these genes may prove to be 
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important novel drug targets and the technology that has lead to their discovery may 
also serve to select patients for these future therapies. 
 
1.10. MicoRNA in tamoxifen resistance 
MicroRNAs are one type of relatively newly identified noncoding RNA. Their 
mature products are small single-stranded species of around ~22 nucleotides in 
length (Bartel et al, 2009). MicroRNA play critical roles in silencing genes, often 
silencing a cluster of about 200 genes, during development. Binding of microRNAs 
to their target genes occurs by perfect match or mismatch base pairing to 
complementary sequences within the 3‟ untranslated region (UTR) of the mRNA. 
This results either in mRNA degradation (Llave et al, 2002), (Palatnik et al, 2003) or 
translational repression (Lee et al, 1993), (Esquela-Kerscher et al, 2006). They have 
a role as onco-miRs or tumour suppressors by regulating apoptosis factors (Cimmino 
A, Proc Natl Acad Sci). The role of microarray in tamoxifen-resistance has recently 
been explored by (Zhao et al, 2008), (Maillot et al, 2009), (Miller et al, 2008) and 
(Pogribny et al, 2007). These studies were mainly on the widespread repression of 
oestrogen-dependent proteins by a specific miRNA in breast cancer line growth (in-
vitro). Only one study (Rodriguez-Gonzalez et al) showed miRNA-30c as an 
independent predictor of clinical benefit of endocrine therapy in advance oestrogen 
positive breast cancer.  
 
MicroRNA 221/221 has been shown to be >1.8 fold upregulated in tamoxifen 
resistant breast cancer cell lines (Miller et al, 2008). The expression of mir-221/222 
was also significantly (>2.0) elevated in ERBB2-positive primary breast cancer 
tissues that are known to be resistant to endocrine therapy. This group elegantly 
showed that ectopic expression of miR-221/222 render the parental MCF-7 breast 
cells resistant to tamoxifen. Furthermore, they shown p27
KIP1
, a known target of 
miR-221/222, and a cell-cycle inhibitor, is reduced by 50% and may be a major role 
in conferring resistance to tamoxifen in MCF-7 cells. 
 
Zhao JJ et al (Zhao et al, 2008) published simultaneously than miR-221/222 
negatively regulates oestrogen receptor-, at post-translational level, and confer 
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tamoxifen resistance in breast cancer. They found that the ER protein but not the 
mRNA is suppressed in the miR-221/222 carriers, they undertook a search in miRNA 
Target Scan Database and found two sequence motif of the 3‟-UTR of ER matched 
miR-221 and miR-222 seed sequences, one of which is highly conserved, between 
human, mouse and rat. This group also found miR-221/222 to be upregulated in their 
ER-negative cancer cell line work and ER-negative primary breast tumour. 
Knockdown of miR-221 and miR-222 in MDA-MB-468 (a cell line which has high 
miR-221/222 and detectable ER mRNA, but ER-protein negative), partially 
restores ER expression and tamoxifen sensitivity. 
 
In my project, I set out to see if my tamoxifen-resistant primary breast tumour cases 
and tamoxifen-resistant breast cancer cell lines carried elevated miR-221. And if the 
positive miR-221 carriers had elevated ERBB2 mRNA expression. As all my 
primary breast tumour cases were ER-positive patients, we were unable to validate 
the findings of Zhao JJ et al, regarding miR-221 negatively control ER protein 
expression. The aim of this exercise is to validate if our series of primary breast 
tumour and our breast cell lines (with their TR counterparts), with that of published 
findings, and I am pleased to say they do. 
 
Then, I set off to investigate for new novel miRNAs from our combined integrated 
microarray analyses, and validated them for correlation with TR cases, in breast cell 
lines and human primary tissue. In the future, if time permit, I intend to carry out in-
vitro study of the most promising miRNA from our study. 
 
1.11. Melanoma Associated Antigens (MAGE) 
The melanoma antigen (MAGE) genes were initially isolated from melanomas based 
on their almost exclusive tumour-specific expression pattern. Subsequently a large 
number of human genes encoding tumour-specific antigens were isolated, including 
melanoma antigen families MAGE, BAGE, GAGE and LAGE (Chen et al, 1998; De 
Backer et al, 1999; Zendman et al, 2002).  The MAGE family has since been divided 
into two sub-families termed Class I and Class II MAGE genes. The only conserved 
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domain found in all members of this family is the MAGE homology domain (MHD), 
a stretch of ~200 amino acids located towards the carboxy-terminus of the proteins 
(Chomez et al, 2001).  Within Class I, the MAGE-A (12 genes), MAGE-B (6 genes) 
and MAGE-C (3 genes) subfamilies are highly (50-80%) homologous and positioned 
on chromosome X. Their lack of expression in somatic adult tissues but frequent 
aberrant expression in tumours defines them as cancer-testis (CT-X) antigens, 
proteins encoded on the X chromosome which are normally only expressed by 
gametes and trophoblast cells (Simpson et al, 2005). The Class II MAGE antigens in 
contrast are encoded by genes found at a variety of chromosomal locations, 
expressed in adult tissues and have not been found to be upregulated in tumours 
(Forslund & Nordqvist, 2001).  
 
The mechanism behind the activation of Class I MAGE genes in cancer has generally 
been assumed to be due to genome-wide DNA hypometylation (Simpson et al, 
2005), which is a frequently observed epigenetic event during carcinogenesis and is 
directly associated with induction of tumours in mice (Ehrlich et al, 2009; Gama-
Sosa et al, 1983). However, it has been recently reported that the multifunctional 
DNA binding protein, BORIS, itself a CT-X antigen, is able to induce epigenetic 
reprogramming (Loukinov et al, 2006) and was shown to act as a potent activator for 
the expression of several MAGEA genes (Vatolin et al, 2005). In this context, 
deregulated BORIS (found in numerous human cancers) could contribute to the 
induction of MAGE expression in tumours. 
 
The precise role of MAGE antigens remains unclear, although Necdin, one of the 
Class II proteins, is thought to regulate growth and differentiation is certain cell types 
(Chapman & Knowles, 2009). The MHD is believed to act as a protein-protein 
interaction domain and MAGE antigens may act as scaffolding proteins to regulate 
the activity of key cellular proteins, including p53. In a study examining the 
involvement of MAGEA2 expression in the acquisition of resistance to etoposide, it 
was suggested that MAGEA2 protein acted to suppress wild-type p53 activity 
thereby protecting chemoresistant cells from apoptosis. MAGEA2 was shown to 
directly complex with p53 and recruit HDAC3 to repress p53 activity as a 
transcription factor (Monte et al, 2006). In a separate study, a number of class I 
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MAGE antigens (from the A, B and C subfamilies) were found to be able to interact 
indirectly with p53 via another scaffolding protein, the transcriptional co-repressor 
protein KAP1, again resulting in a suppression of apoptosis (Yang et al, 2007). 
 
The data above suggest that MAGE protein expression in tumours may therefore be 
associated with treatment failure. These more recent findings have added weight to 
the concept of using MAGE as targets for cancer immunotherapy. The absence of 
expression in somatic tissues, but induction in a variety of tumour types including 
melanoma, small cell lung carcinoma, germ cell tumours and also breast cancer 
(Caballero & Chen, 2009; Grigoriadis et al, 2009) makes MAGE proteins ideal 
tumour-specific antigens. However, the ability of MAGE antigens to induce 
spontaneous cytotoxic T-lymphocyte (CTL)-dependent immune responses in cancer 
patients particularly marks them out as useful targets for immunotherapy (Van den 
Eynde et al, 1995). Cancer vaccine phase II trials based on recombinant MAGEA3 
antigen are currently in progress for lung cancer and melanoma and show promise 
(Atanackovic et al, 2008; Caballero & Chen, 2009). Due to their high sequence 
homology, it is difficult to generate antibodies that can distinguish between MAGE 
subfamily members, therefore it is likely that tumours that express a range of 
MAGEA genes may potentially be targeted using this therapy. 
 
 
 
 
 
 
1.12. EGLN3 (Elg Nine Homolog 3) 
 
Hypoxia Inducible Factor (HIF), is the master transcriptional regulator of hypoxia-
induced gene expression and consists of a labile  subunit and a stable  subunit 
(also known as HIF or ARNT). In the presence of oxygen, HIF family members 
(ubiquitous HIF-1 or cell type-specific HIF-2) are hydroxylated at one of two 
conserved prolyl residues by members of the egg-laying-defective nine (EGLN) 
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family (also termed prolyl hydroxylase domain (PHD) proteins) which act as 
intracellular oxygen sensors. Prolyl hydroxylation generates a binding site for a 
ubiquitin ligase complex containing the von Hippel-Lindau (VHL) tumour 
suppressor protein, and results in HIF degradation via the proteasome. In addition, 
in the presence of oxygen, HIF function is modulated by asparagine hydroxylation 
by FIH (factor-inhibiting HIF), which inhibits HIF recruitment of the 
transcriptional coactivators p300 and CBP, and hence its function as a transcriptional 
activator. During hypoxia, EGLN/PHD activity decreases such that HIF degradation 
is blocked leading to the activation of 
its ~100 target genes including 
VEGF and GLUT1 (see Figure 1.6, 
reviewed Loboda et al, 
2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QuickTime™ and a
 decompressor
are needed to see this picture.
 61 
 
 
 
 
 
 
 
 
 
 
 
 
There are three known members in the EGLN/PHD family, EGLN1, EGLN2 and 
EGLN3 (Taylor et al, 2001), in human and mouse. The minimal HIF-derived 
peptides efficiently hydroxylated by these enzymes are typically long (19 mers), in 
contrast to the X-Pro-Gly peptides acted on by collagen prolyl hydroxylases (Hirsila 
et al, 2003). All three proteins have been reported to hydroxylate HIF and to have 
similar dependence on oxygen and the co-factors Fe (II) and 2-oxo-gutarate. EGLN1 
(PHD2) is considered to be the primary HIF prolyl hydroxylase under normal 
conditions (Ivan et al, 2008). It is possible that EGLN2 (PHD1) and EGLN3 (PHD3) 
regulate HIF under different conditions. EGLN3 is itself upregulated during 
hypoxia and is considered to be a HIF target gene. EGLN2 is primarily nuclear while 
EGLN3 is seen in both the cytoplasm and the nucleus (Metzen et al, 2007; Marxsen 
et al, 2004). 
 
Regulation of EGLN is associated with mitochondrial generated species (Chandel et 
al, 2010), nitric oxide (Metzen et al, 2003), (Sandau et al, 2001; Sandau et al, 2001), 
oncogenes v-src, activated ras and PI3K/AKT (Chan et al, 2002) and of course its 
own expression and stability. Of the three family members, less is understood about 
the role of EGLN3; it has been suggested to regulate apoptosis in neural cells and 
this may involve protein aggregation (Rantanen et al, 2008). In addition, a non-HIF 
hydroxylation target, ATF4, has been reported for EGLN3 (Koditz et al, 2007).  
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The ability to withstand prolonged hypoxia is one of the hallmarks of tumours.  
Numerous studies that have reported aberrant activation of HIF in many tumour 
types and several key HIF target genes are associated with the induction of tumour 
angiogenesis. Consequently, strategies to target HIF in tumours are actively being 
explored (reviewed, Semenza, 2010). The expression of the EGLN proteins has also 
been associated with cancer, in particular EGLN2 has been shown to be oestrogen 
regulated in breast cancer and associate with tamoxifen resistance (Seth et al, 2002). 
More recently, EGLN2 was found to promote proliferation in breast and other tumour 
cell lines in a cyclin D1-dependent, but HIF-independent manner, thereby suggesting 
that small molecule inhibitors of these enzymes currently in development may have a 
role in cancer therapy (Zhang et al, 2009). 
1.13. Aims of Project 
The project is aimed at elucidating the mechanism and genes responsible for 
tamoxifen resistance (TR). The study will be done on in vitro TR breast cell lines and 
human TR breast tissue.  
Cell line study: 
1) Generate in-house TR and oestrogen-deprived (OD) versions of ER+ve cell 
lines T47D and ZR75-1.  
2) Perform gene profiling on Affymetrix HU133 plus 2.0 gene chips on RNA 
from T47D, ZR75-1 and the OD T47D, ZR75-1 cell lines that have been 
transformed into TR. 
3) Compare data with that previously obtained using WT and TR MCF-7 cells. 
4) Validate genes with significantly differentiated expression from profiling 
using real-time PCR (qPCR). Immuno-histochemistry (IHC). 
5) Functional study on biologically relevant/interesting genes by stable 
overexpression in tamoxifen sensitive breast lines to determine their effect 
(+/- tamoxifen) on proliferation, migration, invasion in vitro and if possible in 
xenograft studies. 
6) Determine the relationship of functionally validated gene(s) with response to 
tamoxifen in tumour samples from ER+ve tumours of known outcome on 
tamoxifen monotherapy (see point 3 below). 
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Human TR Breast Cancer Tissue: 
1) Our study aims to determine a set of genetic markers that is predictive of the 
response tamoxifen therapy using EXON expression arrays and genome-wide 
SNP6.0 Affymetrix chips.  
2) The study will be done on a small (n=25 specimens) but unique series of 
fresh frozen samples (training set) from Guys and St Thomas / King‟s 
College London (GSTFT/KCL) Breast Tissue Bank). Cases were selected 
from patients participating in the European Oncology Research Trial 
Consortium (EORTC) 10850 & 10851 studies under the LREC Ref 
06/Q0603/25. The samples are from patients with a known response to 
tamoxifen and for whom complete clinical follow-up is available. 
3) The selected predictive gene-sets will be validated using qPCR and IHC on 
129 validation cases from the same EORTC trial and an independent TMA 
from Bart‟s and the London hospital, for which we have the complete clinical 
follow up data.  
 
In conclusion, the study aim to find predictive markers which are dependent and 
independent on Oestrogen Receptor (ESR1) co-expressed genes for the response 
to tamoxifen. From the TR cell line study, I hope this study will reveal the escape 
mechanisms from the effect of tamoxifen, which may shed light on pathways 
which account for tamoxifen resistance. 
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CHAPTER 2:  MATERIALS AND METHODS 
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2. Cell Culture 
2.1. Mammary Lines 
Cell lines were cultured as described in Table 2.1.  All cells were regularly passaged 
to maintain exponential growth.  Mammary cell lines T47D and ZR-75 were grown 
in DMEM with 10% charcoal stripped Foetal Calf Serum at 10% CO2. These were 
grown for six months and labelled Oestrogen Deprieved (OD) T47D and OD ZR-75.  
All cells were regularly screened for Mycoplasma sp. contamination.  
Cell Line Description Media 
MCF-7 
(WT) Tenovus 
Mammary Carcinoma DMEM, 10% Foetal Calf Serum. 
ZR75-1 Mammary Carcinoma RPMI, 10% Foetal Calf Serum. 
T47D Mammary Carcinoma DMEM, 10% Foetal Calf Serum. 
OD ZR75-1 Mammary Carcinoma 
RPMI, 10% charcoal-stripped Foetal Calf 
Serum. 
OD T47D Mammary Carcinoma 
DMEM, 10% charcoal-stripped Foetal Calf 
Serum. 
Table 2.1 List of cell lines and cell culture conditions. MCF-7 and T47D were 
grown in 10% CO2 at 37
o
C.  ZR75-1 were grown in 5% CO2 at 37
o
C. 
2.1.1. Tamoxifen Resistant Breast Cell lines 
The above cell lines were generated by growing in media containing 10
-7
 M 
hydroxyl-tamoxifen. These were grown for six months with regular media changes 
and labelled Tamoxifen Resistant (TR). 
Cell Line Description Media 
MCF-7 
(Tenovus) TR 
Mammary Carcinoma DMEM, 10% Foetal Calf Serum and 10
-7
 
M hydroxy-tamoxifen. 
ZR TR Mammary Carcinoma 
RPMI, 10% Foetal Calf Serum and 10
-7
 M 
hydroxy-tamoxifen. 
T47D TR Mammary Carcinoma 
DMEM, 10% Foetal Calf Serum and 10
-7
 M 
hydroxy-tamoxifen. 
OD ZR TR Mammary Carcinoma 
RPMI, 10%charcoal-stripped Foetal Calf 
Serum and 10
-7
 M hydroxy-tamoxifen. 
OD T47D TR Mammary Carcinoma 
DMEM, 10% charcoal-stripped Foetal Calf 
Serum and 10
-7
 M hydroxy-tamoxifen. 
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2.2. RNA Interference 
2.2.1. siRNA Selection 
Initially sequences specific to MageA2 were selected for the generation of siRNA 
oligonucleotides based on published suggestions (Yang et al., 2007b).  Also used 
was pool of four siRNAs, based on highly conserved MageA2 sequence 
(SMARTpool; Dharmacon Research). These oligonucleotides were able to knock 
down all tested MageA genes (MageA1,-A2,-A3, and –A6; data not shown). BLAST 
searches were performed to verify the MageA2 specificity. A non-specific random 
sequence, Allstar negative control (Qiagen) was used for a non-silencing control. 
These siRNA target sequences are detailed in Table 2.2 and 2.3.   
Target Name Target Sequence 5‟ - 3‟ 
Mage-A2 
Mage-A2_1 AUUCGUUCACAAUAUAGGCUU 
Mage-A2_2 UCUCCACCGAUCUUUAGUGUU 
Mage-A2_3 GUCCUGGCAAUUUCUGAGGUU 
Mage-A2_4 UAUCACACGAGGCAGUGGAUU 
Mage-A2B 
Mage-A2B_1 AUUCGUUCACAAUAUAGGCUU 
Mage-A2B_2 UCUCCACCGAUCUUUAGUGUU 
Mage-A2B_3 CCUCAGAAAUUGCCAGGACUU 
Mage-A2B_4 UAUCACACGAGGCAGUGGAUU 
Non Silencing Control 
siRNA 
All star 
negative 
control 
AATTCTCCGAACGTGTCACGT 
Table 2.2 siRNA Target Sequences.  The non-specific random sequence (Qiagen) 
was used for a non-silencing control for transient transfection.   
 
Catalogue Number Name GenBank code 
J-006350-09, -10, -11, -12 
Human 
MAGEA2 
NM_175742 
J-019148-09, -10, -11, -12 
Human 
MAGEA2B 
NM_153488 
Table 2.3 MageA2 siRNA targeting sequences from Dhamacon.  The sequence is 
identical to that shown in Table 2.2. 
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2.2.2. Transient Transfection of siRNA 
Oligonucleotides 
T47D TR and OD T47D TR cells at 60 % confluency were transfected in six well 
plates using Oligofectamine as per the manufacturer‟s instructions (Invitrogen).  
Briefly the siRNA was diluted in DMEM to a volume of 185l.  At the same time 
3l of Oligofectamine reagent was diluted in 12 l of DMEM, and allowed to 
equilibrate for 5-10 minutes. The diluted transfection reagent was then added the 
diluted siRNA, mixed by inversion and incubated at room temperature for 20 
minutes.  Following two washes of cells in PBS, 800l of DMEM was added per 
well.  The transfection complexes were then added to the cells and incubated at 37
 
oC. Four hours later 500μl of 3x Complete Medium (DMEM + 10% FCS) was added 
per well, and Mage-A2 knock down was assayed at time points thereafter.  All the 
siRNA concentrations referred to in this report represent the final siRNA 
concentration in 1ml, the volume in which transfection complexes were incubated on 
the cells for 4 hours.   
 
2.2.3. Transfection via Nucleophoresis using 
Amaxa Nucleofector 
The same siRNA from Dharmacon were also transfected via the Amaxa 
Nucleofection method. The optimised protocol can be found on the Amaxa company 
website (Amaxa, url). The Amaxa nucleofection kit came with Nucleofection 
Equipment with the appropriate software installed, (Ver V2.4 for Nucleofector 1 
Device), was available and a kit containing the Nucleofector solution and 
suppliment, pmax GFP (as a positive control) and curvettes was purchased.  
 
1 X 10
6 
T47D TR cells were needed for each well of the 6-well plates used. These 
cells are harvested, trypsinised and gently spun down at 1000 G for 1 minute in a 
15ml falcon tube. The media was removed by vacuum suction and the pellet left 
undisturbed. Meanwhile, the media and nucleofector solution is equilibrated to room 
temperature. The cells are resuspended in 100µl of Nucleofector solution and 
supplements followed by the addition of 0.5-3µg of siRNA, in this case 3µg of 
MageA2 siRNA was found to be optimal. The nucleofector sample is transfered into 
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an Amaxa certified curvette placed in the curvette holder and the program is started. 
T47D cell lines require the X-05 or the X-005 program. The cells were then 
immediately removed and 900µl of pre-warmed culture medium was added to the 
curvette and the total volume of approximately 1000µl is now seeded into each well 
of a 6-well plate containing 1ml of medium per well. The final volume per well is 2 
ml. Cells are incubated at 37ºC and 10% CO2. The cells were than incubated for 24 
hours before lysis and whole cell extraction. 
2.2.4. Generation of Stable MageA2 
Expression Clones  
The MAGEA2  (Clone ID: 8327628) coding sequence was obtained in the pCR4-
TOPO vector from the IMAGE Consortium. The insert was excised using an EcoRI 
restriction digest and cloned into the pcDNA3.1 expression vector, which carries a 
strong mammalian promoter, CMV (cytomegalovirus) and also the Neomycin 
(G418) selection marker. Prior to this, an optimisation experiment of ascending doses 
(200mcg, 300mcg, 400 mcg, 500 mcg, 600 mcg/ml of media) of G418 concentration 
was undertaken to determine the dose just below the kill-dose of specific breast 
cancer lines. Cells were left in G418 containing media for 48 hours. 
An outline of the strategy used to achieve this is shown in Figure 2.1 and the map of 
the final clone is shown in Figure 2.2. 
2.2.4.1.  Enzyme digestion 
All restriction enzymes (RE) used for DNA digestion and related buffers and 
solutions used were supplied by New England Biolabs (NEB). In most cases, 1µg of 
DNA was digested with 1Unit of restriction enzyme in 1× enzyme buffer in a total 
volume of 20µl for 1h at 37ºC. Small aliquots were run on an agarose gel to confirm 
digestion. 
2.2.4.2. Agarose Gel Electrophoresis 
Enzyme digests were analyzed by agarose gel electrophoresis. 20µl of the samples 
were loaded in wells alongside DNA ladder (Hyperladder 1, Bioline) and the gel was 
run for 1h at 100V for optimal separation. In order to make the gel, agarose powder 
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(1%) was added to 1X TBE (108g Tris base/55g Boric Acid/9.3 EDTA in 1L of 
H2O), and dissolved by boiling. 0.5µg/ml of ethidium bromide was added to the gel 
to facilitate visualization of DNA fragments under UV light. Fragments of 
appropriate size (MAGEA2, 1kb, see Results) were excised from the gel and purified 
using Zymoclean Gel DNA Recovery kit.  
2.2.4.3. Ligation  
Linearized expression vector pcDNA3.1 (previously dephosphorylated using Shrimp 
Alkaline Phosphatase in 1× USB RX SAP buffer) was incubated overnight at 16ºC 
with T4 DNA ligase (1µl), insert and T4 DNA Ligase buffer in a total volume of 
20µl. A control reaction with no insert was also prepared. The relative ratio of insert 
to vector was 3:1.This ratio was calculated as follows: amount of vector used (ng) 
was multiplied by the size of the insert (Kb) and the product was divided by the size 
of the vector (Kb). 
2.2.4.4.  Transformation 
2 l of the ligation reaction was transformed into competent E.coli. The protocol is 
as follows: Add 20l ligation reaction to 50l competant cells. Incubate on ice for 5-
30 min. Heat shock for 30 sec at 42ºC, incubate on ice for 2 min. Add 250 µl SOC 
buffer and incubate at 37ºC for 1 hour. 20µl from each transformation was plated on 
a prewarmed agar plate (LB medium +Amplicilin) and incubated overnight at 37 to 
select for positive clones. Next day individual colonies from agar plates were picked 
and placed into separate tubes containing 5ml LB + Ampicilin to grow up. 
2.2.4.5. Maxiprep and Miniprep 
Isolation of small or large quantities of plasmid DNA was achieved by using 
Miniprep or Maxiprep Qiagen kit, respectively, by following the manufacturer‟s 
instructions. 
2.2.4.6.  In vitro translation 
1µg of designed construct, pcDNA3.1/MAGEA2, and 2µg of the control plasmid, 
encoding luciferase (Promega), was used for mRNA synthesis, and the translation 
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reactions were carried out according to the manufacturer‟s instructions using the TnT 
Coupled Reticulocyte Lysate System (Promega). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  Cloning strategy (A) Sub-cloning stages where MAGEA2 on TOPO4 
vector (from the IMAGE consortium) is propagated then amplified by miniprep. The 
MAGEA2 insert is then removed after digested by EcoR1. The construct MAGEA2 
is purified. (B) MAGEA2 is then transferred into vector pcDNA3.1 after pcDNA3.1 
is digested and ligated with MAGEA2. Finally the presence and orientation of the 
insert was verified by EcoR1 and Bgl-11. 
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The orientation of the MAGEA2 insert was determined by a Bgl II digest. This 
enzyme cuts once within the insert (see Figure 8B) and once in the vector. Clones in 
the correct orientation should give a band of 1.7 Kb as shown in Figure 3A for the 
clones in lanes 1, 3, 5 and 7.One of these was selected and prepared for further 
experiments. 
 
Figure 2.2  Characterisation and structure of the MAGEA2 expression plasmid.  
A) Bgl II restriction mapping of 12 miniprep test clones of pcDNA3.1/MAGEA2. 
The samples were separated on a 1% agarose gel. B) Map of the final expression 
construct with MAGEA2 cloned into EcoRI site at position 926 in pcDNA3.1. Bgl II 
cuts pcDNA3.1at 13bp and also cuts asymmetrically within the 1025bp EcoRI 
MAGEA2 insert as shown. Thus, pcDNA3.1/MAGEA2 cut with Bgl II will give a 
fragment of 1.7Kb or 1.2Kb depending on the orientation of the MAGEA2 insert. The 
plasmid constructs that have the correct orientation are those with a 1.7Kb Bgl II 
fragment. 
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2.3. Western Blotting 
2.3.1.  Whole Cell Extracts 
Cells were lysed using extract buffer (8M Urea, 1M Thiourea, 0.5% CHAPS, 24mM 
Spermine, 50mM DTT). Extracts were collected using cell scrapers. The 
approximate protein content of each extract was determined using the Bradford 
Assay (Biorad) and a BSA standard curve ranging from 0 – 20μg/ul. Typically 5g 
of whole cell extracts were used in SDS PAGE. 
2.3.2. SDS PAGE and Western Blotting 
Samples were separated on 6-12% SDS PAGE gels prepared with the BioRad Mini 
Protean system. Full range molecular weight Rainbow Markers (Amersham) were 
loaded to allow size determination of detected proteins.  Separated proteins were 
transferred onto a nitrocellulose membrane (Amersham) using semi-dry blotting 
apparatus (Biorad).  The membrane was blocked (5% Marvel 0.1% Tween-20 in 
PBS) for an hour at room temperature. The primary antibody was diluted in blocking 
solution and incubated with the membrane for an hour at room temperature.  The 
membranes were washed in blocking solution twice and a further 3 times in PBS / 
0.1% Tween-20 to remove excess secondary antibody. Supersignal WestFemto 
reagent (Pierce) was used for chemiluminescence and the membrane was exposed on 
autoradiograph film.  A summary of the antibodies used is shown in Table 2.4. 
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Antigen Animal origin Source Dilution 
Mage-A  (pan-A) Mouse  Zymed 1:500 
Mage-A2 (3ES) Mouse Santa Cruz 1:200 
Mage-A2 Rabbit Abcam 1:100 
PgR Mouse  Santa Cruz 1:200 
PgR Mouse Dako 1:100 
ErbB2 Rabbit Cell Signalling 1:1000 
Egln3 Mouse Gift from Peter Ratcliffe 1:20 
KAP1 Rabbit Abcam 1:500 
Egln3 Mouse Peter Ratcliff, Oxford 1:30 
HDAC3 (B-12) Mouse Santa Cruz 1:500 
p53 (DO-1) Mouse  Santa Cruz 1:500 
Acetyl-p53 Rabbit Cell Signalling 1:1000 
Phospho-p53 (Ser 15) Rabbit Cell Signalling 1:1000 
Phospho-p53 (Ser 20) Rabbit Cell Signalling 1:1000 
Phospho-p53 (Ser 46) Rabbit Cell Signalling 1:1000 
Phospho-p53 (thr 18) Rabbit Cell Signalling 1:1000 
Phospho-p53 (Ser 37) Rabbit Cell Signalling 1:1000 
PARP-1 Mouse Santa Cruz 1:250 
THRAP5 Rabbit Abcam 1:100 
v-Myb Mouse Abcam 1:500 
VGLL1 Rabbit Abcam 1:50 
PDZK1 Mouse Abcam 1:100 
HnRNPA2B1 Mouse Abcam 1:100 
HDAC3 Mouse Santa Cruz 1:100 
ER (HC-20) Rabbit Santa Cruz 1:500 
Inhibin A Mouse R&D systems 1:10 
Ku-70 (C19) Goat  Santa Cruz 1:1000 
Myc (9E10) Mouse Santa Cruz 1:500 
p21 (DCS60) Mouse Cell Signalling 1:1000 
p27 (# 2552) Rabbit Cell Signalling 1:1000 
p53 (DO1) Mouse  Santa Cruz 1:1000 
p300 (N-15) Rabbit Santa Cruz 1:500 
GAPDH Mouse  Santa Cruz 1:100 
PCNA Rabbit Santa Cruz 1:1000 
 
Table 2.4  List of antibodies and their dilutions for Western blotting. 
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2.4. Fresh frozen tissue for microarray study 
Fresh frozen tissues from 25 patients for the microarray studies came from the 
EORTC 10850 & 10851 trial and generously donated to us by Guys and St Thomas / 
King‟s College London (GSTFT/KCL) Breast Tissue Bank the Tissue Bank for the 
study of tamoxifen resistance in breast cancer (Ethnic approval number LREC Ref 
06/Q0603/25). All cases were Oestrogen-receptor positive (ER-positive). They were 
all treated with tamoxifen after surgery. These cases are unique for the reasons 
below: 
1) The patients, which we have defined as tamoxifen Sensitive, were patients who 
had positive surgical margins (i.e. incomplete resection) after their primary breast 
surgery. These patients chose not to return to have a repeat resection. The treatment 
with tamoxifen led to long-term survival. They are „true‟ sensitive cases. 
2) The patients, which we have defined as tamoxifen Resistant, were patients who 
had primary surgery and then adjuvant tamoxifen treatment and relapsed/had a 
recurrent within 2 years. 
3) All their clinical follow-up (1984-1991) data is complete. They were randomised 
to receive either lumpectomy or radical mastectomy followed by tamoxifen 20mg 
daily. No further treatment for their diagnosis of breast cancer. 
4) In the 25 samples, 3 patients had paired samples; where frozen tissues from 
primary surgery and relapsed stage were obtained. The relapsed fresh tissues will 
give informative microarray data, which will represent the tamoxifen-resistance 
mechanism better. 
 
Ten normal breast tissues were donated by Prof Louise Jones for normalisation 
(LREC Ref 05Q403/199). 
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2.5. RNA extraction 
2.5.1. Extraction of total RNA from tissue 
samples 
Total RNA was isolated from tissues with TRIzol Reagent (Invitrogen Life 
Technologies) according to the manufacturer‟s protocol. Briefly, 50 mg of each 
frozen tissue was homogenized in 1 ml of TRIzol Reagent (Invitrogen) using a power 
homogenizer (IKA ULTRA-TURRAX, T25 basic). After centrifugation at 12,000 g 
for 10 min at 4
o
C the supernatant was transferred to a fresh tube and the content was 
sheared 10-20 times using a 20gauge needle/syringe in order to fragment genomic 
DNA. 0.2 ml of chloroform was then added per 1 ml of TRIzol reagent and mixed by 
vigorous shaking for 15 seconds. Following centrifugation at 12,000 g for 15 minutes 
at 4
o
C, the colourless upper aqueous phase was collected. Subsequently, 0.5 ml of 
isopropyl alcohol was added per 1 ml of TRIzol Reagent and incubated at -20
o
C for 
20 minutes. After spinning at 12,000 g at 4
o
C for 10 minutes the supernatant was 
removed and the RNA pellet was washed with 1 ml of cold 75% ethanol and spun at 
7,500 g for 5 minutes at 4
o
C. The supernatant was carefully removed and the pellet 
was air-dried for 5-10 minutes then dissolved in diethyl pyrocarbonate (DEPC)-
treated water.  
 
2.5.2. Extraction of total RNA from cell lines 
Cells were washed twice with ice cold PBS. In each well of a six well plate 250μl 
TRIzol reagent (Invitrogen) was added to the cells and incubated for 5 minutes at 
room temperature. TRIzol extracts were collected using cell scrapers. 50μl 
chloroform was added per 250μl TRIzol, vortexed for 15 seconds, and then incubated 
for 2-3 minutes at room temperature. Samples were then centrifuged at 12,000g for 
15 minutes at 4˚C and the aqueous upper phase was transferred to a new 
microcentrifuge tube.  An equal volume of 70% ethanol was added and mixed by 
pipetting.  The mixture was applied to an RNeasy Mini column (QIAGEN) then 
centrifuged for 15 seconds at 8000g.  RNA clean-up was followed using the 
manufactures instructions, including the DNAse I digestion step. The RNA 
concentration was estimated by spectrophotometer and formaldehyde-MOPS 
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denaturing agarose gel electrophoresis was then used to assess RNA quality. All 
extracted RNA were quantified and quality checke by BioAgilent NanoCHIP 2100 
Bioanalyzer. (Agilent, url) 
2.6.  DNA extraction 
High-quality DNA was extracted from small amount 10mg of breast tissue using the 
DNA easy Micro Kit (Qiagen). DNA was quantified and qualified by NanoDrop ND-
1000 Spectrometer (NanoDrop Technologies). DNA was also checked via agarose 
gel electrophoresis. 
2.7. Gene Expression Microarrays 
2.7.1.  The Affymetrix GeneChip 
All experiments were performed using Human Genome U133 Plus 2.0 high-density 
oligonucleotide arrays (Affymetrix, url).  Oligonucleotides of 25 base pairs in length 
are used to probe message levels in the samples. Each gene of interest is represented 
by a set of oligonucleotides comprised of 11 probe pairs. Each probe pair is 
composed of a perfect match (PM) probe against a section of the mRNA molecule of 
interest, and a mismatch (MM) probe that is created by changing the middle (13th) 
base of the PM with the intention of measuring non-specific binding. The HG-U133-
Plus2 array contains 54,000 probe sets, representing an estimated 47,000 human 
transcripts.  
 
2.7.2.  Target Preparation, Microarray 
Hybridisation, Staining and Scanning 
High quality RNA from each sample was used to prepare biotinylated target RNA, 
according to the manufacturer‟s recommendations (Affymetrix, url). An overview of 
this procedure is shown in Figure 2.3.  Briefly, 5µg of total RNA was used to 
generate first-strand cDNA by using a T7-linked oligo(dT) primer. After second-
strand synthesis, in vitro transcription was performed with biotinylated UTP and 
CTP, resulting in approximately 100-fold amplification of RNA.  This labelled 
cRNA target was quantified and then fragmented before preparation of the 
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hybridisation cocktail. Spike in controls were added to the fragmented cRNA (15µg 
per HG-U133Plus2 array), before overnight hybridisation. Arrays were then washed 
and stained with streptavidin-phycoerythrin, before being scanned on an Affymetrix 
GeneChip 3000 scanner. After scanning, array images were assessed by eye to 
confirm scanner alignment, the absence of significant bubbles or scratches on the 
chip surface, and the absence of slides with very high background (scanning and 
image analysis was performed by Tracy Chaplin, Institute of Cancer, Charterhouse 
Square).   
2.7.3. Data Analysis 
2.7.3.1.    Quality Control 
Quality Control of the probes prepared were analysed by Affymetrix Console® 
(Publicly made available software by Affymetrix launched in 2007). In order to 
ensure the arrays fulfilled a series of Affymetrix recommended quality control 
metrics (described in detail in the Data Analysis Fundamentals Manual, Affymetrix, 
url), the raw data were pre-processed using the “simpleaffy” BioConductor package.  
Simpleaffy uses the Affymetrix MAS 5.0 array processing algorithms (described in 
detail below in section 2.7.3) to provide access to these metrics.   
2.7.3.2.    Data Analysis 
Data analysis was performed using BioConductor (Gentleman et al., 2004) and 
Partek® Genomic Suite (Version 4.0) software.  BioConductor is an open 
development software project, providing access to a wide range of statistical and 
graphical approaches for the analysis of genomic data. It works through the R open 
source programming language (Ihaka and Gentleman, 1996).  Data was processed 
from the *.CEL file format which contains information on background values and 
perfect match and mismatch intensities.  Data processing was done using “affy” 
(Gautier et al., 2004) and “simpleaffy” (Wilson & Miller, 2005) packages in 
BioConductor. 
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Figure 2.3 Affymetrix GeneChip Eukaryotic Sample and Array Processing. A 
more detailed description of this procedure can be found in Section 3: Eukaryotic 
Sample and Array Processing of the GeneChip Expression Analysis Technical 
Manual (Affymetrix, url).   
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2.7.3.2.1.  Average background 
The average background is the level of signal detected by the scanner surrounding 
the signal from the specific features. No Affymetrix guidelines are suggested for 
average background only that the values are similar and typically in the range of 20 
to 100. Any arrays with unusually high background would be discarded from this 
analysis following the visual inspection.  
2.7.3.2.2. Scale factor 
Before the data from different arrays can be compared, a global normalisation 
method needs to be conducted in order to minimise variation between arrays. 
Variation is caused by biological and experimental factors throughout the microarray 
protocol, starting from the sample preparation and ending with data acquisition.  The 
scaling or normalisation factors should be comparable among arrays.  A large 
discrepancy scale factor (3 fold or greater) may indicate significant assay variability 
or sample degradation leading to poor quality data. 
2.7.3.2.3. 3’ to 5’ ratios for β-actin and 
GAPDH  
β-actin and GAPDH are used to assess RNA sample and assay quality. Specifically, 
the intensities of the 3‟ probe sets for β-actin and GAPDH are compared to the 
intensities of the corresponding 5‟ probe sets. The ratio of the 3‟ probe set to the 5‟ 
probe set should generally be no more than 3 for the targets prepared using the one 
cycle target labelling procedure described in Figure 2.3.  A high 3΄ to 5΄ ratio 
indicates degraded RNA or inefficient transcription of cDNA or biotinylated cRNA. 
 
In addition to the “simpleaffy” quality control measures described above, target 
cRNA quality was also assessed using the array-by-array cRNA digestion plot 
produced using the “affy” BioConductor plotAffyRNAdeg function.  This averages 
individual probe intensities by their location in each probe set and following a 
scaling transformation an average can then be taken over all probe sets on the array.  
A side-by-side plot of these averages, then illustrates any global patterns of 5‟ to 3‟ 
probe intensity.  Any abnormally low levels of 3' intensity would illustrate a 
degraded RNA or inefficient transcription of cDNA or biotinylated cRNA.   
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2.7.3.3.   Data Correction, Normalisation 
and Transformation 
After careful consideration of the quality control measures described above the 
correction, normalisation and transformation of raw array data took place, following 
a four-step process of Background Correction, Normalisation, Perfect Match (PM)/ 
Mismatch (MM) Correction and Summarisation.  The data analysis was performed 
using the “affy” BioConductor package using the expresso function.  In order to 
establish the most appropriate method for the microarray experiments performed in 
this study, the Affymetrix recommended mas5 method (Affymetrix, url) was 
assessed along with variations of the Robust Multi-array Average (RMA) process 
(Irizarry et al., 2003), specifically altering Background Correction and PM/MM 
Correction steps.  The detail of each method used is described below.  
 
Background correction 
Background correction is the process of correcting probe intensities on an array by 
subtracting the background level of signal detected by the scanner.  The following 
approaches were assessed. 
 none – no background correction. 
 rma - Developed by Irizarry and colleagues, this correction uses a model that 
assumes observed intensity is the sum of an exponential signal component and a 
linear noise component. PM probe intensities are corrected using a global model 
for the distribution of probe intensities (Irizarry et al., 2003).   
 mas5 – This is the method recommended by Affymetrix (Affymetrix, url), where 
a chip is broken into subgrids, and background is calculated for each region 
based on the lowest 2% of probe intensities. For each region, a weighted average 
background value is calculated using the distances of the probe location and the 
areas surrounding the probes of the different regions. Individual probe intensity is 
then adjusted based upon the average background for each region.  
 GC Robust Multichip Analysis (GC RMA) – Developed and further improvised 
version of the RMA for exploration, normalisation and summarisation of high-
density oligonucleotide probes level data. 
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 Model based Expression Index (MBEL, dCHIP) – Developed by Li and Wang 
(PNAS, 2001, 98(1); 31-36) to calculate expression index computation and 
outlier detection. 
 
Normalisation Methods 
Normalisation is the process of removing non-biological variability between arrays. 
All global normalisation methods work on the assumption that there is no variability 
between different microarrays. Here, we used mas5 - developed by Affymetrix 
which uses a global scaling factor in order to normalise the data between each 
microarray. A scaling factor is calculated based on the average of all the intensities, 
after removing the intensities in the lowest 2% and highest 2%. This factor is then 
used to correct the intensities across all the probe sets on all the arrays.   
 
Perfect Match / Mismatch Correction 
PM correction is the process of adjusting PM intensities based on information from 
the MM intensity values. 
pmonly - No PM/MM correction was performed and only PM values were used for 
analyses. It is widely reported that MM probesets may be detecting signal as well as 
non-specific binding and therefore including the MM parameter will contribute to the 
overall noise in the data analysis (Naef et al., 2002; Irizarry et al., 2003).   
mas5 – Recommended by Affymetrix, in this method an ideal MM value is 
subtracted from the PM intensity value, always leaving a positive value. An 
“artificial” mismatch value is computed when the MM intensity is greater than or 
equal to the PM and results in a PM-MM that is close to zero.  
 
Summarisation Method  
In order to combine the pre-processed probe intensities together in order to compute 
a single expression measure for each probe set on the array, a summarisation method 
was employed  
medianpolish – Described by Irizarry and colleagues (Irizarry et al., 2003), median 
polish uses a multi chip linear model fitted to the data from each probe set and the 
result value is in log2 scale.  
mas5 – Recommended by Affymetrix uses a robust average using 1-step Tukey bi-
weight on log2 scale. 
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2.8.  Exon Array 
2.8.1. The Affymetrix GeneChip®Whole 
Transcript (WT) Sense Target Labeling Assay  
 
All experiments were performed using Human Gene®Chip Exon 1.0 ST Array 
designed to generate amplified and biotinylated sense-strand DNA targets from the 
whole transcript without bias (Affymetrix, url). The WT Assay is not compatible 
with Gene®Chip arrays designed to focus on the 3‟ ends of transcriptions, such as 
the Human Gene®Chip HU 133 plus 2.0.   
Human U 133 plus 2.0 Human GeneChip Exon 1.0 ST 
1.3 Million probes 5.3 Million probes 
54,000 probe sets 
1.4 Million probe sets 
(284,000 core, 523,000 extended and 580,000 full) 
11 Perfect Match (PM)/Mismatch (MM) probe pairs 4 Prefect Match (PM) probes per probe set 
Interrogated strand is ANTISENSE SENSE 
3‟ end of the mRNA 
Whole Transcript level 
(Random Hexamer primers) 
Hybridising intensity =  (PM)- (MM) 
 targeting the 3‟ end 
Detection above background (DABG) 
Which is comparing the PM with the background 
probes 
Few different algorithms used; Robust Multiarray 
Average (RMA), Microarray Suite (MAS 5.0) 
Only Probe Logarithmic Intensity error (PLIER) 
Is used to minimised error at low and high 
abundance 
11micron per feature size  5 micron per feature size 
 
Table 2.5 Table comparing the Affymetrix HU 133 plus 2.0 chip with 
Affymetrix Human Gene Chip Exon 1.0 ST. 
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2.8.2. Sense Target Preparation, Microarray 
Hybridisation, Staining and Scanning 
The Affymetrix GeneChip Whole Transript (WT) Sense Target Labelling assay is 
designed to generate amplified and biotinylated sense-strand DNA targets from the 
entire expressed genome without bias. The „Sense Target‟ prepared with this assay, 
and the probes on the arrays have been selected to distribute throughout the entire 
length of each transcript. 
 
In my study, I have used the 100ng protocol for the reasons that our main interest is 
in the gene-level analysis and that the frozen tissue specimens we have were of small 
quantity.  
 
For more information regarding the performances of the two protocols on Gene 1.0 
ST Array refer to the Whole Transcript Sense Target labelling Assay Performance 
white paper on the Affymetrix website. 
 
As outlined in Figure 2.3, the two protocols merged where double-stranded cDNA is 
synthesized with random hexamers tagged with T7 promoter sequence. The double- 
stranded cDNA is subsequently used as a template and amplified by T7 RNA 
polymerase producing many copies of antisense cRNA. In the second cycle of cDNA 
synthesis, random hexamers are used to prime reverse transcription of the cRNA 
from the first cycle to produce single-stranded DNA in the sense orientation. 
 
In order to reproducibly fragment the single-stranded DNA and improve the 
robustness of the assay, a novel approach is utilised where dUTP is incorporated in 
the DNA during the second-cycle, first-strand reverse transcription reaction. This 
single-stranded DNA sample is then treated with combination of uracil DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1(APE 1) that 
specifically recognises the unnatural dUTP residues and breaks the DNA strand. 
DNA is labelled by terminal deoxynucleotidyl transferase (TdT) with the Affymetrix 
 proprietary DNA Labeling Reagent that is covalently linked to biotin. 
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Figure 2.4 Affymetrix Exon GeneChip (WT) Sense Targeting 1.0 Eukaryotic 
Sample and Array Processing. A more detailed description of this procedure can be 
found in Section 4: Eukaryotic Sample and Array Processing of the Exon 
GeneChip Expression Analysis Technical Manual (Affymetrix, url).   
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2.8.3. Differential Gene Expression Analysis 
for both HU133 plus 2.0 and Exon GeneChip 
WT ST1.0 Arrays 
Filtering 
Expression profiling experiments used to identify genes that change their expression 
between two groups. Therefore, it is important to first filter the data to include only 
those probe sets that change in expression.  A commonly used method is to filter 
genes based on the fold change between the test and reference groups.  However, 
when filtering on fold change there is a risk of ignoring genes that change 
significantly but are below the arbitrary fold change threshold.  A more biologically 
sensitive method is to order genes from low to high standard deviation, in order to 
identify the most variable genes across the conditions analysed.  The top 2500 (for 
HU 133 plus2.0) and 10000 (for Human Exon 1.0 ST) probe sets with highest 
variance can then be used in clustering and statistical testing. 
 
Hierarchical Clustering  
Hierarchical clustering analysis allows the monitoring of overall patterns of gene 
expression between the normalised arrays, and uses standard statistical algorithms to 
arrange the genes according to a similarity in gene expression patters. The 
hierarchical clustering was performed using Partek® Genomic Suite, based on the 
approach used by Eisen and colleagues (Eisen et al., 1998). The hierarchical 
clustering analysis aimed to produce a map of results where probe sets were grouped 
together based on similarities in their patterns of normalised expression across all of 
the microarrays.  The similarity or dissimilarity between a pair of objects in the data 
set was found by evaluating a distance measure and assuming a normal distribution 
of gene expression values, it is appropriate to use the Pearson correlation coefficient, 
which calculates the similarity measure based on a linear model. The objects are then 
grouped into a hierarchical cluster tree (dendrogram) by linking newly formed 
clusters. The same algorithms can then be applied to cluster the experimental 
samples for similarities in the overall patterns of gene expression. Hierarchical 
clustering analysis was preformed on the normalised and filtered gene expression 
data. 
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Statistical Analyses 
This process involves the identification of diferentially-expressed genes between 
different experimental conditions.  The Welch‟s t-test was applied on filtered data 
using the one-way ANOVA setting in Partek® Genomic Suite.  This is a parametric 
test that works on the assumption that log intensity of microarray data are normally 
distributed.  Another common assumption of parametric statistical analyses, such as 
Student‟s t-test, is that the variability of a gene is constant across treatment types.  
This is difficult to assess for microarray data, so it is safest to assume that variance 
may differ between treatment and control. Welch's t-test corrects for difference in 
variability, and does not detect it, therefore is more suitable for microarray data 
differential gene expression analysis.  In a conjunction with this test a False 
Discovery Rate (FDR) multiple test correction was applied across the significant 
genes using GeneSpring.  Multiple testing corrections adjust p-values to correct for 
occurrence of false positives. False positives are genes that are identified as 
significant changes following statistical tests, when their true state is unchanged. A 
False Discovery Rate of 5% (p-value <0.05) on an array of 54000 reporters would 
mean that on any size gene list, 2700 genes would be expect to be false leads.  The 
Benjamini and Hochberg FDR correction was applied across the significant genes 
(Benjamini & Hochberg, 1995).  This test reduces the number of false positives 
without enriching the number of „false negatives‟, which can be the case for other 
types of correction (Benjamini & Hochberg, 1995).  Briefly, the p-values are ranked 
from the smallest to the largest. The largest p-value remains as standard. The second 
largest p-value is multiplied by the total number of genes in the gene list of 
differentially expressed genes divided by its rank. The same approach is repeated 
with the second largest p-value and so on, until no gene is found to be significant.  
The resulting FDR corrected values mean that a FDR of 5% (FDR corrected p-value 
<0.05) on a gene list of 500 would expect 25 to be false leads, regardless of the 
number of reporters on the array.  
 
 
 
 
 
 87 
2.8.4. Ingenuity Pathway Analysis (IPA) 
2.8.4.1. Introduction to IPA 
 
I have used Ingenuity Pathway Analysis (IPA version 4.0), a web-based application 
(www.Ingenuity.com) that enables building signaling networks from gene/protein 
expression data. It is based on IPKB (Knowledge Base database), which is currently 
the largest curated database containing millions of computable relationships between 
genes, proteins, drugs and diseases.  
 
A data set containing Affymetrix probe identifiers and their corresponding „fold 
change‟ values was uploaded in Excel. Each probe identifier was mapped to its 
corresponding object in the IPK base. To build a network, IPA searches the IPKB for 
interactions between focus genes/proteins and all other gene objects stored in the 
Knowledge base („Focus genes‟ show direct interaction with other genes in the 
knowledge base). It then generates a set of networks with a maximum of 35 genes, 
and computes a score for each network. The score shows the likelihood that a gene is 
placed in a network due to random chance (for example, a score of 2 gives a 99% 
confidence that the focus genes are not being generated by random chance). In 
addition, IPA‟s Global Functional Analysis feature provides an overview of 
biological functions associated with a set of dysregulated genes/proteins, with 
functions displaying a p-value <0.05 being significant. The significance values for 
these analyses are calculated using the right-tailed Fisher‟s Exact test. Similarly, the 
Canonical Pathway Analysis feature shows which of the known signalling and 
metabolic pathways are altered in the user input data. IPA‟s canonical pathways are 
based on its own curation as well as on KEGG (Kyoto Encyclopedia of Genes and 
Genomes). 
2.8.5. Affymetrix Human Genome-Wide SNP 
6.0 Arrays  
 
Nsp/Sty 5.0/6.0 Assay protocol, Washing, Staining and Scanning 
The Human Genome-Wide SNP 6.0 Arrays were purchased from Affymetrix (Santa 
Clara, CA, USA), containing 906,600 SNPs in a single chip with a physical distance 
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of on average 23.6kb. SNP array experiments were performed according to the 
manufacturer's instructions. Briefly, 250 ng of tumor DNA was digested by either 
Nsp1 or Sty1 restriction enzyme (New England Biolabs). After ligation to an 
appropriate adaptor for each enzyme, a PCR reaction was carried out using a generic 
primer that recognizes the adapter sequence. The PCR products from four reactions 
were pooled, concentrated, fragmentated by DNase I and subsequently labeled with 
biotin. Hybridization was performed at 45°C for 16h in a hybridization machine 
(Affymetrix). After washing and staining the arrays, the signal intensities were 
measured on an Affymetrix GeneChip Scanner 3000 and the raw images were 
analyzed using the GCOS (Ver1.4) and the GTYPE (Ver4.1) software that 
implements a new genotyping algorithm, BRLMM.  
 
 
SNP 6.0 Data Analysis 
 
To assess DNA copy number variations (CNV) and Loss of Heterozygosity (LOH), 
the Copy Number Analysis from the Partek (Partek, Version 4.0) software was used. 
In the analysis, the inferred copy numbers at each SNP locus was estimated by 
applying the hidden Markov model (HMM) and the segmentation algorithms. With 
the GCH software, nine algorithms were implemented in the “CGHweb” software 
(http://compbio.med.harvard.edu/CGHweb/) {Lai, 2008 #1}; Forward-Backward 
Fragment-Annealing Segmentation, Gaussian Model with Adaptive Penalty, Locally 
weighted scatterplot smoother, Quantile Smoothing, Circular Binary Segmentation, 
Fused Lasso (cghFLasso), GLAD, Wavelet smoothing and Running Average. The 
HMM parameters were set up based on comparison between our reference data 
(Tamoxifen Sensitive samples were used as reference) and the Tamoxifen Resistant 
data. The analysis described above is implemented in Partek (see “Supplementary 
Methods” in ref. 32 for details.). “Automatic analysis” mode was selected in which 
the software performed pair-wise tests for all of the references. Genetic gains 
(DCN≥3) and losses (DCN≦1) were defined according to the working criteria of the 
Partek software. High-level amplifications and homozygous deletions were 
determined to be CN gains ≥ 5 and CN deletion = 0, respectively. The LOH output 
from Partek was verified by the Affymetrix CNAT (Ver3.0) software, in which a set 
of 110 built-in reference files are available to calculate the probability of LOH at 
each probe. (The non-BRLMM data were used for this analysis because the BRLMM 
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data cannot be processed in CNAT Ver3.0.) The great majority of LOH calls from 
Partek agreed with CNAT. To avoid detecting false-positive changes due to random 
noise in allele intensity at individual SNPs, we set a minimum physical length of at 
least five consecutive SNPs for putative genetic alterations. The physical position of 
all SNPs (n=116,204) on the arrays were mapped according to the UCSC Genome 
Browser on Human May 2004 Assembly. The gene annotation was computationally 
determined after combining the information available in RefSeq 
(http://www.ncbi.nlm.nih.gov/RefSeq/) and Ensembl (http://www.ensembl.org) 
databases. Taking structural variation in the human genome into account, recurrent 
regions of copy number variations (CNVs) were also excluded from the analysis 
(http://projects.tcag.ca/variation/) (Iafrate et al., 2004), (Sebat et al., 2004), (Redon et 
al., 2006), (Freeman et al., 2006). 
2.9. Quantitative PCR 
2.9.1. Reverse Transcription Reaction  
 
A microgram of total RNA was used to generate cDNA. Reverse transcription 
reactions were performed using sterile plasticware throughout and aerosol filter tips 
to reduce contamination. All materials were sourced from Applied Biosystems. The 
reactions were prepared on ice as follows; 1g total RNA, 5.5mM MgCl2, 2.5mM 
dNTP mix, 2.5M Random Hexamers, RNase Inhibitor (0.4U/l), MultiScribe 
Reverse Transcriptase (1.25U/l) and RNAse free water to make the reaction volume 
up to 50l. Samples were then transferred to a thermocycler and reactions incubated 
at 25
o
C for 10 minutes, 48
o
C for 30 minutes followed by 95
o
C for 5 minutes to 
inactivate the enzyme. After the RT reaction it can be assumed that 1g of total RNA 
corresponds to 1g of cDNA. 
2.9.2. Quantitative “Real Time” PCR reaction 
(qPCR) 
Pre-designed transcript specific primer-probe sets for use in for qPCR reactions were 
purchased from Applied Biosystems, the details of these are outlined in Table 2.5. 
Briefly, the probe is supplied dye-labelled at the 5‟ end. The fluorescence of this dye 
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is controlled by a quencher at the 3‟end. The probe binds to the DNA between the 
two primers. As the reaction proceeds, the dye is cleaved from the probe and thus 
released from the quencher. Therefore as the reaction progresses the fluorescent 
emission from the dye increases allowing accurate quantification of the target 
sequence.  Reaction mixes (25l) were prepared in triplicate on a 96-well plate using 
15ng cDNA per reaction and Universal PCR master mix (Applied Biosystems) at 1X. 
Approximate controls were included. In order to assess the efficiency of the PCR 
reaction and to allow relative quantification, a standard curve was run alongside the 
samples. The standard curve consisted of four separate dilutions of cDNA per 
reaction and was prepared in triplicate; 25ng, 6.25ng, 1.5625ng and 0.39ng. The PCR 
reaction was carried out on the 7700 Sequence Detection System (Applied 
Biosystems) using the following program as standard: 50
o
C for 2 minutes (AmpErase 
UNG step), 95
o
C for 10 minutes to activate the AmpliTaq Gold, then 40 cycles of 
95
o
C for 15 seconds, 60
o
C for 1 minute.  
 
 
Transcript Assay ID 
Probe Dye 
Layer 
GAPDH 4319413E VIC 
VGLL1  Hs00212387_m1 FAM 
AKR1C3 Hs00366267_m1 FAM 
MAGEA2 Hs00606323_s1 FAM 
MED16 Hs00193899_m1 FAM 
EGLN3 Hs00222966_m1 FAM 
GREB1 Hs00536409_m1 FAM 
PDZK1 Hs00536409_m1 FAM 
MYBL1 Hs00277143_m1 FAM 
HNRNPA2B1 Hs00242600_m1 FAM 
 
Table 2.6 Details of primer-probe sets used in qPCR analyses. All PCR reactions 
were analysed by agarose gel electrophoresis to ensure the presence of a single 
product under standard PCR conditions.  
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Results were initially analysed using the Sequence Detection software version 1.9.1. 
(Applied Biosystems). The amplification plots were observed in both linear and 
semi-log plots, with the background corrected and the threshold cycles determined. 
Following this the standard curve was plotted showing the slope (PCR efficiency) 
and the correlation coefficient. A slope of –3.3 relates a 100% efficient PCR 
reaction, a ten-fold increase in PCR product every 3.3 cycles.  The PCR efficiency 
was considered satisfactory above 98% and only if all the samples fell within the 
points of the standard curve. Data was analysed according to the Standard Curve 
Method for relative quantification (Applied Biosystems, url).  Standard curves were 
prepared for both the target (e.g. Mage-A2) and the endogenous reference (e.g. 
GAPDH). For each experimental sample, the relative quantity of target and 
endogenous reference levels was determined from the appropriate standard curve. 
The target amount was then divided by the endogenous reference amount to obtain a 
normalised target value. The transfection control sample was used as a calibrator and 
each of the normalised target values were divided by the calibrator normalised target 
value to generate the relative expression levels. Triplicate samples were used to 
generate standard errors.   
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2.10. Co-ImmunoPrecipitate Assays 
All of the Co-IP assays presented in this thesis were performed in collaboration with 
Tony Wong, who performed the Co-IP and IP work on MAGEA2 project. 
 
2.10.1. Immunoprecipitation  
Immunoprecipitation experiment was performed as follows. First, cell pellets were 
lysed with IPH buffer (50nM Tris-HCI pH8.0, 150mM NaCI, 5mM EDTA, 0.5% 
NP40, 0.1mM PMSF, 5µM Trichostatin A (TSA) and protease inhibitor cocktail) on 
ice for 30 minutes. 1 mg of cell lysate was incubated with 50µl of Dynabeads® 
(Invitrogen) and either 2µg mouse anti-p53, 4µg anti-MAGEA2 (Santa Cruz) or 
control IgG antibody overnight at 4°C. The next day, immunoprecipitates were 
washed three times with IPH buffer for 5 minutes at 4°C, and resuspended in 45µl of 
2X SDS western loading buffer. The samples were resolved via SDS-PAGE and 
transferred onto PVDF membranes. Protein detection was achieved by western blot 
analysis.  
 
2.11. In vitro functional analysis  
2.11.1. Proliferation assay  
Cell number was determined by counting cells using a Z1 Coulter particle counter 
(Coulter Electronics). 70-80% confluent cells were plated in 2 well plates at a density 
of 2.5 x 10
4
cells/well and allowed to adhere overnight at 37
o
C. The cells were treated 
with their normal media or media with 10
-7
M Tamoxifen (Sigma cat no. H7904) for 
8 days. After treatment, cells were trypsinized, 80 µl of cells was mixed with 20 ml 
of Isoton Coulter balanced electrolyte and loaded in a Coulter counter. Each 
experiment was carried out in triplicate. Cells were counted every 24 hours for 8 
days. Cells were split every third day during cell growth assay. 
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2.11.2. Sulphorhodamine (SRB) assay 
In addition to cell counting, a non-mitochondrial cytotoxicity assay, suphorhodamine 
assay (SRB) was used to evaluate the effect of the clones on cell proliferation in 
normal media and tamoxifen media. This method relies on the uptake of the 
negatively charged pink aminoxanthine dye, SRB by basic amino acids in the cells. 
The greater the number of cells, the greater the amount of dye is taken up, and after 
fixing, when the cells are lysed, the released dye will give a more intense colour and 
greater absorbance. Cells were seeded at a density of 5 x 10
3
 cells/well in 100 µl in a 
96-well plate, nine wells per cell line. After 24 h, the cells were treated with the 
appropriate media, normal or the tamoxifen (10
-7
 M) containing. At a given time 
point, the cells were fixed with ice-cold TCA for 1 hour at 4C. Cells were then 
washed 5 times with distilled water. Cells were then dried at 56C for no more than 
5mins. Fifty l of SRB (0.4% in 1% acetic acid) was added into each well for 30mins 
in room temperature. The cells are then washed quickly with 1% acetic acid five 
times. Finally, 100l of 10mM Tris Base was added, on a rocker for 5mins, and read 
at 492nM wave-length. 
 
2.11.3. Annexin V assay 
The annexin V binds to negatively charged phospholipid, like phosphatidylserine. 
During apoptosis the cells react to annexin V as soon as chromatin condenses but 
before the plasma membrane loses its ability to exclude PI. Hence by staining cells 
with a combination of fluorecenated annexin V and PI it is possible to detect 
nonapoptotic live cells, early apoptotic cells and late apoptotic or necrotic cells. Cells 
from the exponentially growing were collected at the indicated time and added to the 
floating cells and analysed together. Aliquots of cells (>0.5 X 10
6
) were centrifuged 
at 1000 rpm for 5 mins and washed with PBS. The cell pellet was resuspended in 100 
l of labelling solution (Annexin-V-fluos, Boehringer Mannheim) containin 2 l 
annexin V labelling reagent and 0.1 g propidium iodine (Calbiochem. La Jolla, CA) 
and incubated for 10-15 min, as per manufacturer instructions. Immediately after 
adding 0.4ml of incubation buffer (10mM HEPES.NaOH, 140 mm NaCl, 5 mM 
CaCl2) analysis of red (annexin V) and white (PI uptake) fluorescence of individual 
cells was measured with FACScan flow cytometer (Becton Dickinson, 
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Erembodegem, Belgium). The data were analysed using the Prism software package 
supplied by Graphpad Software Inc. Comparisons among treatments were performed 
using one-way analysis of variance (ANOVA). When significance was observed 
(P ≤ 0.05), Tukey's multiple comparison test was performed to determine which 
means differed from the control by a significant margin. All results are expressed as 
the mean ± S.D. of triplicate treatments. Results shown are from single experiments, 
representative of a minimum of three. Where appropriate on figures significance is 
indicated as ***P ≤ 0.001; **P ≤ 0.01, *P ≤ 0.05. 
 
2.11.4. Transwell Migration assay 
Transwell plate which is especially designed to have a total of 24-wells, with an 
inner well cradle in them (24-well size with an 8m pore size filter; Costar). I had 
used 6 wells for MCF-7 VA cells and 6 wells for MCF-7 MAGEA2 expressing clone 
(C24) for this experiment. The bottom (outer membrane) of the inner well is coated 
with 0.5% of BSA in PBS to completely block the membrane. The bottom well is 
then filled with media with 0.5% BSA, using BSA as the cell attractant. The top well 
is then filled with 100000 cells, which has been washed clean of any serum (twice 
washed with PBS), and in serum free RPMI. The plates are left in 37C for 18 hours 
in their normal incubator. 
Cells are trypsinised and counted (Model TTC, CASY 1, Scharfe system Gmbh, 
Rentlinen, Germany) after 18hours. The percentage of cells that are found in the 
bottom well relative to the total cells is calculated and presented as histogram graphs 
by exel software. 
 
2.12. Immunofluorescence (ICC) 
Coverslips (round 13-mm) were placed in a 24-well plate and sterilised with 70% 
ethanol for 20 minutes followed by three washes with PBS. Cells (at 5 x 10
4
) were 
plated onto the coverslips and grown overnight at 37
o
C. After three washes in PBS 
cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature. 
Following three washes in PBS cells were permeabilized (when necessary) with 
0.1% Triton X-100 in PBS for 5 min at 4
o
C. Cells were then washed three times with 
PBS and blocked in 1% BSA for 30 min at room temperature. Subsequently, cells 
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were incubated with primary antibodies diluted in BSA for 1 hour at room 
temperature. After three 10-minutes washes with PBS, cells were incubated with 
secondary antibodies diluted in BSA and incubated for 30 minutes at room 
temperature in the dark. Secondary antibodies were: DAKO (1:200) polyclonal 
Rabbit anti-mouse FITC IgG, and Alexa Fluor 546–conjugated goat anti-rabbit IgG 
(1:200; Molecular Probes, Invitrogen).  After three 10-minutes washes with PBS, 50 
µL DAPI-containing mounting agent gel (Prolong Gold antifade reagent DAPI; 
Molecular Probes) was added on to glass slides with the coverslips with the stained 
cells placed upside down on the glass slides and left in the dark for 1h to solidify. 
The stained slides were analyzed using the laser scanning confocal microscope Zeiss 
LSM 510.  
 
2.13. Independent Validation Cohort 
The independent validation cohort consisted of 76 cases from Guy‟s and St Thomas‟  
(GSTH) Hospital (EORTC 10850 & 10851), 42 cases with full clinical information 
from The Royal London Hospital (RLH), 7 paired-cases (primary and relapsed 
tissue, kindly donated by Dr Simak Ali) from Charing Cross hospital and 71 TMA 
from Leeds (kindly donated by Dr Valerie Speirs). Of which all were paraffin slides 
sliced at 0.4m thick, except the 42 cases from RLH and 71 cases from Leeds, which 
were Tissue Microarray (TMA) made from core punch at tumour cell regions 
selected by Prof Louise Jones (qualified pathologist from RLH). These were 
identified as cases of breast cancer from 1984-2005 with complete post-primary 
surgery follow up data on adjuvant tamoxifen therapy. A third of the cases with no 
recurrence after 10 years were classed as tamoxifen sensitive, and two-thirds of the 
cases were considered to be tamoxifen resistant as the patients relapsed within 2 
years of adjuvant tamoxifen. The latter cohorts, patients from Caring Cross and 
Leeds had other treatment for their breast cancer apart from tamoxifen. In addition, 
in the Leeds cohort, a third of the patients were ER-negative. The 76 cases from 
GSTH were patients where the patients who had tamoxifen monotherapy, with no 
subsequent chemotherapy. This made the cohort unique as their survival analysis is 
purely as the consequent of the effect of tamoxifen on the course of ER-positive 
breast cancer.   
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A summary of our patient characteristics in our 196-validation cohort is shown in 
Table 2.7. For all the genes validated in immunohistochemistry staining, the cohort 
consisted of the 118 cases from GSTH and BTLH. For the two-genes which I have 
also done in-vitro study; MAGEA2 and EGLN3, I have validated them across 
GSTH, BTLH, Charing Cross hospital (paired for primary and relapsed tumour 
paraffin slides) and also from the Leeds cohort, which total up to 196 patients. To 
construct tissue microarrays we have used a Tissue Arrayer (Beecher Instruments, 
MD, USA). This invaluable resource is now ready for my candidate validation step.  
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Table 2.7  Table with the 196 patients and their characteristics. Most 
patients were ER positive and had Tamoxifen treatment. All tumour grades were 
known. Lymph nodes status was known in most cases.  
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2.14. Immunohistochemistry (IHC) 
To confirm expression of selected differentially expressed genes at the protein level, 
immunohistochemical (IHC) analysis was performed using the Ventana Discovery™ 
System (Ventana Discovery™ System, Illkirch, France) following the 
manufacturer‟s protocol.  Paraffin-embedded tissue blocks and tissue microarrays 
were cut into 4 -µm-thin sections and stained with Haematoxylin and Eosin (H&E). 
For IHC, all slides were deparaffinised and processed for antigen retrieval with SSC 
(Standard saline citrate buffer). After blocking, the slides were incubated with the 
respective antibodies. For the negative control, primary antibody was omitted from 
the reaction. Staining for pan-MAGEA, EGLN3 and the human predictive genes 
(EPHA7, PALM2, SNF1LK2, ZBTB16, OR10G7, OPCML, SP2, RUNX1T1 and 
ENPP2) was performed using the 3-3' diaminobenzidine (DAB) detection kit 
(Ventana); the slides were counterstained with haematoxylin. A reddish-brown 
precipitate indicated positive immunoreactivity. The sources and dilutions of 
antibodies are shown in table 2.8.  
Table 2.8 Antibody details and dilutions for Immunohistochemistry (IHC) analyses. 
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2.14.1. Evaluation of staining 
The stained tissue sections were scored by Dr Yaohe Wang (trained pathologist) and 
I on the basis of both the extent and the intensity of the immunoreactivity and 
average scores were taken. The staining intensity was graded on a 0-3 scale 0 
(negative/ no staining), 1 (weak immunoreactivity), 2 (moderate immunoreactivity) 
and 3 (strong immunoreactivity). The extent of immunoreactivity was scored 
according to the percentage of stained cells in relation to the entire section as (0 
points for no staining, 1 point for less than 20%, 2 points for 20-50% and 3 points for 
more than 50% of the cells). The product of the intensity and extent scores was used 
as the final staining score. Negative or weakly positive cases had a score of 0-3 
points, moderately positive had a score of 4-6, and strongly positive cases had a final 
score greater than 6. The mean was then use as a cut off, with all scored above the 
mean, labelled positive and all below the mean being negative. 
 
2.15. Survival analysis 
All analyses were done using Prism (Version 6.0). A p value of <0.05 defined 
statistical significance. Kaplan-Meier curves were plotted from data of disease free 
survival (DFS) and overall survival (OS). Data from patients who were lost (<1%) 
from followed up were treated as censored data. Comparison of survival curves were 
analysed using both Log-rank (Mantel-Cox) test, and Gehan-Breslow-Wilcoxon test. 
As the results were similar, we have shown only the p-value from Gehan-Breslow-
Wilcoxon test. Hazard ratios and 95% Confidence Intervals (95% CI) were also 
given alongside the p-value calculated. 
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2.16. MicroRNA extraction using the miRVana 
PARIS kit, preparation of cDNA and real-time 
PCR with microRNA primers. 
 
Cells (102-107 cultured cells) or fresh frozen tissues (0.5-250mg) can be used for 
extraction of miRNA, small RNA and small nuclear RNA (snRNA) with mirVana 
miRNA isolation kit. The mirVana PARIS kit can effectively extract miRNA and 
small RNA simultaneously with protein extraction (whole cell extract). The protocol 
is easy to follow, and the method involved the principle of organic extraction 
followed by the purification using a silicate matrix (spin columns). The enriched 
extraction protocol efficiently purified all RNA larger than 10nt, and up to 200nt. 
 
 
cDNA were made from miRNA using the high-capasity miRNA reverse transcriptase 
kit (part number: 4366596) from Applied Biosystem (ABI). For qPCR, Tagman 
assay (see below table for the assay ID) for miRNA were purchased, and 
housekeeping miRNA, such as hsa-mir-19a, hsa-mir-106a and RNU24 were used as 
recommended by ABI for breast cancer cell lines and human tissues respectively.  
 
 
 
 
Table 2.9 Part number for the miRNA Tagman probe and primers from 
Applied Biosystems. 
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CHAPTER 3:  RESULTS OF TAMOXIFEN RESISTANT 
CELL LINES 
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3.   Oestrogen, Progesterone and ErbB2 Expression 
in cultured breast cancer (TR) Cell lines  
The work on TR is largely related with the hormone receptor status on the breast 
cancer cells. All breast cancer in the clinical setting is typed for hormonal status. We 
have a series of breast cancer cell lines, which we use for our laboratory work. 
Oestrogen receptor (ER), progesterone receptor (PgR) and ErbB2 receptor (HER2) 
status from all the parental cell lines were typed using immunohistochemistry. Prof. 
Loiuse Jones provided this service (Table 3.1).  
Table 3.1  ER, PgR, HER2, p21(WAF1) and p53 status across a panel of 
parental breast cancer cell lines. Tam RE=Tamoxifen resistant early, Tam RL= 
tamoxifen resistant late. Pos=positive, Neg=Negative, NK=Not known, WT=wild 
type, MuT=Mutant. The immunohistochemistry staining is expressed as percentages 
(%) of cells positive for ER or PgR in the nucleus. 1+ and 2+=low HER2 expression; 
3+=membrane staining. The MCF-7 derived cell lines from the Tenovus Institute in 
Cardiff, which I have labelled as MCF-7 (Tenovus), which were maintained in 
Tamoxifen containing media for 3 and 6 months (RE=resistant early and 
RL=resistant late) respectively. 
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3.1. Generation and characterisation of 
Oestrogen Deprived and Tamoxifen resistant 
T47D and ZR75-1 lines 
As part of our study, we generated Oestrogen deprived cell lines with the aim of 
studying breast cancer cell lines, which are independent of the oestrogen pathway for 
their growth. Oestrogen deprived (OD) T47D and ZR75-1 were generated by 
growing parental cells in medium containing charcoal-stripped serum for duration of 
6 months. The resulting lines were labelled as OD T47D and OD ZR respectively. 
These cells kept the same morphological features and were tested intermittently for 
Mycoplasma contamination. The OD cells grew relatively slowly, and only required 
passaging every 7 days as compared to parental cell lines which required splitting 
every 4th or 5th day. 
 
Tamoxifen Resistant (TR) cell lines were generated by growing T47D, ZR75-1, OD 
T47D and OD ZR in Tamoxifen containing media. Hydroxy-4-OH-Tamoxifen at 10
-7
 
M was added to specific media (See Chapter 2.1.2.) and maintained for 6 months‟ 
duration. Initially cells arrested growth but eventually re-entered the cell cycle and 
could be expanded. At this point they were considered as a separate cell line. The 
lines were labelled T47D TR, ZR TR, OD T47D TR and OD ZR TR. The cells were 
tested intermittently for Mycoplasma contamination. TR cells were slow growing 
and required splitting once every 10-12 days. 
 
Whole cell extracts (WCE) from MCF-7 (CRUK), MCF-7 WT (Tenovus), T47D, 
ZR75-1 and their OD and Tamoxifen resistant (TR) counterparts were assessed for 
ER, ErbB2 and AP-2 levels using Western blotting (Figure 3.1). In keeping with 
the literature (Orso et al., 2004), ER levels were acutely increased in cell lines 
exposed to tamoxifen containing media for 24 to 72 hours. The late TR cell lines 
expressed similar levels of ER as the parental cell lines. The OD TR cell lines 
showed almost complete loss of ER protein expression of. ErbB2 protein 
expression was increased in Tamoxifen late resistant cell lines. This is in keeping 
with the many publications that report an inverse relationship between ErbB2 and 
Progesterone (PgR) (Ponzone et al., 2006). Progesterone mRNA expression was 
significantly down-regulated in TR cell lines in our microarray study (Table 3.3.4). 
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AP-2 expression showed minimal any change in TR lines when compared with 
parental cells. This is contrary to published findings (Orso et al., 2004). 
Figure 3.1  Expression of key breast markers in in-vitro models of tamoxifen 
resistance. WB of WCE (10g) from MCF-7 (CRUK), MCF-7 WT (Tenovus), 
T47D, ZR75-1 and their TR counterparts. C=Control/parental lines grown in normal 
oestrogenic media.  Tam 48h=exposure of the cells to 48h of Tamoxifen  (10
-7
M) 
containing media. Fas 48h=exposure of the cells to 48h of Faslodex (10
-7
M) 
containing media. Tam 72h=exposure of the cells to 72h of tamoxifen containing 
media. TRL=Tamoxifen Resistant Late, grown for 6 months in tamoxifen containing 
media. ErbB2 is Her2 receptor protein, ER is the oestrogen receptor, and AP-2 is a 
transcription factor related to mammary gland genesis and development. PCNA was 
used as a loading control. 
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3.2. Expression profiling of T47DTR, ODT47DTR, 
ZRTR and ODZRTR 
Good quality RNA was extracted (refer to Material and methods 2.6.) from T47D 
TR, OD T47D TR, ZR TR and OD ZR TR cell lines. Probes were prepared 
according to the Affymetrix protocol for the HU133 2.0 plus microarray chip. The 
probes were tested for quality using TEST Chips prior to hybridising on HU133 2.0 
plus. The results were analysed using „Affymetrix Console‟ for quality control (QC). 
 
The analysis of the data was undertaken by a bio-informatics team, Dr Claude 
Chelala. The analysis normalised the TR cell line expression data with parental cell 
line (wild-type) data, obtained from the Gene Expression Omnibus (GEO) Datasets. 
These were T47D (Accession number: GSM70667) and ZR75-1 (Accession number: 
GSM70668), which were also arrayed on HU133 2.0 plus. Our TR cell line 
expression data have been submitted in the Gene Expression Omnibus (GEO) under 
the Accession number GSE22664). Figure 3.2. illustrates two Venn diagrams which 
demonstrate the data set comparisons made to identify common genes deregulated in 
both ZR75-1 and T47D resistant lines that might be considered to confer the TR 
phenotype. There are 428 genes, which are in both subsets of Oestrogen-deprived 
T47D and oestrogen-deprived ZRTR, which may be responsible for the Tamoxifen-
resistance. These 428 genes are within the 555 genes, which is the common altered 
genes between the T47DTR and ZRTR. 
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Figure 3.2 Venn diagrams showing overlap between significantly expressed 
genes from the ODT47DTR over the T47D (WT), ODZRTR over ZR (WT), 
T47DTR over T47D (WT) and the ZRTR over ZR (WT) respectively. The subset 
of genes, which overlapped, is seen as the overlap regions between 2 circles. There 
were 428 significantly altered genes in common between ODT47D TR and ODZR 
TR compared to WT cells (LH panel). There were 555 significantly altered genes in 
common between T47D TR and ZR TR compared to WT cells (RH panel). 
 
 
 
 
 
 
 
 
 
ODT47DTRvsWT   ODZRTRvsWT 
1351  428   736 
     T47DTR vs WT     ZRTR vs WT 
  1354 555     682 
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3.3.  Hierarchical Clustering Analysis 
Bioconductor normalised data were imported into the limma package (R from 
Bioconductor) in order to allow a hierarchical clustering analysis to monitor overall 
patterns of gene expression between the normalised arrays (Materials and methods 
2.7.3; Eisen et al., 1998).  Briefly, a hierarchical clustering analysis produces a map 
of results where probe sets were grouped together based on similarities in their 
patterns of normalised expression across the six arrays.  As the processed data 
follows a normal distribution it is appropriate to use the Pearson correlation 
coefficient, which calculates the similarity measure based on a linear model.  As we 
are interested in genes that change their expression between the reference and test 
groups, data were filtered to include the 10,000 probe sets with the highest variance 
across the six arrays.  The filter cut-off of 10,000 probe sets were used instead of the 
the conventional 2,500 probe sets for higher stringency and to compensate for the 
fact that our reference were single experiment rather than duplicates or triplicates. 
The same algorithm was also applied to cluster the experimental samples for 
similarities in their overall patterns of gene expression. The resulting dendrogram is 
shown in Figure 3.3.  The reference samples formed their own cluster, indicating that 
there is enough distinction in expression in this variable subset of probe sets from the 
TR breast cancer cell lines, T47D TR, OD T47D TR, ZR TR and OD ZR TR.  Arrays 
hybridised were not replicates but formed their own cluster separate from the 
reference samples, i.e.T47D (WT) and ZR75-1 (WT) from the clusters of TR breast 
cancer cell lines. The hybridised arrays of the TR breast cancer cell lines formed 
their own clusters for each breast cancer cell linage, i.e. T47D TR and OD T47D TR 
were separated from ZR TR and OD ZR TR as illustrated in Figure 3.3.  Given that 
both the cancer cell lines, T47D and ZR75-1 are 90% PgR-positive but 80% and 60% 
ER-positive respectively (see Table 3.1), it is likely that their ER-positivity 
differences played a larger part in their expression profile differences than the TR 
factor. 
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Figure 3.3 Hierarchical cluster tree generated with R software after 
normalisation (RMA) using APT tools.  0159_6970_h133+_K-T-47D_cel.txt and 
0159_6371_h133+_L-ZR-75-1_cel.txt were the GEO datasets for T47D(WT) and 
ZR75-1(WT) respectively.  ZRTR, OD ZRTR, T47DTR and ODT47DTR 
(Accession number on GEO repository: GSE22664) were abbreviations for ZR75-1 
Tamoxifen resistant, oestrogen deprived ZR75-1 Tamoxifen resistant; T47D 
tamoxifen resistant and oestrogen deprived T47D Tamoxifen resistant. 
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3.3.1. Quality diagnostics using PLM 
For summarisation of quality assessment of Affymetrix Genechip data, we have used 
the Probe-Level Model (PLM), which allowed us to examine the QC statistic 
described in chapter 2.7.3.3. Normalised unscaled summarised expression (NUSE) is 
a method to estimate summarised expression at Chip level. Each chip will have 
NUSE for each probe, which can be summarised by the median. Specifically, NUSE 
values are computed using: 
 
NUSE (θgi)= _____SE(θgi)____ 
medi (SE(θgi)) 
 
where θgi = log scale estimates of expression for each gene g on each array i. SE is 
standard error and med=median. This provides a useful summary of the residual and 
can be use to judge quality relative to other chip. Median NUSE is a number that 
fluctuates around the value 1.0 - „high‟ values, such as 1.05, indicate „worse‟ 
(unusual) chips. Another similar method, Relative Log Expression (RLE) 
summarises the relative log intensity of the signals. This has a narrower range of 
variance, which makes the obvious outlier, if there is one, easier to spot. Figure 3.4 
illustrates NUSE and RLE quality assessment at chip level of our TR breast cell lines 
cohort. There is some degree of correlation exists between NUSE and RLE 
summaries. 
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Figure 3.4 Quality control assessments on the TR expression array datasets. 
The NUSE (Normalised Unscaled Summarised Expression) and RLE (Relative Log 
Expression) at chip level. This is a method of quality control. 
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3.4.  Statistical Analysis of Tamoxifen Resistant 
Differential Gene Expression 
Summarisation is the process of combining the multiple probe intensities for each 
probe-set to produce an expression value. RMA (Irizarry et al., 2003), is the 
expression measure used in our study. Bioconductor normalised data were imported 
into Limma in R software in order to allow statistical analyses to be carried out.  As 
well as fitting a normal distribution, another assumption of statistical analyses, such 
as the widely used Student's t-test, is that the variability of a gene is constant across 
treatment types.  However, in the absence of accurate diagnosis methods, it is safest 
to assume that variability may differ between our reference and test groups.  As we 
have confirmed that our data fits a normal distribution, it is appropriate to conduct a 
Welch‟s t-test, this is a parametric analysis that corrects for difference in variability.   
 
As we are interested in identifying genes that change their expression between the 
reference and test groups, it was important first to filter the data to include only those 
probe sets that change in expression.  We chose to order the list from low to high 
standard deviation.  This would enable us to identify the genes that are changed the 
most in expression across the six arrays, and remove probe sets from the analysis that 
change very little.  It was felt that this is more informative than filtering on fold 
change, for which there is a risk of ignoring genes that change significantly but are 
below the arbitrary fold change threshold.  
 
Limma software from R was used to calculate a Welch‟s t-test on the 2500 probe sets 
with highest variance across the six arrays.  A Benjamini and Hochberg False 
Discovery Rate (FDR) test (Benjamini et al., 2001) was also applied in order to 
identify the percentage of false positive genes that could have been included in the 
final lists of differentially expressed genes.  Appendix 1 displays the 578 probe sets 
that changed their expression significantly (FDR corrected, p<0.05) between the 
reference (T47D (WT) and ZR75-1 (WT)) and test (Tamoxifen Resistant cell line) 
groups.  
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3.5.  TR Gene Expression Profile Initial 
Observations and validation 
Significant changes in gene expression were observed when TR cell lines were 
analysed against T47D (WT) and ZR75-1 (WT). The significantly up-regulated and 
significantly down-regulation genes are summarised in Table 3.2. The full gene lists 
from the analysis is listed in Appendix A.  A smaller subset of probe sets (180 genes) 
regulated at a p<0.01 probability was used for subsequent Ingenuity Pathway 
Analysis.  In the results presented in this thesis, probe sets were assigned to gene 
symbols and gene descriptions based on the January 2007 release of the HG-
U133_Plus2 Affymetrix NetAffx Annotation files (Liu et al, 2003; 
www.affymetrix.com). 
 
The resulting list of TR genes from this study was compared with results from a 
previous study in our lab (Charlotte Moss, PhD thesis 2009), which compared 
expression profiles of MCF-7 and MCF-7 TRL cell lines. This comparison is found 
in Appendix C. The platform used for the MCF-7 study was HU133A Chips, which 
have fewer probe-sets compared to HU133 2.0 plus, but despite this, there were still 
distinct similarities between our studies. The common TR genes found in both 
studies are AKR1C3, AKR1C2, PGR, DKK1, MARCKS and GPNMB.  
 
We chose to validate 5 up-regulated genes, MAGEA2, AKR1C3, THRAP5, VGLL1 
and EGLN3, and 4 down-regulated genes, GREB1, PDZK1, hnRNP2A1B and 
MYBL1 based on the relevance of these genes to breast cancer in published 
literature, the reproducibility when compared with other breast cell lines, i.e. MCF7 
TR, gene involvement in proposed pathways in relation to resistance to treatment and 
the availability of commercial antibodies. These chosen genes were validated using 
quantitative PCR (qPCR) and immunohistochemistry. 
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MAP symbol NAME Fold change 
13q33 EFNB2 ephrin-B2 3.713047555 
11q13 ALDH3B2 aldehyde dehydrogenase 3 family, B2 4.539575528 
22q13.33 SCO2 SCO cytochrome oxidase deficient homo 2  3.477794836 
Xq26.3 VGLL1 vestigial like 1 (Drosophila) 4.119736333 
10p15-p14 AKR1C3 aldo-keto reductase family 1, member C3  4.081036655 
Xq28 MAGEA12 melanoma antigen family A, 12 4.647332681 
12p12.2-p12.1 LDHB lactate dehydrogenase B 5.573450211 
22q13 SERHL2 serine hydrolase-like 2 6.461724005 
Xq28 MAGEA2B melanoma antigen family A, 2B 3.84036576 
Xq26.3 VGLL1 vestigial like 1 (Drosophila) 6.279577017 
Xq28 CSAG2 CSAG family, member 2 3.580457482 
20q12 ITGB4BP integrin beta 4 binding protein 3.539804845 
14q13.1 EGLN3 egl nine homolog 3 (C. elegans) 3.655909188 
19p13.3 ALKBH7 alkB, alkylation repair homolog 7 (E. coli) 3.521589408 
NA NA NA 3.875260601 
19q13.42 CDC42EP5 
CDC42 effector protein (Rho GTPase 
binding) 5 4.254616896 
20p11.21 ABHD12 abhydrolase domain containing 12 3.519955768 
19p13.3 THRAP5 
thyroid hormone receptor associated protein 
5 4.257983055 
 
 
 
MAP symbol NAME Fold change 
2p25.1 GREB1 GREB1 protein -6.90466979 
1q21 PDZK1 PDZ domain containing 1 -6.57908464 
NA NA NA -5.89388337 
11q22-q23 PGR progesterone receptor -4.93601507 
7p12 EGFR epidermal growth factor receptor  -4.86841307 
9q34.3 OLFM1 olfactomedin 1 -4.76255748 
8q22 MYBL1 v-myb myeloblast viral oncogene homolog -4.69112967 
10q22-q23 RPS24 ribosomal protein S24 -4.14395185 
8q24.12 TRPS1 trichorhinophalangeal syndrome I -4.03544262 
7p15 HNRPA2B1 heterogeneous nucl. ribonucleopro A2/B1 -3.99102865 
12q24.21 THRAP2 thyroid hormone receptor ass protein 2 -3.95992594 
11q13.1 TncRNA trophoblast-derived noncoding RNA -3.94963705 
16p12.2 LOC23117 KIAA0220-like protein -3.94621846 
 
Table 3.2 Significant changes in gene expression in TR cell lines.  Changes 
observed in probe sets between the reference and test (TR cell lines) groups at the 
indicated False Discovery Rate (FDR=0.05). The genes were then exported to 
Ingenuity Pathway Analysis software and the top ten up regulated are shown at the 
top table, while the top ten down-regulated are in the bottom table. Fold changes are 
seen on the right margin. 
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3.6.  Validation of array results  
These chosen genes were validated using quantitative real-time PCR (see Material 
and Methods 2.8.) using RNA prepared from parental and OD and TR versions of 
MCF-7, T47D and ZR75-1 cells. In addition, RNA from the MDAMB231 line, 
which is ER-negative and PgR-negative and therefore inherently Tamoxifen resistant 
was also tested as a control. Where appropriate antibodies were available, genes 
where also validated with immunohistochemical staining of cell pellets embedded in 
paraffin (Appendix D). 
 
I have simplified the results in the table below (Table 3.3), which showed that the 
genes were positively correlated with microarray results when validated with qPCR. 
Commercially available antibodies for the genes/protein were purchased and used on 
breast cancer cell line and the tamoxifen-resistant cell line pellet, to assess if 
antibodies are good biomarker. We used the best antibodies for IHC-P staining for 
further validation across an independent cohort of breast cancer patients. MAGEA2 
and EGLN3 antibodies were used with the results shown in Chapter 3.7.7 and 
Chapter 3.8.6. 
Table 3.3 Positive validation of the genes/proteins from the tamoxifen-
resistant microarray study. MCF-7, T47D and ZR75-1 and their Tamoxifen-
resistant (TR) counterparts were grown and made into cell pellet and set into a 
paraffin block. These were then made into paraffin slides, used for staining with the 
commercially available antibodies for our genes of interest. These cells were also 
extracted for RNA, which we made into cDNA. The cDNA (1:3 dilution) was used 
with Tagman primers for the genes to access for mRNA expression in the three 
breast cancer cell lines and its TR counterparts.  
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3.7. Functional study (in-vitro) of MAGEA2 in TR 
 
3.7.1. MageA2 
MAGEA2 was chosen to study further as it was consistently up regulated in T47DTR, 
ODT47DTR, ZRTR and ODZRTR. In addition it was not detected in MDAMB231 
(our negative control), which does not express negative hormone receptors. As 
described in the Introduction (see Chapter 1.10), the MAGEA gene family is not 
expressed in most adult tissues but is frequently up regulated in several tumour types 
including malignant melanoma, germ cell tumours and, to a lesser extent, breast 
cancer. Little is known about MAGEA function but there are recent suggestions of 
involvement in chemotherapy resistance, and regulation of apoptosis via the p53 
pathway (Monte et al., 2006). It was suggested that MageA2 could form a complex 
with p53 and thereby reduce its activity as a transcription factor. I set out to examine 
if MAGEA2 over-expression may also have a role in the development of Tamoxifen 
resistance in breast cancer cells.  
 
3.7.2. MAGEA2 is over-expressed in a panel 
of Tamoxifen-Resistant cell lines  
To aid our study into gene expression changes in Tamoxifen resistant breast cell 
lines, additional lines (both ER positive and negative) were generated by maintaining 
the cells in Tamoxifen-containing media (10
-7
M) for at least three months (see 
Chapter 2.1.1). Cell lysates were prepared from the panel of TR cells and their wt 
counterparts and analysed for MageA2 expression by immunoblotting (see Figure 
3.5B). All the ER-positive cell lines, MCF-7, T47D, MDA-MB361 and HCC1500, 
showed no or very low MageA2 protein expression in the wt lines with significant 
induction expression in the TR lines. The ER-negative SKBR3 line is considered to 
be inherently Tamoxifen resistant since it carries an amplification of the ERBB2 gene 
(see Table 3.1). Interestingly, the wt SKBR3 cells already expressed elevated levels 
of MageA2, which were maintained when the cells were grown in Tamoxifen media.  
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MAGEA2 expression was also examined at the mRNA levels using qPCR with 
broadly similar results (Figure 3.5C).  
 
The mRNA expression resonated the same result as seen in protein immuno-blotting, 
apart from the data from MCF-7 and MCF-7 TR. We did not succeed in detecting 
MAGEA2 by real-time PCR, despite using different probes and primer, or various 
different starting cDNA amounts. We analysed clones of tamoxifen-resistant MCF-7 
cell lines to test for mRNA expression with no avail. When using the generic 
MAGEA probe and primer from ABI, we detected mRNA and an up-regulation of 
MAGEA. (A possible explanation is that MCF-7 has a very low level of MAGEA2 
mRNA, due to its low turn-over of the MageA2 protein).  
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3.7.3. Generation of MAGEA2 overexpressing cell 
lines 
Since induction of MAGEA2 overexpression appears to be a characteristic of several 
tamoxifen resistant cell lines, I decided to investigate if the encoded protein can play 
a functional role in resistance to tamoxifen. To achieve this, I generated stable 
MAGEA2 overexpressing lines in wt, tamoxifen sensitive MCF-7 and T47D breast 
tumour lines. As a first step, a MAGEA2 mammalian expression construct was made 
using a cDNA clone obtained from the I.M.A.G.E Consortium. As detailed in the 
Materials and Methods (Chapter 2.2.4), the insert was excised and cloned into the 
pcDNA3.1 expression vector which carries a strong mammalian promoter, CMV 
(cytomegalovirus) and also the Neomycin selection marker. 
 
T47D and MCF-7 cells were transfected with the pcDNA3.1/MAGEA2 plasmid or 
“empty” pcDNA3.1 (vector alone, VA, negative control) by nucleoefector technique. 
Conditions were optimized for T47D and MCF-7 cell lines as suggested by the 
manufacturer (Amaxa, see Chapter 2.2.4.6.). Separate transfection experiments used 
either circular or linearised plasmids. In the latter case plasmids were digested using 
the restriction enzyme Kas I within the ampicillin resistance cassette. In order to 
optimise transfection conditions, different concentrations of cells were plated and 
two different concentrations of the construct added, 1µg or 2g. The selection drug 
(G418) was added to the media the day after transfection at a previously optimised 
concentration (see Chapter 2.2.4). For the vector alone controls, a pool of G418-
resistant colonies for each cell line was made and maintained as separate cell lines, 
named MCF-7/VA and T47D/VA, grown in standard media supplemented with 
G418. For the MAGEA2 transfected cells, individual colonies were picked after 16 
days. The colonies were expanded and levels of MAGEA2 expression were 
determined using qPCR and Western blotting. Two high-expressing, positive clones 
(c18 and c24 for MCF-7, and c30 and c34 for T47D) were used in subsequent 
experiments (see Figure 3.7A & Figure 3.8A). 
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3.7.3. Growth of MAGEA2 expressing clones 
in Tamoxifen-containing media 
To test if expression of MAGEA2 is able to confer resistance to Tamoxifen, cell 
count assays were performed in triplicate for each cell line comparing wild-type (wt) 
cells, vector alone (VA), and two MAGEA2-expressing clones in Tamoxifen-
containing media. For the MCF-7 derived cells (see Figure 3.6B), there was a highly 
significant difference between growth of the clones, which continued to proliferate in 
Tamoxifen-containing media, and their VA and wt counterparts which showed 
growth arrest (p-value of 0.00185 for MCF-7 c18 versus VA averaged from day 1 to 
day 8, Students t-test). Broadly similar results were also obtained when the T47D 
derived cells were analysed (shown in Figure 3.6D) with the MAGEA2 expressing 
clones again able to sustain growth in Tamoxifen–containing media (p-value of 
0.00435 for T47D c30 versus VA averaged from day 1 to day 8, Students t-test). This 
experiment was repeated again in triplicates a month later with the similar results.  
To investigate further the growth differences between control and MAGEA2-
expressing lines, I analysed if the MAGEA2 clones showed a proliferation advantage 
in normal media over parental / VA control cells using a BrdU incorporation assay to 
measure the proportion of cells in S-phase and sub-G1. However, there was no 
significant difference found between control and MAGEA2-expressing cells 
suggesting that MageA2 expression does not confer an inherent cell cycle 
proliferation advantage to cells. (data not shown). I next examined if MageA2 
expression can protect cells from apoptosis, particularly in the presence of 
Tamoxifen. The MCF-7 control (wt and VA) cells and the two MageA2 clonal lines 
were grown in the presence and absence of Tamoxifen-containing media for 48 
hours and then assayed for Annexin V binding, a recognised hallmark of early 
apoptotic cells. The samples were additionally stained with propidium iodide (PI) to 
differentiate between intact cells (AnnV-PI-), early apoptotic (AnnV+PI-) and late 
apoptotic/necrotic cells (AnnV+PI+) using FACS analysis. As expected, the control 
cells (wt and VA) showed increased percentages of dead and dying cells when 
Tamoxifen was added to the media, but both c18 and c24 had reduced levels of cell 
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death in Tamoxifen (pvalue=0.027* and 0.043* respectively for VA and C18, and 
VA and C24 in Tamoxifen media, see Figure 3.7). Similar results were also found for 
the T47D derived lines (Figure 3.8).  
 
Figure 3.6  MageA2 stable over-expressing clones have a proliferation 
advantage in MCF-7 and T47D breast cancer cell lines in tamoxifen containing 
media. (A, C) Western blot showing stable MAGEA2 overexpression in MCF-7 and 
T47D. (B, D) The cell count study showed that there was an increase in cell 
population compared with non-transfected and mock-transfected MCF-7 or T47D in 
tamoxifen-containing media compared clones with VA. This analysis was obtained 
from two individual experiments with triplicates for each group. (Asterisk (*,**) 
p<0.001 relevant to vector alone control, student t‟ test) 
Cell counting for two individual MAGEA2-expressing stable MCF-7 lines (Clone 18 
and 24) and T47D lines (Clone 30 and C34) compared to wt cells and those 
transfected with vector alone (VA). 75,000 cells/well were seeded into 6-well plates 
in media supplemented with 10
-7
M tamoxifen. Cells were counted from triplicate 
wells (Coulter cell counter) daily for eight days. This analysis was obtained from one 
of two individual experiments which both gave very similar results. Growth rates at 
later time points declined due to cell confluence. 
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Figure 3.7  MAGEA2-expressing clones show reduced apoptosis in Tamoxifen media 
compared to controls. For each line (wt MCF-7, VA, c18, c24) 100,000 cells/well were plated in 
6-well plates, and grown in normal media either without or with 10-7M Tamoxifen, using triplicate 
wells for each line and condition. Cells were harvested at 24 hours and were processed using 
ApopNexin Annexin V FITC Apoptosis Kit (Millipore) according to the manufacture‟s protocol and 
analysed on a FACScalibur Flow Cytometer. Quadrant statistics were used to identify the percentage 
of apoptotic (propidium iodide-negative, annexin V-positive) cells – seen on graph (A) as white box. 
There are reduced apoptosis cells in the clones (C18, and C24) when compared with WT and VA 
when exposed to Tamoxifen media. (for methods, see Chapter 2.9.1) 
(B) Immunoblot showed the MageA2 protein is present in C18 and C24 as seen in the last four 
lanes. Tamoxifen when added into the media and left for 24 hours are indicated as + when 
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present and – when absent. BAX protein is elevated in all the Tamoxifen containing experiments, 
and more distinct in the C18 and C24, even when they are in their normal media without the 
Tamoxifen. 
 
(C) Graph showing the percentage of apoptosing cells in the Annexin V and PI study in their 
normal media and Tamoxifen containing media. The percentage of apoptosing cells is higher in 
the Tamoxifen containing media for WT and VA, as expected. But in the MCF-7 clones, C18 and 
C24, there was less apoptosis in the Tamoxifen media when compared with their normal media.
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Figure 3.8 MAGEA2-expressing clones show reduced apoptosis in 
Tamoxifen media compared to controls. For each line (wt T47D, VA, c30, c34) 
100,000 cells/well were plated in 6-well plates, and grown in normal media either 
without or with 10
-7
M Tamoxifen, using triplicate wells for each line and condition. 
Cells were harvested at 24 hours and were processed using ApopNexin Annexin V 
FITC Apoptosis Kit (Millipore) according to the manufacture‟s protocol and 
analysed on a FACScalibur Flow Cytometer. (A, C) T47D positive clones have more 
total live cells (A) and less apoptosing cells (C) than WT and VA after exposure to 
Tamoxifen containing media, as shown by Annexin V and PI study. (B) Immunoblot 
showed that positive T47D clones have an increase expression of BAX in both their 
normal media as well as Tamoxifen containing media as compared with WT and VA. 
There was no convincing difference in the acetylated p53 between the positive clones 
and WT/VA. 
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3.7.4. Co-Immunoprecipitation (Co-IP) study 
showed MAGEA2 interacts with p53 to 
regulate its pathway 
As mentioned in the introduction, previous studies have shown MAGEA2 is able to 
associate with p53 providing a cell survival advantage and chemotherapy resistance 
in melanoma cells and U2OS cell models (Monte et al., 2006). I therefore examined, 
using co-immunoprecipitation (coIP) assays, if MageA2 is able to complex with p53 
in MAGEA2-expressing clones and whether this reduces p53 signalling in 
Tamoxifen-containing media leading to reduced growth arrest and apoptosis.  
 
T47D-derived lines were used for the coIP experiments as they express quite high 
levels of p53. Although they carry mutant p53, this mutation (L194F) still retains 
DNA binding activity and the ability to induce p53 target genes and wt T47D cells 
can still carry out p53-dependent apoptosis ((Chopin et al., 2002; Kato et al., 2003; 
Toillon et al., 2002). Whole cell lysates were prepared from T47D/VA control cells 
and the MAGEA2-expressing clone 30. Cells were grown in their normal media, and 
immunoprecipitated (IP) for MageA2 or p53. To perform immunoprecipitate, I used 
IgG as control antibody, and p53-antibody (total p53) and MAGEA2 antibody on 
T47D and c30 lysates. Each IP was western blotted for both antigens which revealed 
that MageA2 and p53 formed a complex since p53 was detected in MageA2 
immunprecipitates and p53 was found in MageA2 precipitates in lysates from clone 
30 but not from control VA cells (Figure 3.9, top left panels). Control western blots 
of these lysates were also probed for acetylated p53 (p53Ac) which showed lower 
levels of p53Ac in clone 30 cells, although total p53 levels were similar in both lines. 
Levels of the p53 target gene p21
WAF
 were also reduced in clone 30 compared to VA 
cell lysates (Figure 3.9, right panels). This Co-IP study therefore supports the 
hypothesis that MageA2 interacts with p53, leading to reduced levels of acetylated, 
transcriptionally active p53 and hence reduced expression of target genes such as p21 
resulting in continued growth in tamoxifen-containing media. 
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Under normal circumstances, deacetylase inhibitor (Trichostatin A) increases 
acetylation of p53, as seen in the VA lane in Figure 3.9B, but with exogenously 
expressed MAGEA2, this acetylation of p53 is not seen, and subsequently p21 is 
down-regulated. Down-regulation of p21 is not readily seen in MCF-7 that stably 
overexpressed MAGEA2 in their normal media. Down-regulation of p21 in up-
regulated MageA in other cell line study (such as in ovarian study) is also seen in a 
publication with melanoma (Liu et al., 2008), and unpublished data (as 
communicated by Prof McNeish‟s team). 
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Figure 3.9  MAGEA2 interacts with p53 to regulate its pathway. Whole cell 
lysates were prepared from T47D VA and clone 30 cells and 30 g of lysate was 
immunoprecipitated for either MageA2 or p53. (A) Co-immunoprecipitation 
indicated that MAGEA2 was immunoprecipitated with antibody to MAGEA2 or p53. 
IgG was used as control antibody alongside Also, overexpression of MAGEA2 
down-regulated the acetylation level of p53 and its downstream effector, p21. (B) 
Deactylase inhibitor (Trichostatin A) treatment also showed that exogenous 
expression of MAGEA2 prevents p53 acetylation and subsequently p21 up-
regulation.  
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3.7.5. MAGEA2 and p53 co-localise in 
cytoplasmic compartment 
To date, there has not been any published data on the intracellular 
immunocytochemistry localisation of MAGEA2 in cells. We have shown in our 
study that the presence of MageA2 appeared as early as 12 hours after exposure to 
Tamoxifen containing media in both T47D and MCF-7 wild-type. The 
overexpressing clones of both cell lines co-localised with p53. The distribution of 
MageA2/p53 complexes was generally cytoplasmic apart from a few cells, which 
appeared to be either undergoing apoptosis, or had undergone apoptosis. In these 
cells, MAGEA2/p53-complexes are localised in the nucleus. 
In MCF-7 VA control cells, there was no or little MAGEA2 in keeping with RT-PCR 
results indicating low or no expression of MAGEA2 in MCF-7 WT (Figure 3.5). As 
MCF-7 wild type does not carry mutant p53, cells grown in their normal media do 
not express p53 protein, as seen in our confocal immunoflourescent results (Figure 
3.10). Upon exposure of MCF-7 VA control cells to Tamoxifen, expression of 
MageA2 was detected. Futhermore p53 localisation followed the same distribution as 
MageA2 (Figure 3.10B, 2
nd
 row). In the MCF-7 VA, after exposure to Tamoxifen 
containing media, most of the cells were undergoing apoptosis. In keeping with the 
immunohistochemistry study, we observed that the MageA2 and p53 localisation was 
in the nucleus (Figure 3.10B, 3
rd
 row). In healthy dividing cells, MCF-7 c18, 
MageA2 and p53 were localised in the cytoplasm. This finding is in keeping with our 
survival analysis of the immunohistochemistry results; cytoplasmic MageA2-staining 
was correlated with a worse prognosis, hence there appears to be greater cell survival 
potential. 
In T47D vector alone control cells, there is moderately low expression of MageA2 as 
expected as T47D wild type cells have a detectable level of MAGEA2 by real-time 
PCR (see Figure 3.11B). As T47D carry mutant p53, the intensity of p53 protein 
expression was seen in T47D VA (control cell) even when grown in their normal 
medium. The intensity of MageA2 and p53 increase in overexpressing clones (C30) 
particularly in Tamoxifen containing media.  
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Figure 3.10  MageA2 co-localises with p53 in MCF7. (A) Western blot indicates 
that MAGEA2 is localized in the cytoplasmic compartment of MCF-7 cells. 
Interestingly, overexpression of MAGEA2 up-regulated the protein level of p53 in 
MCF-7 cells. Cells (MCF VA and MCF-7 MAGEA2 clone, C24) were stained with 
anti-MAGEA2 and p53 (DO-1). Cells were treated with either with or without 10
-7
M 
taxmoifen for 24 hours. Cellular localisation was determined by confocal 
immunofluorescence microscopy, MAGEA2 is shown in green, and p53 is shown in 
red. Nucleus was stained with DAPI (blue). In healthy surviving cells, MageA2 is 
mainly localised in the cytoplasm of MAGEA2 overexpressed cells. In contrast, 
MageA2 and p53 became localised to the nuclear compartment of both cell lines in 
apoptosing-cells, or post apoptotic cells. 
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Figure 3.11  MageA2 co-localises with p53 in T47D. (A) Western blot indicates 
that MAGEA2 is localized in the cytoplasmic compartment of T47D cells (MageA2 
band as seen as the bottom most band with this antibody. Overexpression of 
MAGEA2 up-regulated the protein level of p53 in T47D cells is not so easily 
appreciated as T47D (WT/VA) normally carry detectable mutant p53. Cells (T47D 
VA and T47D MAGEA2 clone, C30) were stained with anti-MAGEA2 and p53 
(DO-1). Cells were treated with either with or without 10
-7
M taxmoifen for 24 hours. 
Cellular localisation was determined by confocal immunofluorescence microscopy, 
MAGEA2 is shown in green, and p53 is shown in red. Nucleus was stained with 
DAPI (blue). In healthy surviving cells, MageA2 is mainly localised in the cytoplasm 
of MAGEA2 overexpressed cells (see C30 in normal and also Tamoxifen media). In 
contrast, MageA2 and p53 became localised to the nuclear compartment of both cell 
lines in apoptosing-cells, or post apoptotic cells (see VA in Tamoxifen). 
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Transwell Migration study 
Transwells were used to used for the study of chemotactic response of MCF-7 (VA) 
and MCF-7 MAGEA2-expressing clone, C24. MAGEA2-expressing clones were 
significantly more chemotactic than control (VA) to media with serum (fetal bovine 
serum) at 18 hours. The migration towards serum was measured as total cells at the 
bottom of the well (cells which penetrated the filter), as a percentage of total cells 
(cells at the top well plus cells from the bottom well). The experiments were done in 
triplicates and at two separate times. The percentage of cells, which migrated to the 
bottom in the MAGEA2-expressing clone was visibly and objectively higher than 
MCF-7 vector alone (VA). The Student‟s t-test showed there was a statistical 
difference between the two groups with a p-value of 0.00023. 
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Figure 3.12 MAGEA2-overexpressing clone, C24 has a significantly higher 
migratory chemotactic ability when compared with VA in MCF-7 cell line. 
200,000 cells were plated into 24-well chemotaxis chamber and polyvinyl-
pyrolidone-free polycarbonate filters with 8 m pore size (Costar) and performed 
essentially as describe (see Chapter 2.11.4). After 18 hours, cells from the bottom 
well, and cells from the top well were trypsinised and counted separately. 
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3.7.6. MageA2 Immunohistochemistry Study 
 
An immunohistochemistry study was performed on breast cancer tissue. A cohort of 
129 patients, who had completed Tamoxifen treatment and had a complete clinical 
follow up. Seven cases were from relapsed patients‟ paraffin slides, which were 
provided by our collaborators at Charing Cross hospital. Of the 129 patients, a third 
were Tamoxifen-Sensitive (TS) while the majority 66% were Tamoxifen-Resistant 
(TR). A summary of the origin of the paraffin slides and the response rate in primary 
tissue and relapsed tissue is listed in Table 3.4. 
 
Table 3.4 MageA2 was positive in 31% of Tamoxifen-Resistant primary 
breast tissue, and 62% of relapsed breast cancer tissue. Total of 129 cases of 
paraffin slides were stained by using automated Ventana (see material and methods); 
at 1:50 dilution. Most paraffin slides were made from standard paraffin blocks, 
which have been kept in archive library (some for a duration of >15 years). 
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As described above, the microarray study indicated MAGEA2 to be significantly up-
regulated in Tamoxifen resistant in-vivo breast cancer cell lines. Hence MageA2 is 
likely to play as significant role in cell survival in relapsed tissue. For this reason, 
analysis for immunohistochemistry staining was separated into categories; in the 
primary breast tissue (n=121), and a rare but smaller collection of relapsed tissue 
(n=8). Relapsed tissues specimens are difficult to obtain, given that most patients 
with relapsed or metastatic breast cancer do not return to surgery as their subsequent 
line of treatment. Rather, they are restaged with radiology, and treated for metastatic 
breast cancer. In the relapsed samples were from ipsilateral breast cancer or locally 
relapsed breast cancer. The sensitivity for MageA2 was 62% in the relapsed tissue 
cohort, twice the sensitivity of primary tissue (31%). In the paired cases of primary 
and relapsed paraffin cases (7 cases from Charing Cross Hospital, and 1 case from 
Bart‟s and the London Hospital) in tamoxifen resistant cases (n=8), only 3 out of 8 
primary tissues were MageA2 positive, while 5 out of 8 relapsed cases were MageA2 
positive. The specificity for Tamoxifen-Resistant (TR) cells is considered high as 
only one sample of the Tamoxifen-Sensitive (TS) cells cohort was positively stained.  
 
When the positive cases were analysed in detail, MageA2 was either distinctly 
positive or not there at all (Figure 3.13D). The intensity of the positive stained slides 
were clearly positive, and localised to breast tumour cells. (There are however two 
types of staining, either cytoplasmic or nuclear staining). We analysed the series for 
survival with MAGEA2-positive against negative patients, as well as distinguishing 
between cytoplasmic or nuclear staining. The results showed a statistical significant 
survival advantage in the positively stained versus the negatively stained tissue in the 
group A category (Guy‟s and St Thomas‟ Hospital) and group B (Bart‟s and the 
London, and Charing Cross Hospitals), with p=0.0455 and p=0.0286 respectively 
(see Figure 3.13A and B). 
 
There was also a significant overall survival difference between the samples with 
cytoplasmic and nuclear staining, with nuclear favouring a better survival, p=0.0488 
(Figure 3.14B). This observation led us to carry out immuno-flourescent analysis (IF) 
with the intention to localise MageA2 within a cell with respect to p53. 
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Analysis was also independently undertaken by the statistical department at the 
Wolfson Institute (within the Charterhouse Square) to provide the exact value of 
MageA2 as a biomarker for predicting tamoxifen resistant in primary breast tissue 
(see Table 3.5). MageA2 is a good biomarker with a high specificity (80%) and a 
good sensitivity (38.5%) to predict tamoxifen resistant (TR) primary breast cancer 
tissue. MageA2 has a positive predictive value of 89%, which suggests that when 
MageA2 is positively stained, it has 89% likelihood that the primary tissue is 
predictive of TR. MageA2 has diagnostic odd ratio of 2.59 (95% CI; 1.07 to 6.28). 
Youden index is a measure for assessing the quality of a diagnostic test and is 
calculated from the sensitivity and specificity as Youden index = sensitivity + 
specificity -1. Positive predictive value (PPV) is very important proportion of a 
diagnostic; it is the probability that a patient has the disease when restricted to those 
patients who test positive. It is calculated as PPV = TP/(TP + FP). Whereas the 
positive likelihood ratio (PLR) tells you how much the odds of the disease increase 
when a test is positive and is calculated as PLR = Sensitivity/(1-Specificity). The 
diagnostic accuracy refers to the ability of a test to identify a condition of interest. It 
is (TP + TN) / (TP + FN+FP + TN). Diagnostic odds ratio (DOR) summarises the 
performance diagnostic test. It is calculated as DOR=(TP*TN)/(FP*FN). The higher 
the odd ratio, the better the „test‟. 
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Figure 3.13  Kaplan-Meier survival curves showing the relationship between 
positive and negative staining of MAGEA2 on disease-free and overall survival. 
Graph (A) composed of patients from Guy‟s and St Thomas‟ hospital (GSTH) and 
(B) of patients from Bart‟s and the London hospital (BTLH). A significant OS 
difference (p=0.0455 and 0.0286 was found respectively) between the MageA2-
positively stained and the MageA2-negative cohort. (C) Graph C is the combined 
analysis of GSTH and BTLH stained positive patients (only). A significant 
difference was detected in OS between the cytoplasmic and the nuclear MageA2-
stained tissue; p-value=0.0448, with the cytoplasmic staining cohort conferring a 
worst prognosis. (D) Immunohistochemistry staining of MAGEA2; left image shows 
positive staining and right image, negative staining.
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Figure 3.14 Cytoplasmic MageA2-staining predicted a worse prognosis than 
the nuclear MageA2-staining in disease free survival (DFS) and overall survival 
(OS). (A) Positive cytoplasmic MageA2-staining predicted a worse disease free 
survival prognosis compared with the positive nuclear MageA2-staining patients, 
with a significant p-value difference of p=0.0106*. (B) Positive cytoplasmic 
MageA2-staining predicted a worse overall survival prognosis compared with 
positive nuclear MageA2-staining, with a significant difference of p=0.0448*.  
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Table 3.5 MageA2 is a good biomarker with a high specificity (80%) and a 
good sensitivity (38.5%) to predict Tamoxifen resistant (TR) primary breast 
cancer tissue. MageA2 has a positive predictive value of 89%, which suggests that 
when MageA2 is positively stained, it has a 89% likelihood that the primary tissue is 
predictive of TR. MageA2 has diagnostic odd ratio of 2.59 (95% CI; 1.07 to 6.28).  
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Functional study (in-vitro) of EGLN3 (PHD3) 
EGLN3 is a member of the prolyl hydroxylase domain PHD family (also called 
EGLN family) that consists of three members, PHD1, PHD2 and PHD3 (Table 3.6). 
PHDs are Fe (II) and 2-oxoglutarate-dependent oxygenases that hydroxylate N- and 
C- terminal prolyl residues in HIF1a subunits. HIF (Hypoxia Inducible Factor) is a 
heterodimeric transcription factor composed of two subunits, HIF1α and HIF1β. 
(Percy et al., 2003) Hydroxylation of HIF1a, under normal oxygen conditions, on 
specific prolyl residues in ODD (oxygen-dependent degradation) domains (Pro564 
and Pro402) by PHDs generates a binding site for the pVHL (von Hippel-Lindau 
protein)-ubiquitin E3 ligase, tumour suppressor protein that promotes ubiquitination  
 
Gene Name Synonyms Intracellular localisation 
EGLN1 PHD2, HPH-2 cytoplasmic 
EGLN2 PHD1, HPH-3 nuclear 
EGLN3 PHD3, HPH-1, SM-20 (Rat) cytoplasmic and nuclear 
 
Table 3.6 HIF prolyl hydroxylase nomenclature and intracellular localization. 
 
 
 
and subsequent proteasomal degradation of HIF1α (del Peso et al., 2003), (Hagg and 
Wennstrom, 2005) (Figure 3.15). PHDs function as intracellular oxygen sensors due 
to the fact that the prolyl hydroxylation reaction is oxygen dependent. Under low 
oxygen conditions, HIFα is not hydroxylated and is translocated to the nucleus, 
where it dimerises with HIF1 and activates the transcription of HIF target genes 
such as GLUT1, p53, VEGF and EGFR (Chung et al., 2009; Pietras et al., 2010; 
Rigopoulos et al., 2010; Sendoel et al., 2010). HIF1β is not oxygen dependent 
(Rankin and Giaccia, 2008). PHD activity depends not only on the availability of 
molecular oxygen, but also on the availability of amino acids (Serra-Perez et al., 
2010). EGLN1 appears to be the primary HIF prolyl hydroxylase under normoxic 
conditions. EGLN2 and EGLN3 have only partial effects on HIF1α hydroxylation 
and therefore stability, and it is possible that they are mainly induced under specific 
conditions like hypoxia. 
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Figure 3.15  Regulation of HIF1α by PHDs and pVHL. Under normal oxygen 
conditions, HIF1a is hydroxylated on certain prolyl and asparagyl residues by PHDs 
and FIH (Factor Inhibiting HIF1) respectively, resulting in pVHL binding which 
leads to the polyubiquitination and proteasomal degradation of HIF1α. In hypoxic 
conditions, PHD and FIH are inactive and HIF1α is stabilized and translocates into 
the nucleus where it activates transcription [Figure taken from Abcam].   
 
Amatschek et al, measured the levels of EGLN3 by microarray analysis and 
RT-PCR in a number of normal tissues and cancers. They established that EGLN3 is 
highly expressed in renal cell cancer and lung squamous cell cancers whereas in 
normal breast tissue and breast cancer it was not expressed, or expressed at very low 
levels (Amatschek et al., 2004). Finding upregulation of EGLN3 in our Tamoxifen 
resistant cell line study was unexpected, but may represent a hypoxia-independent 
cell survival pathway. 
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3.7.7.  EGLN3 mRNA and protein 
overexpression in TR cell lines 
 
The microarray study on TR cells (see Figure 3.5 and Table 3.3) had shown that 
EGLN3 was up-regulated by 3.6 fold compared with wild-type. In order to confirm 
the microarray data, mRNA levels of EGLN3 in a number of different wt and TR cell 
lines were measured by RT-qPCR. EGLN3 expression showed a range of fold up-
regulation in almost all the TR cell lines compared with the TS breast cancer cell 
lines (Figure 3.16A). Of noteworthy, SKBR3, intrinsically Tamoxifen-resistant, and 
ER-negative breast cell line, also showed an increase in Egln3 in its TR counterpart. 
MDA-MD-361, a ER-positive breast cell line had no change in the level of Egln3 
protein in its TR counterpart. To validate that EGLN3 mRNA overexpression 
correlates with increased expression at the protein level, Western blotting was 
performed on breast cancer cell lines (Figure 3.16B). Egln3 upregulation was 
founding each case. In addition the oestrogen deprived cell lines, ODZR and 
ODT47D also had increase levels of Egln3 protein.  
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Figure 3.16  EGLN3 overexpression in TR breast cancer cell lines measured 
and assessed by qPCR and immunoblotting.  (A) RNA was extracted from TS and 
TR derivatives of breast cancer cell lines as indicated. cDNA was prepared and the 
levels of EGLN3 and GAPDH mRNA levels were quantified by qPCR. All cDNA 
products were diluted 1:3. Results were analysed using the standard curve method 
and were normalized against GAPDH levels. TR cells had previously been generated 
by growing wild type cells in media supplemented with tamoxifen for 6 months. Fold 
changes in expression between TS and TR lines is indicated for each pair of cell 
lines. 
(B) Whole cell lysate (10 μg) from wt and TR breast cancer cell lines were separated 
by SDS-PAGE and analysed by Western blotting, probing with antibodies against 
EGLN3 (24 kDa, the lower band) and HSC70 (70 kDa; loading control) as indicated.  
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3.7.8. Generation of EGLN3 overexpressing 
lines 
To examine functionally the association of EGLN3 with Tamoxifen resistance in 
breast cancer, stable T47D and MCF7 EGLN3 overexpressing clones were produced 
by transfecting wt cells with a pcDNA3.1/EGLN3 expression vector. For control 
lines I used the pcDNA3.1 transfected vector alone (VA) lines generated previously 
for the MAGEA2 study.  
 
A number of individual, G418-resistant stable clones were established in each cell 
line. Before using these clones, they were verified for expression of both EGLN3 
mRNA and protein.  
 
RT-qPCR results (Figure 3.17A) show that all but one of the individual clones 
overexpressed EGLN3 mRNA compared with the wt and VA controls. For T47D, 
almost all the clones express similar levels of EGLN3 except for T47D C15, which 
was used as an additional negative control. For MCF7, all clones overexpressed 
EGLN3 but C3 showed the highest levels compared with all the other clones. Protein 
levels of EGLN3 were also higher in the clones compared with the wt and VA 
controls as shown in Figure 3.17B. Furthermore, protein levels were broadly in line 
with mRNA levels. All the T47D clones showed similar expression and MCF7 C3 
clearly expressed greater levels of EGLN3 than the other clones. Subsequently, 
EGLN3 clones MCF-7 c3 and c7, and T47D c8 and c12 were used for functional 
study. 
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Figure 3.17  EGLN3 overexpression in T47D and MCF7 clones validated by 
qPCR and immuno-blotting. T47D and MCF7 wt cells were transfected with 
pcDNA3.1/EGLN3 vector and grown in selective media with G418. (A) cDNA was 
produced using RNA extracted from wt and VA cells and individual clones 
numbered as indicated. Levels of EGLN3 and GAPDH mRNA were quantified by 
qPCR. Wt cells and vector alone (VA) cells were used as negative controls. EGLN3 
levels were calculated using the standard curve method and were normalized against 
GAPDH levels. Pooled + is a pool of positive clones. (B) WCL (20 g) from T47D 
and MCF7 wt, VA and EGLN3-expressing cells were separated by SDS-PAGE. 
EGLN3 (24kDa) and GAPDH (32kDa) levels were detected by Western blot using 
the appropriate antibodies as described in Materials and Methods. Both wt cells and 
VA clones represent negative controls and GAPDH was used as a loading control. 
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3.7.9. T47D and MCF7 EGLN3 positive clones 
are less sensitive to tamoxifen 
 
In order to characterize the clones that overexpress EGLN3 and also to see how 
Tamoxifen affects their viability and proliferation, growth curves were produced. 
T47D and MCF7 wt cells and VA controls plus two EGLN3 clones for each line 
were grown in normal and Tamoxifen-containing media and the number of cells was 
counted daily over 7 days. 
 
For T47D cells, clones and controls proliferated at a similar rate in normal media 
(Figure 3.18A). However, in Tamoxifen-containing media, while the control cells 
declined in number over the 7 day time course, the EGLN3 expressing clones 
continued to proliferate although at a much slower rate than in normal media (Figure 
3.18B). This proliferation advantage reached significance in both EGLN3 clones (p-
value ≤ 0.05). 
 
Slightly different results were observed for MCF7 cells where the EGLN3-expressing 
clones appeared to have a growth advantage in both normal and Tamoxifen 
containing media (Figure 3.19A). Although this is significant in both normal and 
Tamoxifen containing media, only in the presence of Tamoxifen is the p-value ≤0.01.   
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Figure 3.18 EGLN3 expressing T47D cells have a proliferation advantage in 
Tamoxifen-containing media. 75,000 cells of wt, VA, EGLN3 C8 and C12 were 
plated in 6 well plates in triplicate for each condition and grown in normal media, 
(NM) or treated with 10
-7
M tamoxifen. Cells were harvested on days 3-7, trypsinised 
and counted (CASY counter). (A) Combined results of cell number for T47D cells in 
NM and Tam media from day 3 to day 7. (B) Expanded graph of cells grown in 
Tamoxifen from A to show differential growth of EGLN3 clones compared to 
controls. *P≤0.05. (C) Western blot of 20g/lane probe for Egln3 and Hs70 loading 
control as indicated.
 148 
 
 
Figure 3.19  Proliferation advantage of MCF7 EGLN3 clones. MCF7 wt, VA 
and EGLN3 C7 cells were plated as described in Figure 3.1 and counted. (A) 
Combined results of cell number from day 3 to 7 in normal and tamoxifen containing 
media. (B) Expanded graph for proliferation in normal media * p≤0.05. (C) 
Expanded graph for proliferation in tamoxifen-containing media ** p≤0.01. (D) 
Western blot of 20g/lane probed for Egln3 and Hs70 loading control as indicated. 
In order to study whether overexpression of EGLN3 affects cell viability and 
survival, the number of necrotic and apoptotic cells after incubation with Tamoxifen 
was determined using Annexin V and Propodium Iodide (PI) staining as used 
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previously to study MAGEA-expressing cells. Annexin V binds specifically to 
phosphatidylserine (PS), which is translocated from the inner membrane during early 
apoptosis. PI is used to distinguish apoptotic from necrotic cells. Necrotic cells are 
characterized by permeabilisation of the cell membrane (lysis) and therefore they can 
be detected by the DNA binding dye PI. Annexin V in conjunction with PI is used to 
differentiate live, apoptotic and necrotic cells.  
 
For T47D wt and VA cells the proportion of live cells after incubation for 24 or 48h 
in tamoxifen was lower, and the proportion of apoptotic cells had increased 
compared to cells maintained in normal media. In contrast, for both EGLN3-
expressing clones, C8 and C12 the number of live cells (light green columns) was 
higher in tamoxifen-containing media compared to normal media, further confirming 
that EGLN3-expressing cells have an advantage in tamoxifen-containing media 
(Figure 3.20A). The results for MCF7 derived lines were very similar to those for 
T47D (Figure 3.20B).  
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Figure 3.20  EGLN3 overexpression results in an increased proportion of live 
cells in Tamoxifen media. T47D and MCF7 wt, VA and EGLN3 clones were plated 
in 6-well plates at 200,000 cells/well and incubated for 24 and 48 hours in normal 
(NM) or Tamoxifen containing media (TAM). At harvest, cells were stained with 
Annexin V and PI and then were analysed by Flow Cytometry (see Chapter 2.11.3). 
In this assay live cells are non-fluorescent, apoptotic cells stain only with Annexin V 
and necrotic cells stain with both Annexin V and PI. All the incubations were done in 
triplicate. (A) T47D cells, 24h incubation. (B) MCF7 cells, 24h incubation.  
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3.7.10.  Localisation of EGLN3 expression in 
the presence and absence of Tamoxifen 
I wanted to see if the localization of Egln3 differs between VA from the EGLN3-
overexpressing clones in both cell lines. Immunoflourescent study was undertaken 
after probing the cells with Egln3 antibody and other potentially associated proteins 
(as postulated by publications), such as HIF1, phosphorylated-Rb and also 
MageA2. The later being a random screening as we were also working on MageA2 at 
the same time, and the ingenuity pathway analysis suggested that the two pathways 
(MageA2 and Egln3) might be linked. 
 
As seen from Figure 3.21, EGLN3 is overexpressed in Tamoxifen resistant cells. 
Immunofluorescence microscopy was used for the localization of EGLN3. By using 
the same method of antibody staining, HIF1α, MAGEA2 and pRb were localized. 
Furthermore, investigated the effect of EGLN3 overexpression on these proteins. The 
same set of cells, MCF-7 VA and C7, and T47D VA and C12 (C7 and C12 are 
positive-EGLN3 clones respectively) were stained in their normal media and the 
Tamoxifen containing media. 
 
T47D and MCF7 VA and EGLN3 cloned cells upregulated EGLN3 and MAGEA2 
when they were treated with Tamoxifen for 24h. This result can be compared with 
the protein levels found by Western blot in (Figure 3.16). EGLN3 is expressed in 
both the cytoplasm and the nucleus. HIF1a is not expressed or is expressed at very 
low concentrations in all the T47D cells. In fact, it is down-regulated in Egln3 clones 
(C12, in Normal Media, NM) as seen in Figure 3.22 and at higher resolution of 
Figure 3.20. 
 
In the T47D and MCF-7 VA, the up-regulation of MAGEA2 is most distinct when 
exposed to Tamoxifen containing media. The positive T47D and MCF-7 EGLN3 
clones have shown up-regulation of MAGEA2 but to a lesser extend. 
Egln3 protein co-localised with phos-Rb protein as seen in both Figure 3.21 and 
3.22. 
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Figure 3.21  EGLN3 localisation in T47D cells and overexpression when cells 
are treated with Tam. Four million cells (T47D VA and T47D C12) were seeded on 
9cm plate containing five sterile glass coverslips and incubated for 24 hours in 
normal or tamoxifen containing media, fixed with paraformaldehyde, permeabilised, 
blocked, probed with primary antibody overnight and then with secondary antibody. 
Coverslips were then stained with DAPI and examined using the 
immunofluorescence microscope (Confocal). DAPI is stained blue (nuclei), mouse 
Ab green (EGLN3) and rabbit Ab red (HIF1α, MAGEA2, pRb). NM=normal media, 
TamM=Tamoxifen containing media.   
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Differentially, in MCF7 cells, HIF1α is expressed at higher levels and it seems that is 
coexpressed with EGLN3, with a slight predominance in the cytoplasm. Finally, pRb 
is coexpressed and co-localised with EGLN3 especially in cells treated with 
tamoxifen (Figures 3.19 and 3.20).  
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Figure 3.22  EGLN3 localisation and overexpression in MCF7 cells. MCF7 VA 
and C7 cells were prepared as described in Figure 3.8 for the T47D cells, probed 
with the same antibodies and examined in the immunofluorescence microscope 
(Confocal). 
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3.7.11. Does EGLN3 expression alter levels of 
hypoxia-associated proteins? 
 
In order to look for a connection between EGLN3 expression and other molecules 
associated with the hypoxic response that may also be implicated in tamoxifen 
resistance we examined a number of proteins by Western blotting including HIF1α, 
HIF1β (ARNT), acetyl-p53, pAkt, BNIP3 and GLUT1. As described in the 
introduction, the EGLN3 family of proteins is mainly implicated in the hypoxia 
pathway since HIF1α is their most well defined substrate. Moreover, EGLN3 is 
normally a HIF1 target gene during the response to hypoxia. For this reason I first 
looked at the proteins that are main players in that pathway, HIF1α and HIF1β. In 
T47D clones that overexpressed EGLN3 there was a decrease in HIF1α levels  
compared to controls. HIF1β and GLUT1 (another HIF1α target gene) protein levels 
were also examined in both cell lines. GLUT1 levels were constant in all lines while 
HIF1β levels appeared to be increased in the EGLN3 clones compared to most of the 
controls (Figure 3.23).  
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Figure 3.23  Expression of hypoxia pathway proteins in EGLN3 lines. WCE 
(20μg) from T47D and MCF7 wt, VA and EGLN3 overexpressing cells were 
separated by SDS-PAGE. EGLN3 (24kDa), HIF1α (120kDa), HIF1β (87kDa), 
GLUT1 (55kDa) and GAPDH (32kDa) levels were detected by Western blot using 
the respective antibodies as indicated. Both wt cells and VA clones were used as 
negative controls. T47D C15 did not express EGLN3 (see Figure 3.15) and was used 
as an extra negative control. GAPDH was used as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24  Expression of acetyl-p53, pAkt and Raf in EGLN3 clones. WCE 
were examined by Western blot as described in Figure 3.25 for acetyl-p53 (53kDa), 
pAkt (60kDa), Raf (68kDa) and GAPDH (32kDa) proteins. GAPDH was used as 
loading control. 
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HIF is a usually is diverted to ubiquitinate with VHL protein by EGLN1 and 2 (or 
also known as PHD 1 and PHD 2) and subsequently degraded. We expected EGLN3 
to decrease HIF as well. But with the HIF availability reduced, the HIF 
transcription factor should also be deactivated, or not activated. Hence, what 
alternative pathway is actually stimulating cell proliferation, in the absence of HIF-
transcription, p53, P13K/Akt and Ras/Raf pathways were studied in our VA and 
EGLN3-overexpressing clones for the reasons that we were looking for alternative 
pathways (Figure 3.24) which may be responsible for the cell survival advantage.  
 
For MCF-7, HIF1 protein is not down-regulated at all in EGLN3-overexpression in 
the clones. As stated in Introduction Chapter, a number of cellular oncogenes have 
been reported to promote HIF stabilization, which in turn might facilitate solid 
tumour growth. Some oncogenes, such as activated Ras, block HIF prolyl 
hydroxylation and thereby promote HIF accumulation (Chan et al., 2002). In contrast 
PI3K/AKT can promote HIF accumulation without an apparent change in HIF 
hydroxylation, possibly through activation of mTOR and HIF hydroxylation. There 
is a marginal increase in pAkt in the both the T47D and MCF-7 EGLN3 expressing 
clones compared with VA.  
 
P53, PI3K/Akt and Ras/Raf pathway proteins are all implicated in cell proliferation, 
survival signaling and resistant to Tamoxifen, and therefore might play and 
important role in Tamoxifen resistant role caused by EGLN3 overexpression. In my 
experiments, I have not found substantial connection between these pathways with 
the over-expression of EGLN3. 
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3.7.12. Investigating if MAGEA2 is downstream 
from EGLN3 and if it is responsible for cell 
proliferation in Tamoxifen Resistance 
In some experiments where samples from EGLN3-expressing clones had been 
examined together with MAGEA2 clones, I noted that MageA2 levels seemed to be 
higher in Egln3 clones than the controls. Interestingly while MAGEA2 was not 
expressed in wt or VA cells in either cell line as expected it was overexpressed in all 
the EGLN3 positive clones in both MCF-7 and T47D derived cell lines (Figure 3.25). 
Subsequently the MAGEA2 clones were examined for EGLN3 expression by qPCR 
but EGLN3 was not detected in any of the MAGEA2 expressing lines (data not 
shown). 
 
 
 
Figure 3.25  MAGEA2 overexpression in EGLN3 positive clones. cDNA was 
prepared from RNA extracted from T47D and MCF7 wt, VA and EGLN3 clones as 
indicated and the level of MAGEA2 and GAPDH mRNA levels were quantified by 
qPCR (see Chapter 2.9.2). All cDNA products were diluted 1:3. Results were 
analysed using the ΔCt method and were normalized against GAPDH levels. + pool 
is a pool of EGLN3 positive T47D clones.  
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As I found there was an up-regulation of mRNA of MAGEA2 in all the EGLN3 
clones (see Figure 3.25), but no up-regulation of EGLN3 in MAGEA2 positive 
clones, I set out to test if MageA2 is expressed downstream of Egln3 or if MageA2 is 
up-regulated concurrently with Egln3 (indirect). I used the Smart pool-Dharmacon 
siRNA (4 siRNA: Genome and on-Target; L-004274-00-0005) for Egln3 knockdown 
and achieved 90% protein knockdown (Figure 3.26). I immunoblotted for MageA2 
with the same lysate, which showed no knockdown. A proliferation study was 
undertaken using the suphorhodamine assay (SRB) to evaluate the effect of the 
clones on cell proliferation in normal media and tamoxifen media. This method relies 
on the uptake of the negatively charged pink aminoxanthine dye, SRB by basic 
amino acids in the cells. The greater the number of cells, the greater the amount of 
dye is taken up. After fixing, when the cells are lysed, the released dye will give a 
more intense colour and greater absorbance when measured by spectrophotometer. 
The benefit of this assay is that viable cells can be quantitated within 12 hr to 72 hrs. 
As Egln3 has been shown to support cell survival, in the knockdown of Egln3 we 
expected the reverse finding.  
 
The knockdown of Egln3 in positive Egln3 clones (rescue knockdown) cells were 
less in numbers and by SRB assay as shown in our graph in Figure 3.26. However, 
MageA2 is up-regulated in siRNA (Egln3) cells compared with non-silenced cells, 
which suggest that althought MageA2 is found to be up-regulated in mRNA levels in 
Egln3 positive clones, the knockdown of Egln3 did not reverse the MageA2 levels at 
48 hr. We conclude that siRNA of Egln3 in positive Egln3 clones resulted in less cell 
viability and MageA2 is not downstream of Egln3 expression. 
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Figure 3.26 Rescue knockdown of Egln3 in Egln3-positive T47D cell lines 
resulted in decrease cell viability within 48 hrs. (A) Graph showed that T47D 
Egln3-overexpressing clones c8 and c12  which had successful Egln3-siRNA 
knockdown was significantly less viable than non-silencing (control) c8 and c12, 
with a p-value of 0.0012 and p 0.0009 for c8, and c12 respectively, by 
suphorhodamine (SRB) assay. The experiment design included two positive Egln3 
clones, c8 and c12 in T47D. Cells were seeded at a density of 5 x 10
3
 cells/well in 
100 µl in 96-well plate in triplicates. Cells were then transfected with either non-
silencing vector (All star) or by siRNA EGLN3 as detailed above. Cells were 
incubated for 48 hrs after transfection with AMAXA Nucleofection. Then read at 
492 nM with a spectrometer. 
 
In rescue knockdown of Egln3, MageA2 protein expression is retained or even 
increased, therefore expression of MageA2 is not a consequence of Egln3 
expression. (B) Immunoblot of 30g of WCL (whole cell lysate) of the non-
silencing (NS) c8, NS c12, with siRNA (Egln3) c8, siRNA (Egln3) c12, the far  left 
is a postive control for MageA2. Hs70 was used as a loading control. 
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3.7.13. Immunohistochemistry study of Egln3-
staining 
3.7.13.1. Survival analyses for positive 
EGLN3-staining in primary breast cancer 
tissue 
Tissue samples of the same cohort of 129 patients as used for the MAGEA2 
immunohistochemistry study, were stained for Egln3 using the same 
immunohistochemistry protocol.  The slides were scored by myself and an 
independent trained pathologist, Dr Yaohe Wang. The antibody was optimised on a 
paraffin block made of MCF-7 EGLN3-expressing clone (clone 7), and tonsil as 
recommended by the protocol. The dilution were optimised by testing it against 1:25, 
1:50, 1:100 and 1:200. I used 1:300 for primary antibody and 1:200 goat anti-rabbit 
secondary antibody. 
The histopathology scores were calculated using an equation which combined the 
intensity of staining with that of percentage of tumour cells involved. A final score of 
either 0, 25, 50, 75 or 100% multiplied by 1, 2 or 3 (according to intensity) was 
calculated. The highest possible score was 300, while the lowest score was 0. Most 
slides were positively stained and had an intensity of 1, with areas of 25%. A cut-off 
of 150 was used as a positive EGLN3 score. 
Using the positive EGLN3 score cases, I analysed the disease-free survival (DFS) 
and overall survival (OS) using Prism (Version 6.0). Analysis of outcome data was 
based on information received as of March 2009. Kaplan-Meier curves were used to 
quantify the values of disease free and overall survival. This software calculated the 
median days of survival, and also the p-value between the positively stained and the 
negatively stained cases using the Gehan-Breslow-Wilcoxon test. 
There was no significant difference between the positively stained and the negatively 
stained tissue samples in either DFS or OS as shown in Figure 3.27. Moreover, 
EGLN3 appeared to be present in almost ever slide, in every type of cell. However it 
was much more intense in the Tamoxifen-resistant group, and breast carcinoma cells. 
This suggests that it may be a protein which cells require for sustainance but is 
expressed in abundance in TR cell type. 
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Figure 3.27 No significant difference in overall (OS) or disease free survival 
(DFS) between positive and negative EGLN3 samples. Immunohistochemistry 
staining of 1:300 dilution of Egln3 (Ab30782) using the automatic Ventana machine 
(see Chapter 2.14). (A) Positive EGLN3-staining on the breast cancer primary tissue. 
(B) Negative EGLN3-staining. (C) Using the Gehan-Breslow-Wilcoxon equation,the 
OS was not significant between the positive EGLN3-stain from the negative EGLN3-
stain with a p value of 0.5748, with a HR=1.058 (95% CI; 0.6022-1.858). (D) There 
was no significant in DFS between the positive EGLN3-stan from the negative 
EGLN3-stain, with a p-value of 0.1816; HR=1.493. 
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When the data were analysed by an independent statistical faculty (Wolfson Institute, 
under J Cuzack), Egln3 as a biomarker was found have a sensitivity of 42.8% in 
Tamoxifen resistant primary breast cancer tissue, with a specificity of 66%, with a 
diagnostic odd ratio of 1.5. This  means that Egln3 has greater negative predictive 
value (85%) than it does as a positive predictor, i.e. a negatively stained TR primary 
breast cancer tissue is highly unlikely to be TR. The table below gives the results of 
formal statistical analyses by an independent statistic institute. 
 
 
 
 
 
 
 
 
 
Table 3.7 Statistical analysis showed Egln3 as a stand alone biomarker had 
a good sensitivity (42%) but a poor specificity ( 66%) for predicting Tamoxifen-
resistant (TR) in primary breast cancer tissue. The negative likelihoofd ratio of 
85% is high, which indicate that a negative Egln3 is likely to be a true negative, 
hence a high possibility of the patient being Tamoxifen sensitive (TS). 
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3.7.13.2. Survival analysis for combined 
MageA2 and Egln3-staining in primary 
breast cancer tissue 
 
As MageA2 was incidentally found in EGLN3 overexpressing clones in MCF-7 and 
T47D breast cell lines, we decided we will analyse the survival of the cohort who 
had positive staining of both MageA2 and Egln3. Eighteen of the 129 patients were 
MageA2 and Egln3 positive. This made up 18 out of 72 total Tamoxifen Resistant. 
This supported a sensitivity rate of 25% of the TR tissue samples.  
 
When survival analysis was carried out (Figure 3.28), the combined MageA2 and 
Egln3 positive stained tissue of the patients had a trend for poorer prognosis in DFS 
and OS but did not reached statistical significance. The p-value 0.239 between the 
double positive staining with the patients with double negative staining (HR=0.4041; 
95%CI: -0.09to 0.89). The DFS graphs suggested that the most distinct difference in 
the double-positive staining is seen within the first 4000 days from day of diagnosis, 
but the four lines soon converge on longer follow-up. 
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Figure 3.28 (A and B) Double positive-staining (MageA2 and Egln3) in human 
tissue (n=122) had a trend towards a poorer prognosis in DFS and OS, but this 
did not reach statistical significance. (A) Disease free survival graph depicting the 
survival of the four subgroups; Red=combined positive MageA2 and Egln3 staining, 
Green=Positive mageA2, and negative Egln3 staining, Black=Negative MageA2, and 
positive Egln3, Blue=Double negative MageA2 and Egln3. There is a trend for the 
double positive staining (red) to predict for poorer prognosis, but this did not reach 
statistical significance. (B) Overall survival graph showed there was a trend for 
double positive staining to predict worse OS, but this did not reach statistical 
significance. 
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CHAPTER 4:  ANALYSIS OF 
BREAST CANCER HUMAN TISSUE USING 
EXON GENE-EXPRESSION AND GENOME-WIDE  
SNP6.0 PROFILING. 
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4.  Study design 
The main aim of this study was to use array technology to try to determine a set of 
genetic markers in breast cancer patients that is predictive of response to tamoxifen 
using a small but unique set of samples identified in the breast tumour bank from 
Guys and St Thomas / King‟s College London (GSTFT/KCL) Breast Tissue Bank. 
Patients were selected from those recruited between 1984-1991 into the European 
Oncology Research Trial Consortium (EORTC) 10850 & 10851 studies and access 
was granted under the LREC Ref 06/Q0603/25.  
 
Cases from these trials were selected because: 
1. These were elderly patients (all greater than 70 years old) - a population for 
whom the prolongation of tamoxifen effectiveness is highly clinically relevant. 
2. There is long-term, complete clinical follow up data for these patients 
maintained in a curated, computerised database. 
3.  All the tumours were ER+ and patients were randomised to receive either 
radical mastectomy or wide local excision (WLE) followed by 20mg 
tamoxifen daily.  
4. No further treatment was administered for their disease, therefore clinical 
outcome represents either tamoxifen sensitive (TS; defined as cases with no 
recurrence for 10 years) or tamoxifen resistant (TR; defined as relapsed 
within 5 years) breast cancer. 
5. A subset of patients had a positive margin after their WLE primary surgery 
but chose not to have re-excision surgery, and were instead put on tamoxifen. 
Interestingly, this small group of patients were all found to be tamoxifen 
responsive with no recurrence for 10 or more years. Microarray data from 
these cases may therefore be particularly representative of a tamoxifen 
sensitive cohort of patients.  
6. All primary tumours were formalin fixed but in a proportion of cases part of 
the tumour was cryopreserved in RNAse-free conditions in liquid nitrogen 
and therefore potentially suitable for recovery of RNA for array analysis. 
7. Two of the patients had paired samples; where frozen tissues from both 
primary surgery and the relapsed stage were obtained. The relapsed fresh 
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tissues will give informative microarray data, which may be indicative of 
resistance mechanisms. 
 
Cases for which frozen material may be available and therefore potentially suitable 
to use for an array-based study were identified by a previous clinical fellow 
(Charlotte Moss, PhD Thesis, 2008), using the selection criteria outlined above (see 
Table 4.1). A “training set” of 25 fresh frozen specimens (17 Tamoxifen resistant, 8 
Tamoxifen sensitive) were selected for analysis on Exon Expression arrays, SNP 6.0 
genome-wide chops and microRNA analysis. Although limited in number, the 
uniqueness of these samples (in particular the TS), make this study valuable. Our 
hypothesis was that by studying this unique set of tamoxifen treated patients in 
highest molecular detail using these Array Chips, the maximum amount of 
information would be generated which would, over time, allow the data to be mined 
in multiple ways as new generations of analysis software becomes available. 
 
 
4.1. Sample Handling 
 
For those cases where frozen tissue was available, 0.5cm
3
 samples were made 
available to us. In addition to the frozen tissue, 25 freshly cut paraffin sections per 
patient and a slide with H&E staining were obtained. For validation purposes, 25 
paraffin sections were also received from each of a further 50 unselected ER+ cases 
from the same trials (see Materials & Methods, section 2.13). 
 
From the H&E sections, two independent trained physicians quantified the 
percentage of tumour from the block of fresh frozen tissue. These are documented 
Table 4.1. The average percentage tumour content was 75% per sample. The average 
weight per sample received was 160mg. As the percentage of tumour content was 
high, I decided against using laser capture microdissection (LCM) with the benefit 
that the tissue would undergo less manipulation. In the one case where 20% of the 
block was tumour, I have also included the whole tissue for extraction of RNA and 
DNA.  
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Table 4.1  Characteristics of the „Training‟ set samples 
Two independent clinicians estimated the percentage of tumour from the H&E slide 
to determine the tumour content of the fresh frozen samples (7
th
 and 8
th
 column). The 
Tamoxifen Response status of each patient was given as R=resistant and S=Sensitive 
(2
nd
 column). Where surgical margin was documented, pos=positive margin and 
neg=negative. The precise weight from the tissue is shown in the 5th column. Tissues 
were either obtained at primary diagnosis (before endocrine therapy) or at relapse. 
This is documented in the 4
th
 column. Specimens highlighted in yellow represent the 
paired-samples; 5008 & 5009 and 5018 &5018_2 (diagnosis & relapsed tissue 
respectively). 
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4.2. Optimisation of RNA and DNA Extraction 
Method 
 
I optimised the extraction of RNA and DNA by comparing a number of available 
methods as charted in Table 4.2 using fresh frozen normal breast tissue (obtained 
from Prof Louise Jones) and some normal liver, kidney and spleen tissue from rats. 
The human „practice‟ tissue had been stored for approximately as long as our training 
set frozen tissues (15 years). Other studies that have used tissue from this same breast 
tissue bank (GSTH) have reported good quality RNA and DNA extraction (Loi et al., 
2008). The preferred method for extracting RNA was found to be using the RNeasy 
Mini Kit from Qiagen. This gave the purest RNA without compromising the quantity 
retrieved. The method settled on for extracting DNA, after testing several 
reagents/kits was using the DNeasy Mini kit from Qiagen. Again, this method gave 
the most consistent quality of DNA with the quickest protocol. Various other 
methods were assessed using rat organ tissues and normal breast tissues.  
 
Quality of the RNA was checked with Agilent 6000 Nanochips to determine the 
RNA Integrity Number (RIN). Samples with a RIN value of less the 6 are not 
considered suitable by our Microarray Facility (Tracy Chapman, personal 
communication). Quality of DNA was measured using agarose gels. Quantity was 
measured using nanodrop photospectrometer. The ratio of absorbance at 260 and 280 
nm was used to assess the purity of DNA and RNA in addition to the Agilent 
nanochip. A ratio of ~1.8 is generally accepted as “pure” for DNA; a ratio of ~2.0 is 
generally accepted as “pure” for RNA. If the ratio is appreciably lower in either case, 
it may indicate the presence of protein, phenol or contaminants that absorb strongly 
at or near 280 nm.  
 
260/230 ratio is a secondary measure of nucleic acid purity. The 260/230 values for 
“pure” nucleic acid are often higher than the respective 260/280 values. They are 
commonly in the range of 1.8-2.2. If the ratio is appreciably lower, this may indicate 
the presence of co-purified contaminants.  
 
I extracted RNA and DNA from all the training set samples using the optimized 
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procedures and confirmed all had good quality RNA and DNA using the above 
criteria. 
 
 
Methods Tissue Amount RNA total DNA total 
Quality 
RNA Quality DNA 
TRIzol alone NBrT 1 60mg 11 µg   RIN=7   
TRIzol alone NBRtT2 72mg 86 µg   RIN=7   
TRIzol alone NBrT2/2 186mg 230 µg   RIN=6   
TRIzol alone NBrT3 128mg 48.7µg   RIN=6   
TRIzol/RNeasy kit NBrT4  90mg 27µg   RIN=7   
DNA/RNA midi kit (Q) S(M) 60mg 106 µg 43 µg RIN=0.3 good 
DNA/RNA midi kit (Q) K(M) 62mg 35 µg 14 µg RIN=6.2 good 
DNA/RNA midi kit (Q) H(M) 50mg 9.3 µg 14.5 µg   good 
DNA/RNA midi kit (Q) Lung(M) 50mg 47 µg 65 µg   good 
TRIzol/RNAeast kit L(M) 50mg 49 µg   RIN=3.5 good 
DNA/RNA midi kit (Q) L(M) 30mg 2 µg 39 µg RIN=2.2 good 
DNA/RNA midi kit (Q) S(M) 30mg 2.4 µg 2.9 µg RIN=1.5 good 
DNAeasy mini kit L(M) 10mg   10.1 µg N/A good 
DNAeasy mini kit L(M) 10mg   4.5 µg N/A good 
RNeasy mini kit K(M) 10mg 15.2 µg   RIN=7.4 N/A 
RNeasy mini kit  K(M) 10mg 21.7 µg   RIN=7.5 N/A 
TRIzol/RNeast kit K(M) 12.5mg 45.7 µg   RIN=7.4 good 
TRIzol/RNeast kit K(M) 12.5mg 46.3 µg   RIN=7.5 good 
 
 
Table 4.2 Optimisation of RNA and DNA extraction from tissue. 
TRIzol/RNeasy=Improvised combined TRIzol and RNeasy protocol, DNA/RNA 
midi kit (Q)=Commercially available simultaneous extraction of RNA and DNA 
from Qiagen. The 2
nd
 column specifies which tissues were used for the optimisation: 
NBrT=Normal Breast Tissue, S(M)=Spleen(Mouse), K(M)=Kidney(Mouse), 
H(M)=Heart(Mouse), Lung(M)=Lung(Mouse), L(M)=Liver(Mouse). The 3
rd
 column 
shows the amount of starting tissue used. The 4th and 5
th
 columns show the final 
amount of RNA and DNA respectively. Quality of RNA was assessed using the 
Agilent Bioanalyser, RIN=RNA Integrity Number (value from 1-10, 10 being the 
highest quality and most intact RNA). N/A=not applicable. 
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4.3. Exon expression array processing and 
quality control 
Latest generation human expression Affymetrix array chips, the Human GeneChip 
Exon 1.0 ST, were used for our human samples of breast cancer in preference to the 
Human U 133 plus 2.0 used in the cell line study. The key differences between the 
two types of expression chips are described in the Materials & Methods (Section 2.8) 
together with a more detailed description of the array procedure. Two configurations 
of the WT Sense Target labelling assay are available. The 100ng total RNA protocol 
is recommended for analysis of the gene level as this protocol allows for the 
omission of the ribosomal RNA (rRNA) reduction procedure, and hence benefits 
from a larger number of high-quality probes selected from the entire transcript. The 
1g total RNA with the ribosomal reduction procedure is recommended for Exon 
level analysis. A recent report from the Patterson lab 
(www.affymetrix.com/userforum), found Exon-level results were still good without 
the ribosomal reduction stage (riboMinus). They hence have supported the use of the 
100ng protocol in cases where RNA quantities are limited. In some samples where 
we had sufficient tissue, an optimising experiment was carried out using the same 
amount of starting total RNA with and without the ribosomal reduction stage. The 
resulting mRNA samples were then compared. I used real-time PCR to quantify for 
housekeeping genes such as 18S and GAPDH. I found that although residual rRNA 
levels in the non-ribosomal reduced were higher, the mRNA were otherwise very 
similar. I therefore processed all the samples using the 100ng protocol. 
 
Briefly, 100ng of total RNA was extracted from human breast tissue and prepared 
into probes as per Affymetrix GeneChip®Whole Transcript (WT) Sense Target 
Labeling Assay (i.e. Exon) protocol. Biotinalyted cRNA (A260/A280 ratio between 
1.8 and 2.1) was prepared for each experimental sample and hybridised to 
Affymetrix GeneChip®Whole Transcript (WT) arrays. There are two quality control 
steps in the preparation of the probes. One is the amount of the cDNA after the IVT 
steps, and the other is qualification of the fragmented ssDNA using Agilent. All 
probes reached acceptable standards. Hybridisation, scanning and image analysis was 
performed by Tracy Chaplin (Institute of Cancer); after scanning, array images were 
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assessed by eye to confirm scanner alignment, the absence of significant bubbles or 
scratches on the chip surface, and the absence of slides with very high background.  
 
Raw data were assessed for quality using the Affymetrix Power Tool statistical 
package (Affymetrix Console, url) as described in Materials and Methods 2.8.  
 
4.4. Normalisation and Transformation of Raw 
Array Data 
The aim of these analyses was to identify differentially expressed genes in tamoxifen 
resistant samples (TR) from those of tamoxifen sensitive samples (TS).  In order to 
minimise variation between arrays caused by biological and experimental factors, it 
was important to perform appropriate data transformation and normalisation. First of 
all, data were transformed into CEL files. The Affymetrix GeneChip®Whole 
Transcript (WT) (Exon Array) has a universal background correction known as 
Detection of Average Background (DABG).   
 
Subsequent analysis involved normalisation and transformation of raw array data 
using the Robust Multi-array Average (RMA) (Irizarry et al., 2003) from the 
Affymetrix Power Tool (APT) software. The RMA method was used for gene-level 
summary and probe-set level summary. Box plots of all of the normalisation methods 
confirmed that transformation of the data is such that the distribution of probe 
intensities for every array in the set of the twenty-five arrays used in this experiment 
are the same and fit the same distribution (See Figure. 4.1A).  However, it is clear 
from the histograms that this distribution is a normal distribution, which is applied to 
any downstream parametric statistical analysis (Figure 4.1B). This confirms the data 
appears to be transformed in such a way that the distributions of probe intensities for 
every array in the set of twenty-five arrays used in this experiment are the same and 
the data resembles a normal distribution.   
 
Further criteria set on the data filter included: 
 removal of control and un-annotated probe sets, detection above background 
(BG) p value >0.05; removal of the genes which were absent or un-
transcribed, 
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 removal of probe sets that do not change significantly i.e. remove flat 
profiles and coefficient of variance (cv)=0.01. 
 removal of probe sets which did not change significantly in at least one of 
the samples with an absolute value at the 10
th
 percentile. 
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Page for Fig 4.1 A and B 
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4.5. Hierarchical Clustering Analysis 
RMA normalised data were imported into the Affymetrix Power Tool (Part of the 
available Affymetrix Console) in order to allow a hierarchical clustering analysis to 
monitor overall patterns of gene expression between the normalised arrays (Materials 
and Methods 2.8.3; (Eisen et al., 1998).  Briefly, a hierarchical clustering analysis 
produces a map of results where probe sets are grouped together based on similarities 
in their patterns of normalised expression across the twenty-five arrays.  As the 
processed data follows a normal distribution it is appropriate to use the Pearson 
Correlation Coefficient, which calculates the similarity measure based on a linear 
model.  Because we are interested in genes that change their expression between the 
reference and test groups, data were further filtered to include the 10,000 probe sets 
with the highest variance across the twenty-five arrays.  
 
The same algorithm was also applied to cluster the experimental samples for 
similarities in their overall patterns of gene expression. Arrays hybridised with the 
reference samples formed their own cluster, indicating that there is a pattern of 
differential gene expression in the subset of TR patients compared to the TS ones.  
There was a general pattern of TR arrays clustering apart from TS arrays (BTB357, 
5025, 5026, BTB378 and 5012 and 5027 in Figure 4.2). There were three outlier TS 
samples (5014, 5024 and 5023) but even these clustered in the opposite arm of each 
hierarchy branch.  
 
4.5.1. Principle Component Analysis 
 
Principle Component Analysis (PCA) is a statistical method of identifying patterns in 
data, and expressing it in such a way as to highlight similarities and differences. 
Since patterns can be hard to find in data of high dimension, where graphic 
representation is not available, PCA is a powerful tool for analysing microarray data. 
The other main advantage of PCA is that once you have found these patterns in the 
data, you can compress the data by reducing the number of dimensions, without 
much loss of information. This is a non-parametric analysis and the result is unique 
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and independent of any hypothesis about data probability distribution. However, the 
latter two properties are regarded as weaknesses as well as strengths. 
The differences in clustering between TR versus TS were also found to be distinct 
when using PCA (Materials & Methods 2.8.3.1.). Using a commercially available 
statistical analysis software from Partek®, PCA diagrams of the normalised data 
were generated, illustrated in Figure 4.3A. This represents another way of looking at 
how the data cluster with respect to each other. Our PCA analysis confirmed the 
clustering of the TR group away from the TS group, and to a lesser extent, clustering 
of the relapsed tissue specimens from the diagnostic tissue specimens (Figure 4.3C). 
To investigate operational error, as only 5 probes were able to be prepared per week, 
PCA was carried out according to the date on which the probes were processed 
(Figure 4.3B). The PCA analysis did not show any clustering from specimens 
processed on the same date, which demonstrates that there was minimal batch and 
operational influence on our data. 
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4.6. Predictive Tamoxifen Resistant Differential 
Gene Expression Analysis 
RMA normalised data were imported into LIMMA in R software for statistical 
analyses.  As well as fitting a normal distribution, another assumption of statistical 
analyses, such as the widely used Student's t-test, is that the variability of a gene is 
constant across treatment types.  However, in the absence of accurate diagnosis 
methods, it is safest to assume that variability may differ between our reference (all 
the TS) and test (all the TR) groups.  As we have confirmed that our data fits a 
normal distribution, it is appropriate to conduct a Welch‟s t-test, which is a 
parametric analysis that corrects for difference in variability.  Most of the subsequent 
data analysis (for both Exon and SNP arrays) was done by Dr Claude Chelala 
(Bioinformatics group, Institute of Cancer) using in-house software. In a few stated 
incidences I have also used Partek software when it offered a better illustration of the 
results than the in-house program. 
 
As we are interested in identifying genes that change their expression between the 
reference and test groups, LIMMA was used for differential expression between TR 
and TS samples. Using a 2-fold cut-off and a p value <0.05, the list generated was 
one of 20 genes with significant change (see Table 4.3). However, it was felt that it 
would be more informative to look at the top 500 significant genes based on p value 
<0.05 rather than filtering on arbitrary fixed fold change, as with the latter there is a 
risk of ignoring genes that change significantly but are below the arbitrary fold 
change threshold. Using LIMMA, the top 500 most significant genes have been 
generated (See Appendix A, where the top 100 genes are listed). 
 181 
Table 4.3  Top 20 most significantly altered genes in TS cases when 
compared with TR breast cancer samples. Genes whose expression had a 
minimum 2-fold change and a p-value of <0.05. The transcript cluster identification 
is in the left column. The gene symbols are in the 2
nd
 column, while r=resistant and 
s=sensitive for normalised probe intensity. The TS versus TR fold changes are seen 
in the 5
th
 column, while the last column shows the TS versus TR p-value. 
4.7. Mining biological pathways using Ingenuity 
Pathway Analysis (IPA) 
To explore the relationships between genes that form the TR gene signature at the 
molecular level, the top 500 genes were analysed using IPA, to generate the most 
common canonical pathways that involve these 500 genes (Appendix B). Figure 
4.4A illustrates the gene-level analysis and Figure 4.4B illustrates the splice-variant 
(Exon level) analysis, which was analysed using Partek. The latter analysis uses 
similar filtering and p-value to minimise false discovery. The crucial difference is 
that the latter analysed the individual exon-probe intensities as individual events, 
hence reporting the most significantly altered exon/probe in the analysis, while the 
gene-level analysis uses the probes sets of a particular gene as a unit. Here, I have set 
the filter for greater than 50% of the probes sets, i.e. >2 out of the 4 probes per exon 
of a gene, and > 50% of the probe sets (exons) of a particular gene must be 
significantly altered to be included in the analysis.  
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The results from the two IPA analyses are quite different. When analysed at the 
„gene-level‟ (Figure 4.4A), the pathways identified are similar with published data 
regarding associations with breast cancer, such as the Integrin signalling, PI3K/AKT 
signalling and p53 signalling. The canonical pathways associated with Exon-level 
(using the same chip and sample but analysed as the change of the intensity of each 
probe of the four probes per exon) analysis (Figure 4.4B) are associated more with 
metabolism, such as aminosugars metabolism, tyrosine metabolism, glycolipid 
metabolism, glycolysis, xenobiotics by cytochrome p450, -alanine and 
phenylalanine and purine metabolism. There are two cardiac associated pathways, 
the -adrenergic signalling and coagulation system. One possible hypothesis is that 
detectable Exon changes are more reflective of acute daily events. All of our training 
set patients were elderly (>70 years), and probably had existing cardiac conditions, 
or were taking correcting cardiovascular drugs such as -blockers, anticoagulants 
(warfarin), thyroid-correcting drugs (thyroxine or carbamazipine) and various 
polypharmacy, which may have augmented the p450 cytochrome pathway.  
 
There are two common conical pathways between the IPA analyses; PPAR/RXR 
activation and -adrenergic signalling. Peroxisome proliferator-activated receptor-
alpha (PPAR) has been shown to increase fatty acid oxidation, decrease cytokine 
levels and is implicated in insulin production. A doubling of breast cancer risk 
among women with a PPAR polymorphism versus common homozygous alleles 
has been reported and PPAR has been shown to be involved in the growth 
inhibitory effect of arachidonic acid on breast cancers (Bocca et al., 2008; 
Golembesky et al., 2008). Beta-adrenergic signalling has no published association 
with breast cancer. 
 
4.8. Affymetrix GeneChip® SNP6.0 arrays 
The genomic aberrations of all 25 samples were also analysed using the GeneChip® 
Human SNP6.0 array. The experiments were performed according to the standard 
protocol (see Chapter 2.8.5). The raw median-normalised log2 ratio at each SNP was 
extracted from the Affymetrix Chromosome Copy Number Analysis Tool (CNAT 
Ver4.0.1) software. The data normalisation was performed against SNP6.0 data from 
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10 normal breast samples (LREC Ref 05Q403/199), which were prepared in an 
identical manner to the 25 tumour specimens.  
Copy number analysis was performed using nine different algorithms (Materials & 
Methods 2.8.5). The threshold for genetic “gains” or “losses” was determined as a 
median log2 ratio ≥+0.162 or ≤-0.162, respectively (±3 standard deviations (SD) of 
the interquantile range) {Cavatorta, 2004 #50}; {Tonon, 2005 #24}. “High-level 
amplifications (HAs)” and “homozygous deletions (HDs)” were defined as a median 
log2 ratio ≥+0.419 or ≤-0.401, respectively, which corresponds to 97% or 3% 
quantiles. In order to avoid false-positive changes due to random noise in signal 
intensity at each SNP, we set a minimum physical length of at least 20 consecutive 
SNPs for putative genetic alterations. All identified altered regions were then verified 
by assessing the raw normalised data. 
4.9. Quality control of SNP6.0 arrays 
Figure 4.6 illustrates the PCA as part of QC analysis of the SNP array. The 
separation of TR from TS samples is distinct, when normalised using data from the 
10 normal breast tissues. Unsupervised clustering was performed, again after 
normalisation with the 10 normal breast samples. The dendrogram in Figure 4.6 
again shows clear clustering of the TR away from the TS samples, except for two 
samples. The two-paired samples from two separate patients (indicated by the green 
box) also clustered away from the other samples, showing that the SNP patterns in 
samples from the same patient have clear similarities, as expected. In the case of one 
pair of samples (5008 and 5009), where relapse occurred in less than 6 months, there 
was very little difference at all in the SNP patterns, offering another level of 
reassurance. The expression array patterns from these paired samples were however 
distinct (see Figure 4.2). 
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4.10. Genome-wide analysis of CNV and data 
integration with expression EXON data 
The physical position of all SNPs (n=906,600) on the arrays was mapped according 
to the Human Genome Sequence (NCBI, Build 36). Colleagues at the Institute of 
Cancer have developed their own visualization software to merge all genetic 
aberrations with the gene annotation from the Ensembl Ver.37 
(http://www.ensemble.org) public database. Taking structural variation in the human 
genome into account, this software integrated the Copy Number Variation, CNV 
(http://projects.tcag.ca/variation/) data into our analysis (Iafrate et al., 2004), (Redon 
et al., 2006). We then merged our EXON array dataset (6.5 million features; up to 4 
features to an exon) with that of our SNP6.0 data. The software is able to find the 
most significant regions of CNV, which have the most significant changes in the 
expression study simultaneously. This is the first such analysis in breast cancer for 
tamoxifen resistance. All the raw data are available in the Gene Expression Omnibus 
(GEO) (http://www.ncbi.nlm.nih.gov/geo/). 
 
The Copy Number Analyser for Affymetrix GeneChip (CNAG) analysis for all 25 
tamoxifen-treated human breast cancer samples identified chromosome regions of 
CNV throughout the whole genome of these breast cancer patients (Figure 4.7). 
These data were normalised against the 10 normal breast tissues, and “smoothed” 
using the Hidden Markov model (HMM) algorithm (see Chapter 2.8.5). The most 
frequent genetic gain was detected at 8q24.22 where 15 of the 17 tamoxifen-resistant 
patients had CNV gain of the ST3GAL1 gene. However, this was also gained in the 
tamoxifen-sensitive cohort, in 4 out of the 8 patients. Other gains were found at 
16p13, 20q13, 12q13, 1q25 and 1q32 with high frequency in TR patients (13 out of 
17), but they were also found in TS. These may be SNP regions associated with 
breast cancer alone. Figure 4.7 illustrates the chromosomal location of CNV of the 
combined significant results with red regions being most amplified and blue regions 
being most deleted. The parameters were set at above 1.7 ratio of amplification and 
less than 0.7 for regions of deletion. The software was asked to only show results 
where more than 10 arrays had the aberration in a region. There is a visual 
appreciation that chromosomes 11, 17, 8, 1, 20 and 6 have the most significant 
regions of CNV aberration. Although this software only uses one algorithm (HMM),  
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it is regarded as one of the most robust of the available algorithms. Reassuringly, the 
analysis using Partek was concordant with results from our in-house bioinformatics 
software (illustrated in Figure 4.8), which identified the actual number of significant 
CNVs which occurred in a segment of each chromosome. This also required 
normalisation against the 10 normal breast tissues, and data was smoothed using the 
10 stringent algorithms, which are used in the R-conductor software (see Chapter 
2.8.5). The most significant CNV losses were on 11q22-25, with 13 out of 17 TR 
patients showing loss of OR8D4, NP_001013765.1 and NP_055530.2 genes. These 
losses were not seen in any of the TS patients. Hence these genes may be very 
specific to tamoxifen response.  
 
Analysis by visual observation (Figure 4.7) and by filtering of significant 
overlapping regions between significant SNPs in the CNV and EXON expression 
data revealed three regions of interest. The filtering was generally done by: 
1) Excluding all the regions/probes, which were not altered at all. 
2) Selecting the regions with >20 SNP length. 
3) The specific criteria (i.e.>than 10 out of all 15 TR) of gains regions in one cohort 
(i.e. TR) while setting the reciprocal loss in the other cohort (i.e. TS). 
4) Analysing in conjunction with the merged data from expression array. 
 
The three regions of interest thus highlighted were: 
1) 8q24: This region (see Figure 4.9) was represented in 184 out of the 282 SNP 
regions which were significantly altered (DNA copy number gain) and was found in 
15 out of the 17 TR patients, and conversely in less than 3 out of the 8 TS patients. 
The gain in this region overlapped with two genes, which were downregulated in the 
exon expression array study; RUNX1T1 and ENPP2 (by –4.57 and –3.92 fold 
respectively). These genes were later validated by qPCR in our cohort of combined 
122-tissue microarray and paraffin slides from tamoxifen treated patients (see 
Section 4.13). MicroRNAs that were mapped to this region of gain were hsa-mir-
661, hsa-mir-338, hsa-mir-30b and 30d. According to the miRBase database they 
potentially regulate genes which have been found to relate to tamoxifen resistant 
breast cancer, including AP2A1 (AP-2 complex subunit Alpha-1), TAF2, RAD54L, 
SOCS1, PARP16, BRAF, MAP3K5, S100A10, MAGEE1, SIAH1, TP73, PDZK1IP1, 
MAP4K2, THRAP5, ALDH3A1, PARP10 and MAGEC3. 
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2) 11q23-25: This region (see Figure 4.10) was represented in 21 out of the 99 SNP 
regions which were significantly altered (DNA copy number loss) and was found in 
more than 13 out of 17 TR patients, but also in more than 2 out of 8 of the TS 
patients. Four genes from the expression data were found to overlap with this region, 
SNF1LK2, ZBTB16 were downregulated by –4.02 and –4.99 fold respectively while 
OR10G7, OPCML were upregulated by +3.99 and +3.92 fold respectively. 
 
3) 17q21-25: This region of chromosome 17 represented 1655 of the total 31206 
SNP regions which were significantly altered. 2322 DNA copy number gains were 
found in all chromosomes in more than 10 out of 17 TR patients, of which 377 copy 
number gains regions (see Figure 4.11) were at 17q21-25. There is published data 
available on the amplification of genes on 17q22; such as HOXB13, COL1A1, which 
are positioned in the second of three regions of the 17q21 HER2 amplicons {Jansen, 
2005 #34;Sgroi, 2004 #39;Jansen, 2005 #176}. In our merged SNP and EXON 
datasets, 3 genes from the expression data overlapped with this region; SP2 
(Transcription factor Sp2), CHRDL1 and XR_000549.1 were found to have –4.26, -
6.69 and +4.60 fold changes respectively. This region also contains microRNA 657 
(17q25.3) which potentially regulates the expression of many known genes related to 
tamoxifen resistance, including HOXB13, TGF1, MMP9, THRAP5, ESRRB (ER-
related receptor ), LOXL4, ERBB2, and KIAA1324L which is related to an AP-2 
regulated gene studied in our lab (Ka Yi Chan, PhD Thesis, 2010). Genes related to 
breast cancer, such as TP53, ADAM2 and S100A1 may also be regulated by has-mir-
657. We have hence chosen this miRNA to study further (see Chapter 4.15). 
 
Regions of SNP which encode microRNA were searched using the UCSC website. 
The link from this website to miRBase (Welcome Trust Sanger Institute) and 
TargetHumanScan (Whitehead Institute of Biomedical Research) were used to scroll 
through the related genes which each microRNA has been linked to. The available 
software packages score the strength of its association based on site-type 
contribution, 3‟ pairing contribution, local AU contribution and position 
contribution. 
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4.11. Ingenuity Pathway Analysis of the 8q24 
region 
The integrated analyses list showed 3 regions where significant copy number 
aberration; namely 8q24 (gain), 17q21-25 (gain) and 11q23-25 (loss). In the 282 
SNP regions that were significantly changed in more than 10 of the 17 TR patients, 
but were seen in less than 3 out of the TS patients, 184 SNPs were located within the 
8q24 region. This is a disproportionately high gain region, which led us to study this 
region further. When the genes associated with all 182 8q24 SNP regions, were 
computed into the ingenuity pathway biological analysis tool, the most significant 
canonical pathways were p53 and IGF-1 signalling, and androgen and oestrogen 
metabolism, (Figure 4.12). The p53 pathway was also found to be directly related to 
our in vitro TR mechanism (see Chapter 3.0 MAGEA2 mechanism of action via 
p53), while androgen and oestrogen metabolism, PTEN and IGF-1 signalling 
pathways are established published tamoxifen resistance related mechanisms 
(McCubrey et al., 2006; Parisot et al., 1999; Shoman et al., 2005). Hence this 
analysis reinforced the fact that our array study is consistent with both our in vitro 
study and with published data at least using this biological mining website. 
 
When I analysed the combined data from our TR cell line microarray study with the 
SNP array data using IPA, I found overlapping networks. The networks with the 
most significant molecules have been merged and is shown as Figure 4.13. The 3 
networks comprise of 20 genes from combined datasets; microarray HU 133plus2.0, 
EXON 1.0 ST and SNP6.0, which includes RUNX1, MGMT, MYBL1, PLP2, 
Camodulin, CALM2, and centred around the TP53 and Akt pathways.  Interestingly, 
molecules which have supporting published data for tamoxifen resistant has also 
been found in the merged network, such as E2f and Akt. 
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4.12. Validation of genes from integrated analysis 
of Exon and SNP arrays  
4.13.1  Quantitative real-time PCR 
Nine genes were further validated from the combined analysis. These were EPHA7, 
PALM2, SNF1LK2, ZBTB16, OR10G7, OPCML, SP2, RUNX1T1 and ENPP2. In 
brief, these genes were found in SNP CNV regions, which were significantly altered 
in the majority of TR cases (TR>10, out of 17 cases) but not in TS cases (TS<3, out 
of the 8 cases). As described in section 4.11, these genes mapped within the altered 
regions and were also significantly altered in expression on the Exon arrays.  
 
Quantitative real-time PCR was used for validation of cDNA from the training set 
normalised to GAPDH and compared with normal breast (10 samples). When more 
than one choice of probe sequence was given, I chose the „inventorised‟ option with 
the shortest sequence (see Materials & Methods, section 2.9.2), unless if these 
probes not listed. For two genes, PALM2 and ZBTB16, the probe and primers were 
undetected despite trying again with higher concentration of starting cDNA. One 
possible explanation is that we may have not bought the optimised probe and 
primers. We intend to repeat these experiments again when we purchase new probes. 
 
A summary of the results is shown in Table 4.5. All the genes were directionally 
positive in their correlation with the Exon array findings, for example where a gene 
was expected to be downregulated in TR cohorts, the qRT-PCR experiments showed 
downregulated mRNA of the particular gene when compared with their TS 
counterparts. This is illustrated for individual genes in Figures 4.13 and 4.14. 
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4.12.1. Immunohistochemistry 
Commercially available antibodies against the encoded proteins of all 11 genes were 
obtained and each was optimised for immunohistochemistry on paraffin sections 
(IHC-P) using positive control specimens as suggested by the manufacturer.  In two 
cases, the optimisation failed, however the other antibodies were used to stain my 
independent validation series of 129 cases of ER+ breast cancer (see Materials & 
Methods, section 2.13).  Although the Ventana Discovery automated staining 
instrument was used in each case, only 5 sets of slides were suitable for scoring, 
with the antibodies giving a specific and relatively sensitive signal. The failure of 
the unsuccessful antibodies were due to either weak staining (despite optimisation) 
or indiscriminate staining (i.e. staining connective tissues and smooth muscles as 
well as breast tumour). This is summarised in Table 4.4. 
 
 
 
Table 4.4        Summary of validation experiments  
RT-PCR was performed on the 25 cases from the training set. The p-values were 
calculated with Whitney-Mann non-parametric statistical analysis (Prism) between 
the TR cases from the TS cases; two genes (marked *) reached significance. 
Immunohistochemistry (IHC) validation was performed for 7 proteins on an 
independent series of 122 cases (see Materials & Methods, section 2.13); 5 sets of 
slides where the staining was specific were scored. Antibody optimisation failed for 
2 proteins (marked “not done”). 
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The sets of slides for OCPML, OR10G7, SNF1LK2, PALM2 and ZBTB16 were 
scored by myself and a qualified pathologist, Dr Yaohe Wang. Disease free survival 
(DFS and/or overall survival (OS) were then calculated for each gene by Kaplan-
Meier curve, from the Prism software. As illustrated in Figures 4.14 to 4.18, genes 
were validated for their mRNA expression using Tagman probe and primers on the 
human primary breast cancer tissues cDNA. Using a non-parametric (one-tail) 
Mann-Whitney Equation, we analysed a scatter plot with a p-value calculated if 
there is a difference between the TR group from the TS group. This sets apart if the 
mRNA expression for that gene can differentiate the TR from the TS significantly. 
Following that, the independent 122 primary breast cancer tumours in their paraffin 
slides were validated for this gene of interest‟s protein expression by 
immunohistochemistry. The staining results were analysed for their effective 
prognosis by using Kaplan-Meier curve, using Prism software. Disease-free survival 
analysed if the positive staining of the slides had any prognostic value in predicting 
the period between diagnosis and time when disease recurs. Overall survival 
measures the period between diagnosis dates with time of death.  
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4.13. miRNAs in Tamoxifen Resistant 
4.13.1. hsa-mir-657 from our integrated array 
analysis 
As discussed in the Introduction, recent studies have highlighted the key regulatory 
roles of miRNAs in all fundamental cellular processes including cancer.  From the 
integrated analyses of the SNP6.0 and Exon array data, hsa-mir-657 was highlighted 
as an interesting miRNA, with a potential association with predicting tamoxifen 
resistance. The regions of 8q24, 11q22.2-25, and 17q21-25; (the three most 
significant from our combined analysis) were mapped with the miRNA library by Dr 
Claude Chelala‟s software. There are currently 4,000 mature miRNA listed. Table 
4.5 lists the most significant miRNAs, which mapped within these 3 regions of SNP 
aberration (see Chapter 4.11).  
Chr Band From To miRNA TR 
Proteins negatively 
control 
1 q32.1 203684053 203684149 
hsa-mir-
135b 10 
S100P, ESRRB, 
BNIP1,  
            
ESR, ENPP7, 
MDM4 
8 q24.22 135881945 135882032 
hsa-mir-
30b 10 
SOCS1, PARP16, 
TAF2,  
            RAD54L 
8 q24.22 135886301 135886370 
hsa-mir-
30d 10 
SOCS1, THRAP6, 
MAGEE1,  
            PDZK1 
8 q24.3 145091347 145091435 
hsa-mir-
661 11 
TP73, THRAP5, 
MAGEC3 
              
17 q25.3 76713671 76713768 
hsa-mir-
657 10 
HOXB13, TGF-1, 
MMP9, PGF, 
            
THRAP5, 
ESRRB, ERRB2, 
TP53 
17 q25.3 76714278 76714344 
hsa-mir-
338 10 
HOXA3, FGFR2, V-
FOS 
            
MAP3K3, ADAM 
17 
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Table 4.5 The five significant miRNAs found in more than 10 out of 17 TR 
and less than 3 out of 8 TS cases. The genes, which are negatively controlled by 
the miRNA, which are related to breast cancer and (*) specifically with tamoxifen 
resistance are listed in the last column as found from the miRBase database. 
 
Hsa–mir-657 is located at 17q25.3, As listed in Table 4.5, this miRNA is associated 
with many breast cancer genes and seven genes in particular have a published 
association with tamoxifen resistance; THRAP5, HOXB13, TP53, MAP2K2 and 
AKR1B1. For this reason I decided to study its relevance in our human primary 
breast study and in the TR breast cancer cell line series. Using the mirVANA PARIS 
kit, I simultaneously extracted protein lysates and miRNA from primary fresh frozen 
tissues from the training set (n=25). Real-time qPCR for hsa–mir-657 showed that 
the difference in mRNA expression between the TR and the TS groups was not 
significant (p-value of 0.3705). Interestingly however, the same 11 cases from the 
training set from the combined SNP and EXON analysis, were found to have mRNA 
expression of hsa-mir-657 by RT-qPCR. Only 2 of the 8 TS expressed this miRNA 
(25%), as compared with 9 out of 17 of TR (53%). The p-value does not reach 
significance different between the two groups due to the small size of our training 
set. Conversely, the sensitivity in the TR group was high. 
I have shown: 
1) A trend for increased qPCR detection of hsa-mir-657 in our human primary 
tissue of the TR cohort compared with the TS cohort. 
2) Majority of the genes potentially regulated by hsa-mir-657; i.e. THRAP5, 
MMP9 and TP53 have no significant mRNA expression difference between 
TR and TS. HOXB13 and KIAA1324L mRNA expression in TR was 
significantly different from TS. For HOXB13, the mRNA difference may be 
due to the fact that sample size in the TS group was small, due to poor 
detection of the probe despite higher concentration of cDNA. As for 
KIAA1324L, this may well be a true significance.  
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3) The protein expressions of HOXB13, THRAP5 and KIAA1324 are reduced 
in cases with hsa-mir-657 as shown in immuno-blotting (Figure 4.16). P53 
however was less consistent in its protein expression reduction in has-mir-
657 carrying lysates. There are no good existing KIAA1324L and MMP9 
antibodies for immuno-blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 209 
 
4) 
 210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 211 
 
4.13.2. hsa-mir-221  
MicroRNA, hsa-mir-221/222 was shown to negatively regulate ER expression and 
associate with tamoxifen resistance in vitro (Zhao et al., 2008). Transient 
knockdown of this miRNA caused breast cancer cells to re-express ER and recover 
sensitivity to tamoxifen. In contrast, ectopic expression of miR-221/222 rendered 
parental MCF-7 cells resistant to tamoxifen by reducing the protein levels of the cell 
cycle inhibitor p27
KIP1
, and increasing ErbB2 expression (Miller et al., 2008). I 
performed qPCR on our human primary tissues (training set) cDNA for hsa-mir-221, 
and for ERBB2 as a cross study comparison to the references above.  Here the p 
values for hsa-mir-221 and ERBB2 are of significance, 0.0484* and 0.0310* 
respectively for the TR versus the TS cohorts. This suggests that our study sample of 
patients is consistent with the expected findings from the published data stated 
above. 
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Figure 4.17 Expression of has-mir-221 and ERBB2 are significantly 
associated with TR. Scatter-plot showing the fold change of mRNA of hsa-mir-221 
and ERBB2 real-time PCR of the tamoxifen resistant primary breast tissue (TR) as 
compared with the Tamoxifen sensitive primary breast tissue (TS), in n=25 of our 
training set. Stock solution of cDNA (5l) of each patient were plated in triplicates 
and added with mastermix and Tagmanprobe for hsa-mir-221 and ERBB2. 
Standard 40 cycles of real time PCR program using the ABI7500. P-value analysed 
using Mann-Whitney non-parametric equation, using Prism software. 
 
P=0.0484* 
P=0.0310* 
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4.13.3. miRNA in Tamoxifen Resistant Breast 
Cancer Cell lines 
 
Here expression of the two miRNAs (hsa-mir-657 and hsa-mir-221) was also 
investigated in parental and TR breast tumour cell lines (see Chapter 3.0). As listed 
in table 4.16, we extracted miRNA and protein whole cell extract using miRVana 
PARIS kit from these parental and their TR counterpart breast cancer cell lines. I 
made cDNA from the miRNA extracted using the microRNA high-capacity cDNA 
kit (see Section 2.13) following their RT-PCR protocol. Real-time PCR were then 
performed on the samples with hsa-mir-221 and hsa-mir-657 primers. There is a 
consistent fold change increase of hsa-mir-221 in 6 out of 9 TR paired breast cancer 
cell lines. Some fold-change was more significant than others. These results were 
done in duplicates with very tight error bars (Figure 4.18). 
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Figure 4.18 (A) Expression of hsa-mir-221 in TR and parental breast cell 
lines. In the table the cell lines are presented as ER-positive breast cancer cell lines; 
MCF-7, T47D, MDA-MB-361, HC1500, HC38, H3396 and ZR75-1, or as ER-
negative; MDA-MB-453 and BT20. WT (wild-type) and TR (Tamoxifen resistant) 
are shown as their absolute amount after normalising with endogenous control, 
SNU24. Five l of the stock cDNA is used for real-time PCR. (B) The fold change 
(FC) was measured as normalised (with miRNA endogenous control SNU24) 
expression of hsa-mir-221, as seen in the graph below the table. 
 
 
 
A 
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One possible explanation for the undetectable has-mir-221 in HC1500 could be that 
it may not carry any miRNA hsa-mir-221 in its genome. An explanation of MDA-
MB-361 and 453 had a down-regulation of hsa-mir-221 in their TR counterpart 
could be that as they are the only 2 breast cell lines (of my series shown in Figure 
4.18A) which carries over-expression of ErbB2 in their wild-type form, this may 
have spared them from the route of hsa-mir-221, which we know from publication 
that hsa-mir-221 up-regulate ERBB2 mRNA expression but the reverse is not true. 
 
In the experiment to detect hsa-mir-657 from this same TR breast cancer cell line 
series, we have been able to detect low levels. Although low, there is an up-
regulated trend in the TR counterpart in cell lines apart from MDA-MD-361, H3396, 
HC38, ZR75-1 and MDA-MB-453 (Figure 4.19). HC38 and MDA-MB-453 both 
had undetected levels of hsa-mir-657 in their WT, which may suggest that these cells 
do not carry this particular miRNA. 
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Figure 4.19 (A) Expression of has-mir-657 in TR and parental breast cancer 
cell lines. In the table the cell lines are presented as ER-positive breast cancer 
cell lines; MCF-7, T47D, MDA-MB-361, HC1500, HC38, H3396 and ZR75-1, or as 
ER-negative; MDA-MB-453 and BT20. WT (wild-type) and TR (Tamoxifen 
resistant) are shown as their absolute amount after normalising with endogenous 
control, SNU24. Five l of the stock cDNA is used for real-time PCR. (B) The fold 
change (FC) was measured as normalised (with miRNA endogenous control 
SNU24) expression of hsa-mir-657, as seen in the graph below the table. 
B 
 217 
 
 
 
 
 
 
 
 
 
CHAPTER 5: DISCUSSION 
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5.  Breast Cancer Derived Cell Lines And Human 
Primary Tissue Molecular Profiling Study 
Tamoxifen is the oldest and most commonly used drug against oestrogen receptor  
(ER+) breast cancer. Tamoxifen treatment in the adjuvant setting reduces the 
recurrence rate and improves overall survival; when used for treatment of metastatic 
breast cancer, it provides remission for over half the patients. De novo and acquired 
resistance to tamoxifen are important clinical problems since almost all metastatic 
patients, and up to 40% of adjuvant patients, will relapse and die from breast 
disease. Despite many studies using derived cell lines with selected tamoxifen 
resistance (TR), and many studies on resistant breast cancers, mechanisms of 
resistance are still not fully understood. 
What we know so far is that progesterone receptor-negative (PR-) status in ER+ 
cases has been shown to be an independent predictive factor for benefit of adjuvant 
tamoxifen (Dowsett et al., 2005; Howell et al., 2005). Patients with highly expressed 
HER2/ErbB2-positive cancers also fail to benefit from tamoxifen treatment (Mc 
Ilroy et al., 2006; Piccart et al., 2001; Shou et al., 2004; Smith et al., 2005). There is 
an inverse relationship between Progesterone and HER2 receptors (Lal et al., 2005). 
It was suggested that the overexpression of HER2 may activate mitogen-activated 
protein kinase, which in turn activates ER by phosphorylation at Ser118 
{Yamashita, 2008 #33; Thomas, 2008 #36; Yamashita, 2005 #51; Thomas, 2008 
#187; Yamashita, 2005 #188} and AIB1 (an ER co-activator) may be activated by 
signalling downstream of Her2, and in the presence of the two, the agonist activity 
of tamoxifen may be enhanced {Azorsa, 2001 #95;Reiter, 2004 #87;Tikkanen, 2000 
#189;Azorsa, 2001 #190}. Stabilisation of the interaction between ER and SRC1 
by cyclin D1 were reported to be related to resistance in vitro (Nakuci et al., 2006). 
These advancements are important as individual predictive biomarkers but the 
challenge for a full understanding of the mechanism of tamoxifen resistance is far 
from complete. Continual selection of pathways which constitute tamoxifen 
 219 
resistance in a wider range of breast cancer derived TR cell lines (such as in this 
thesis), in parallel with confirmatory analysis of these markers in situ in large breast 
cancer patient cohorts will define the pathways leading to tamoxifen resistance. We 
hope by understanding these pathways reliable target(s) for therapy can be 
identified. 
Overall, there was a high degree of similarity with the results of our TR (breast 
cancer cell lines) profiling with those of published data defining oestrogen-
responsive genes in ER-positive breast cancer lines by microarray. ESR1, PGR, 
GATA3, GATA4, MYBL, GREB1, GREB7, PDZK1, SCUBE2, IGF1R, ErbB2, 
CYBSR1 and AR genes have all been identified in most ER receptor gene 
expression profiling studies (Ma et al., 2009). Loi et al (Loi et al., 2005) showed a 
chosen „13-gene cluster signature‟ to validate on independent cohorts with 32%-45% 
correlation with the Dutch group (Knauer et al., 2010) and 21-gene signature 
(Mamounas and Paik et al., 2010). These are explained in greater detail in section 
5.4. As we had good Quality Control (QC) control for our probe preparation and our 
data (see result Chapters 3 & 4), as seen as a clear distinction of the test TR from 
reference TS groups, it is somewhat not surprising that our data had good correlation 
with the published group. Our bioinformatics analyses showed similar correlation, 
namely MYBL, GREB1, PDZK1, EGFR, ErbB2, ESR1 in our TR breast cancer cell 
line study, and c-MYC, PGR, ESR1, GATA3, IGF1, IGFBP6, AKR1C3 from the 
human primary breast tissue (predictive biomarker) when we analysed against the 
available breast cancer gene-expression database of the cohorts mentioned above 
from their publications. 
For the breast cell line work, from which our microarray selected oestrogen 
dependent and oestrogen-independent (as we also array oestrogen-deprived breast 
cancer cell lines) significant molecules associated with TR, I have selected less 
characterised genes for further studies. This included genes that have no published 
association with tamoxifen resistance (TR) or breast cancer but some association 
with drug resistance in the literature. Our aim was to characterise the function of the 
genes and the pathways, which may be supporting TR. Full details of the TR cell 
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line microarray are seen in Appendices A. I have chosen the genes (i.e. MAGEA2 
and EGLN3) with proliferation pathways to study further. 
 
5.1. MageA2 
 
MAGEA2 was chosen as the first gene, as it was 4-fold upregulated in TR, and had 
been suggested to have a role in chemotherapy (Etoposide) resistance in melanoma 
cell lines (Monte et al. 2006). MAGEA2 was not detected in our breast cancer cell 
line panel (MCF-7, ZR75-1, MDA-MB 453, H3396, HCC1500, HCC38) apart from 
T47D (mutant p53), MDA-MB-361 (WT p53), SKBR3 (mutant p53) and MDA-
MB-436 (latter two both ER-/PgR- cell lines). It was also not present in normal 
tissue apart from placenta and germ cells. It is however up-regulated in TR cell lines, 
which makes it a potential predictor gene for tamoxifen resistance (see Figure 3.3) as 
well as a target gene/protein for reversing tamoxifen-resistance. The presence of 
MageA2 in an ER-receptor negative cell line suggests that it is regulated 
independently of the ER and this is supported by evidence from the literature 
examining MageA expression in tumours (Cho et al., 2006) Grigoriadis et al., 2009). 
As seen in our microarray cell line study, MAGEA2 was up-regulated in all our 
tamoxifen-resistant cell lines (T47D TR, ZR TR, as well as the oestrogen-deprived 
TR cell lines, OD T47D TR and OD ZR TR).  
 
Our work focused on the mechanistic relationships among MageA2, p53 and p21 
and deacetylation of p53 in breast cancer cell lines. First, I showed that the stable 
expression of MAGEA2 in MCF-7 and T47D lines had a positive effect on 
proliferation and decreased apoptotic events in normal media and tamoxifen 
containing media (see Figure 3.7 and Figure 3.8). Compared to the difference in 
growth between the control (VA), and the MAGEA2 expressing clones, the 
significant difference was more marked (p-value=<0.001) in tamoxifen-containing 
media. Second, we showed a direct interaction between p53 and MageA2 in our 
overexpressing lines, with a consequence of reduced p21 levels (see Figure 3.9). 
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Reduced p21induction in these lines on exposure to tamoxifen suggested that the 
complex with MageA2 may repress the activation potential of p53. Monte M et al 
(2006) have proposed that MageA2 represses p53 by recruiting HDAC3 in a co-
repressor complex with MageA2 acting as a scaffold protein bringing p53 and 
HDAC3 together. In my study (See Chapter 3.7.4), in co-immunoprecipitation 
experiments suggested that MageA2 interacts directly with p53, leading to reduced 
levels of acetylated, transcriptionally active p53 and hence reduced expression of 
target genes such as p21 resulting in continued growth in tamoxifen-containing 
media. The total available acetylated-p53 is reduced in the stable overexpressed 
MAGEA2 clones. .  
 
Yang B et al (2007) also suggested Mage can suppress p53-dependent apoptosis but 
that a range of MageA-, B- and C- proteins had similar activity. We aim in future to 
examine if other Class I Mage antigens can also confer tamoxifen resistance by 
testing MageA3, MageB and MageC overexpressing cells in the same way I have 
done for MageA2-expressing lines.  
  
In the MAGEA2 stable-expression clones I showed co-localisation with p53 (wild-
type) using confocal immunoflourescence. There was a trend for cell survival when 
the staining of MageA2 was found in the cytoplasm (as seen in thriving TR cells). In 
contrast, in dying or apoptosing cells, such as control, VA in tamoxifen-containing 
media, MageA2 were concentrated in nucleus. This supports the hypothesis that 
MageA2 is able to sequester the available wild-type p53 in the cytoplasm essentially 
reducing available p53 (and acetylated p53) for interaction with growth 
inhibition/apoptosis-related target genes, thereby conferring a cell 
survival/proliferation advantage, as seen particularly in media containing tamoxifen.  
 
In the immunohistochemistry validation of an independent cohort (n=125), patients 
staining positively for MageA (pan-MageA, Zymed antibody) were statistically 
significantly worse off in their overall survival compared with those who were 
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negatively stained for MageA (see Figure 3.13). In addition, when all of those who 
were positively stained were statistically analysed with the Kaplan-Meier curve for 
survival, those who stained for MageA in the cytoplasm did significantly worse than 
those who stained positive in the nucleus (p=0.0448).   This study also showed that 
MageA had a 62% sensitivity rate in relapse TR tissue samples, and 38% in primary 
human tissue of patients we know are TR. Several cancer/testis antigens (including 
MageA) have already proved to be useful biomarkers for several types of cancer: 
breast ER negative receptor (Grigoriadis A et al, 2009), lung (Van den Eynde and 
van der Bruggen, 1997), melanoma (Carrasco et al., 2008), pharyngeal (Pastorcic-
Grgic et al., 2009) and colorectal cancer (Toh et al., 2009). The work of Grigoriadis 
et al suggested that MageA expression is most commonly found in ER-negative 
breast cancer. Interestingly, the proposition of MageA staining tumours in ER-
positive cases doubled in their cohort of metastatic tumours compared to the primary 
cohort. This supports our suggestion that MageA may be a good biomarker for 
picking up TR cases. Even though all our cases were ER-positive, my data imply 
that MAGEA may be used to predict the patients who will be more likely to become 
TR, despite their favourable ER-positive receptor status. More importantly, MageA 
poses as a real candidate biomarker for tamoxifen resistance prediction (sensitivity 
of 38% (95%CI; 0.309-0.464), specificity of 80% (95%CI: 0.639-0.918, Positive 
predictive value=89%: 95%CI: 0.802-0.958). This is an exciting finding because we 
are now in an era, where we know Mage-A proteins have pivotal roles in many 
cancers, and in resistance to treatment. Moreover, there is a vaccine available against 
MAGEA3, which has a safe profile to date for Phase 2 treatment in non-small-cell 
lung cancer, colorectal cancer (Toh HC, 2009) and melanoma. 
 
In this regard it is interesting that MAGEA3 was also upregulated in our 
collaborators microarray of tamoxifen and fulvestrant resistant breast cell lines (Dr 
Julia Gee, personal communication), and it is also found at the protein level in our 
TR lines. If we can also establish that overexpression of MAGEA3 also confers 
resistance to tamoxifen in cell lines this would indicate that the commercially 
available vaccine against MAGEA3 may be useful in the treatment of TR/metastatic 
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breast disease where MAGEA upregulation is detected.  Since MageA antigens are 
highly homologous, it is likely that the vaccine may induce an immune response 
against a number of MageA proteins, so the precise expression profile may not be 
important. 
 
I am currently undertaking an animal study designed to compare the proliferation of 
an MAGEA2-expressing MCF-7 clone with the VA control when both lines are 
grown as xenografts in overectomised mice. Mice were implanted with pellets 
containing either oestrodiole or tamoxifen or both. A different growth response has 
been seen in the tamoxifen pellet alone mice, with only the MAGEA2 clone forming 
tumours. As we have not reached the endpoint of our animal study yet, I have not 
described this aspect in the results chapters, but the aim is to test the MAGEA2-
expressing cells in a more in vitro setting. Ultimately we may be able to use 
immunocompetent mouse model, to see if the vaccine will reverse the tamoxifen-
resistance of the MAGEA2- (or MAGEA3-) expressing cells.  
 
5.2. EglN3 
 
ELGN3 is synonymous with egl nine homolog 3 (C. elegans) and is a member of the 
egg-laying-defective 9 (EglN) prolyl-hydroxylases. This was one of the most 
significantly upregulated genes in our TR study but with the least published data on 
the gene‟s relationship with breast cancer. EGLN3 is one of the three known prolyl 
hydroxylases which catalyse the hydroxylation of Hypoxia-induced factor (HIF).  
The heterodimeric HIF (a transcriptional regulator) is regulated by proteolysis of its 
alpha-subunits, following oxygen dependent hydroxylation of specific prolyl 
residues. Examination of the literature has shown that the prolyl hydroxylase, 
EGLN3 can be alternatively spliced to produce both active and inactive forms 
(Cervera et al., 2006).  
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It is highly interesting that EGLN3 was found to be 3.8-fold upregulated in our 
tamoxifen-resistant breast cancer cell lines. As little is known about how, and in 
what conditions EGLN3 is expressed, I carried out an in-vitro study on EGLN3-
expressing breast cancer lines in MCF-7 and T47D. I aimed to study its role in 
proliferation, and apoptosis, in normal and tamoxifen-containing media. In addition I 
aimed to localise its distribution in cells to establish its site of action, when 
conferring a cell survival advantage. 
 
EGLN3-expressing clones were found to have a proliferation advantage in both 
normal and in tamoxifen-containing media, and reduced apoptosis in tamoxifen 
containing media as demonstrated by two different proliferation assays, the cell 
count study and the Annexin V and PI study. The growth advantage of the EGLN3-
overexpressing clones in tamoxifen-containing media may be in part attributed to the 
simultaneous increased expression of HIF1, MageA2 (in particularly for MCF-7 
C7) and most importantly pRb (in particular for T47D, see Figure 3.21). We have 
shown the knockdown EGLN3 in our clones (rescue knockdown) reversed the cells 
into sensitivity to tamoxifen again (see Figure 3.26). 
 
It is intriguing that MCF-7 EGLN3-overexpressing clones possessed a significant 
proliferation advantage even in their normal media, with no notable change in the 
protein level of HIF1 (see Figure 3.25). In contrast, T47D EGLN3-overexpressing 
clones had a trend for increased proliferation (although this did not reach statistical 
significance) in their normal media, but the HIF1 protein level was notably down-
regulated when compared with WT and VA (see Figure 3.25). Excess of EGLN3 
could theoretically generate more of the unique binding site for ubiquitin ligase 
complex containing the von Hippel-Lindau (VHL) tumour suppressor protein, which 
results in HIF1 destruction. This should divert away from the pathway of the 
master transcription regulator of hypoxia inducible (HIF) genes. I hypothesise that 
there are alternate pathways, which is contributing to the proliferation advantage of 
the EGLN3-expressing clones. 
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A number of cellular oncogenes have been reported to promote HIF stabilisation, 
which facilitates tumour growth. Oncogenes such as v-Src and activated Ras, block 
HIF1 prolyl hydroxylation and therefore lead to HIF accumulation (Chan et al., 
2002). In contrast, the PI3K/AKT pathway promotes HIF accumulation without any 
change in HIF hydroxylation, possibly through the activation of mTOR and HIF 
translation (Zhong et al., 2000), (Arsham et al., 2003), (Brugarolas et al., 2003), 
(Zundel et al., 2000). 
 
In T47D EGLN3-expressing clones, the HIF pathway is adequately switched off by 
the hydroxylation of HIF by EGLN3 even in normoxia condition. I showed that 
there is a compensatory increase in pAKT and Raf protein level (Figure 3.26) in 
T47D EGLN3-overexpressing clones, which might account for the slight cell 
proliferation advantage. Conversely, MCF-7 EGLN3-overexpressing clones may be 
using the Ras pathway as shown in Figure 3.26, where the protein level of Raf is up-
regulated in the clones. This is consistent with the finding of accumulation of HIF1 
due to inhibition of HIF prolyl hydroxylation despite the presence of EGLN3. It is 
still unclear how EGLN3 switches on the Ras/Raf pathway in MCF-7. 
 
The next step would be to establish if the hydroxylation activity of EGLN3 is 
required to confer the proliferation advantage in overexpressing lines. We intend to 
study this by transfecting MCF-7 and T47D wild-type cells with an expression 
construct for “catalytic-dead” (H196A) EGLN3 (given as a gift by Dr W Kaelin) and 
perform a further in-vitro study on the proliferation of these clones in their normal 
and tamoxifen-containing media. In addition, Dr Kaelin‟s group in Boston is 
undertaking a screen of our EGLN3-expressing clones to see if they can identify any 
novel hydroxylation targets linked to tamoxifen resistance since they have 
preliminary data suggesting the existence of non-HIF targets in some breast cell 
lines. This group has recently published (Zhang et al, 2009) that the related EGLN2 
regulates cyclin D1 activity and tumourigenesis in ER+ breast tumour lines, 
although the pathway between EGLN2 and CCND1 was not defined. 
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As EGLN3 was found to be upregulated as a consequent of the breast cancer cells 
developing Tamoxifen resistant, we also validated them across a series of 196 of 
independent primary breast cancer tissue of patients treated with Tamoxifen, as an 
adjuvant endocrine treatment, to assess if EGLN3 is a good predictive biomarker.  
EGLN3 has a positive predictive value of 85% (95% CI: 0.75-0.92), with a 
sensitivity of 42%, and specificity of 66% of all TR primary breast tumour. 
 
The up-regulation of MAGEA2 mRNA and protein (as seen in Figure 3.21, 3.22 and 
3.24) in EGLN3-overexpressing clones was somewhat a surprise finding in our 
study. We know that in the MAGEA2-overexpressimg clones, there was no increase 
in EGLN3 mRNA or protein (data not shown). I have established that MageA2 is 
not directly downstream of Egln3 in our rescue knockdown study of the EGLN3-
overexpressing clones (see Figure 3.26). As discussed above, MageA2 has been 
shown to sequester p53, and subsequently reduce available acetylated p53. In Figure 
3.26, I have shown that T47D EGLN3-overexpressing clones have reduced 
acetylated p53. This further supports our hypothesis that MageA2 is up-regulated 
concurrently in EGLN3-overexpressing clones. In our microarray study of TR cell 
lines, both of these genes were the most widely up-regulated. As to how precisely 
EGLN3 influences MAGEA2 expression remains unknown, and needs further study.  
 
Should time and funding permit, we would like to repeat the rescue knockdown of 
EGLN3-expressing clones experiments, to be certain that MageA2 id definitely not 
directly downstream of Egln3. Then we will carry out knockdown with siRNA pool-
EGLN3 experiments on the T47D TR and ZR TR cell lines. We will then test to see 
if this has any effect on MageA2, which we know is overexpressed in TR cell lines. 
We could also knockdown a wild-type breast cell line which carries a high level of 
EGLN3, such as MDA-MB-361 (see Figure 3.16), and screen the cell line for 
MageA2 when efficient knock down is achieved. Intriguingly, MDA-MB-361 was 
one of the four WT breast cancer lines, which expressed detectable levels of 
MageA2 (see Figure 3.5A). 
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5.3. HUMAN BREAST CANCER STUDY 
The main aim of our study from the human TR breast cancer specimens was to try to 
identify a highly selective and specific predictive molecular signature, which would 
predict response to tamoxifen in primary breast cancer tissues of patients. Currently, 
there exist three groups who are playing major roles in molecular profiling in 
oestrogen receptor-positive breast cancer. The initial group under Christos Sotiriou 
(Loi S et al, 2008) developed a gene classifier that predicts clinical outcome in 
tamoxifen-treated ER+ breast cancer. The gene classifier consisted of 181 genes 
belonging to 13 biological clusters. Six of the 13 gene clusters presented pathways 
involving cell cycle, migration, angiogenesis, ER-related, ERBB2-related and 
proliferation (see Figure 5.1). In an independent set of adjuvant treated primary 
samples (n=362, ER+ breast cancer with adjuvant tamoxifen treatment), the 
classifier from the „proliferation‟ gene set was able to define a distinctly poor 
prognostic group (p=0.00000001), which was termed gene expression grade index 
(GGI). The six clustered pathways have a high degree of similarity with the second 
group (Paik, 2006), whose work has led to the success of a predictive gene chip, 
which is now widely used in the United States, known as Oncotype DX (see 
Introduction Chapter 1.8.1). They use a 21-gene signature (see Figure 5.2) to 
calculate a recurrence score (RS) which predicts if ER-positive patients, who are 
lymph node negative may fall into a high risk category that will benefit adjuvant 
chemotherapy, which conventionally if classified by histological (i.e. lymph node-
negative) parameters, would not be offered adjuvant chemotherapy. The 21-genes 
broadly cover the same sub-clustering of biological pathways as the GGI, namely 
oestrogen-related, ERRB2-related, proliferation, migration, and inflammation. 
Although each group used different genes in each cluster, the bulk of the gene 
signatures prior to pruning down to the crucial few had similarities. 
A third group at The Netherlands Cancer Institute (van de Vijver et al., 2002) has 
generated a 70-gene signature predictive for lymph-node negative patients for ten-
year metastasis-free survival. This has now been made available as a commercial 
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gene chip (Mammaprint) approved by the FDA in the United States. Both the 21-
gene (OncotypeDx) signature and the 70-gene signature chip have overlapping 
genes which both the signatures share. 
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Figure 5.1 (A) The six clusters of genes, which have been found to predict 
prognosis of ER-positive breast cancer patients who had anti-endocrine 
treatment by the Jules Bordet Institute. The 6 biological clusters from (Gene 
Grade Index) were broadly labelled ER-related, ERBB2 related, proliferation/GGI, 
stromal invasion, angiogenesis and immune response. N=no of patients which 
carried the genes in each cluster. The analysis was found from n=2000 array study, 
or primary breats cancer treatment. (B) Forest plots of hazard ratios obtained from 
the six clusters when compared with conventional pathological classification with 
prognosis. Here, we see that the proliferation (GGI) and the stromal invasion cluster 
have the highest p-values in the prediction of prognosis. 
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Figure 5.2 Oncotype Dx (Genomic Health) recurrence score (RS) genes and 
algorithm. HER, human epidermal growth factor; ER, oestrogen receptor; PR, 
progesterone receptor. 
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Predictive gene profiling and genomic signature studies have many limitations. As 
in any predictive study, the signatures which can directly cause an event are usually 
more diverse and variance between one person to another, influenced by their 
genetics i.e. racial background, cell or organ susceptibility, or influence by 
environment i.e. the epigenetic, nutritional or prescription poly-pharmacy such as 
cardiovascular drugs, the contraceptive pill etc. For this reason, predictive genetic 
studies ideally need to be large and prospectively planned to generate adequate 
statistical power. Here, we acknowledge the limitation of our small study with only 
25 fresh frozen samples, but we have tried to maximise the outcome by integrating 
data from genome-wide SNP6.0 chips (1.2 Million SNPs, previous generation 500K 
had 500,000 SNP features) with Human Gene®Chip Exon 1.0 ST Array (6.5 million 
features; the previous generation of gene-level arrays had approximately 600,000). 
In addition, we have combined the in-vitro breast cell line TR gene expression data 
with that of our human predictive data to mine for related pathways with associated 
potential mechanisms of TR (from the breast cancer cell lines) with that of the 
predictive signature.  
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The three chromosomes, which had the most significant regions of copy number 
aberration, were chromosomes 11, 17 and 8 (see Chapter 4.11). The region 8q24 
(146 out of 152 significant SNPs localised to chromosome 8) not only represents a 
large proportion of Copy Number Variation (CNV) regions of TR human predictive 
signatures, it also encompasses the canonical pathways which to date have been 
associated with tamoxifen resistance mechanisms of action namely p53 signalling, 
Integrin, IGF-1 signalling and hormone steroid pathways (see Chapter 4.12). 
 
Genetic variation in this region of 8q24, a few hundred kilobases telomeric to the 
Myc amplicon (8q24.21; 128817498 to 128822853) has also been associated with 
increased susceptibility to prostate and colorectal cancer and has been described as a 
“gene desert”. Recent work has identified a series of enhancer elements that act to 
regulate transcription of the Myc gene (Sotelo et al, 2010). Multiple genetic variants 
on chromosome 8q24, in particular rs13281615 have been found to be associated 
with an increase in breast cancer risk (Easton et al., 2007). This specific region was 
amplified in my SNP data in ten out of 17 of our TR cases. 
 
The group of Dennis Sgroi has studied the 17q amplification region (Goetz et al., 
2006) in specific subsets of ER-positive patients who either developed recurrence or 
who did not while on tamoxifen monotherapy. Our study design consists of the same 
patient criteria, apart from the fact that they had a larger cohort, and used different 
platforms. A novel approach would be to look into regions of significant SNP (copy 
number changes) aberration, which are sensitive across a high percentage of TR 
specimens and look into the „flanking regions‟ for translocation footprints. There is 
already published data on the amplification of genes on 17q22; such as HOXB13, 
COL1A1, which are positioned in the second of three regions of the 17q12 HER2 
amplicon {Jansen, 2005 #34; Sgroi, 2004 #39}. We have correlating significant 
data: 58.8%; 10 out of the 17 TR patients had amplification, whereas less than 2 out 
of 8 TS patients had amplification in SNP regions at the 17q21-25 arm. In fact this 
region is the second most aberrant site in our genomic analysis (see Chapter 4.11). 
The expression patterns of genes and variation in SNP regions from our study are 
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centred around chromosome 17q21 to 17q22 and possibly correlated with 
HER2/ERBB2 amplification, whose over-expression is associated with reduction of 
response to first line endocrine therapy (Musgrove & Sutherland, 2009). We 
hypothesise that the control of TR may originate from this region, and set about to 
test the genes, Sp2 (see Chapter 4.12.1 and Table 4.7), their splice variants (future 
work should time permit), if any, in this region when we complete our full combined 
statistical analysis. 
 
I have also identified at least 5 very specific biomarkers, PALM2 (9q31.3), 
SNF1LK2 (11q23.1), ZBTB16 (11q23.2), OR10G7 (11q24.1) and OPCML (11q25), 
which can be used for prognostic (predicts risk of recurrence) and predictive (i.e. 
predictive of tamoxifen response) of TR. Interestingly, 4 out of these specific 
biomarkers for TR are on chromosome 11q23-25. The statistical analysis of the 
immunohistochemistry validation on 125-independent cohort of primary breast 
cancer tumour from patients who had been treated with Tamoxifen, showed that 
these genes individually is an acceptably specific biomarker (OR10G7, 48% for TR, 
SNF1LK2, 66%, PALM2, 44% and ZBTB-16, 56%) and relatively high sensitivity 
(OR10G7, 54%, SNF1LK2, 45%, PALM2, 37% and ZBTB-16, 58%) but more 
importantly, they carry high negative predictive values (OR10G7, 68%, SNF1LK2, 
71%, PALM2, 59%, and ZBTB-16, 73%). This means that as a biomarker, if the 
genes/proteins are stained negatively, it has a high likelihood to be true tamoxifen 
sensitive. (We intend to study this region further in the future, should time and 
funding permit). These have low false positive, (but extremely high specificity) but 
also a low sensitivity for all TR. In part this is in keeping with our claim which we 
made regarding the limitations of this study as predictive signatures are much more 
diverse.  
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5.4. The role of microRNA-657 in predicting 
tamoxifen resistant in primary breast cancer 
tissue 
 
This part of the study utilised micrarray approach, in particular the new SNP6.0 
where the probes include specific regions of miRNA within the genome, and the 
combined integrated analysis of mRNA expression array, Exon ST1.0 (with the 
largest number of probes in an expression chip), to further investigate novel 
signalling pathways regulated by microRNAs (miRNAs), which may be predictive 
of tamoxifen response. 
 
I previously carried out a microarray study on breast cancer cell lines, which I made 
tamoxifen resistant. The significantly altered genes from this study are likely to 
represent genes involved in cellular mechanisms of escape from the control of 
tamoxifen. Whereas from the SNP6.0 and Exon array studies of the human frozen 
specimens, genomic susceptibility and predictive expression patterns inform us of 
the signatures which could make an individual more likely to develop resistance. As 
miRNA play a critical role in gene silencing, I set out to find a specific miRNA 
which has potential control a large set of ER-positive breast cancer related genes. I 
also took an interest in miRNAs, which can act as onco-miRs or tumour suppressors 
(see Table 4.6). Hsa-miR-657 was chosen as the most interesting miRNA for further 
study from our combined analyses.  This miRNA has been found to potentially 
control the post-translational expression of many of our TR cell line genes (where 
the microarray study included oestrogen-deprived breast cancer cell lines made into 
TR: hence the pathway of TR is likely to be non-ER receptor dependent), including 
THRAP5, HOXB13 (also found by the Sgroi group as an accurate gene predictor of 
response to tamoxifen), MMP9, AKR1C3, ESRRB, ERBB2, TGF-, and also TP53. 
A high percentage of our TR human primary breast cancer tissue specimens carried 
this miRNA, 10 to 11 out of 17 cases of TR. Conversely, less than 3 out of the TS 
cohort carried this miRNA.  
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There has been recent increased interest in miRNA and their potential role in 
endocrine therapy resistance. Four published reports have shown miR-221/222 to 
play a role in TR, though the two different groups showed different targets, p27
KIP1
 
(Miller et al., 2008) and ER (Zhao et al., 2008), that are negatively regulated at the 
protein level. The latter group found that miR-221 and miR-222 inhibit ER 
translation by direct interaction with the 3‟-UTR of the ER and hence suggest a 
molecular mechanism of ER regulation at the post-transcriptional level in breast 
cancer. They also showed that by knocking down miR-221/222, they restored the 
expression of ER and sensitivity to tamoxifen induced cell growth arrest and 
apoptosis. 
 
In my study, I have shown that our TR human primary tissues have significantly 
higher expression of hsa-mir-221 by qPCR than the TS group. In keeping with the 
publication of Miller (Miller et al., 2008), I have shown that our elevated has-mir-
221 primary human breast cancer TR group also has significantly higher ERBB2 
mRNA expression (see Chapter 4.15.2). This part of my study suggests that our 
study sample of patients is consistent with published data.  
 
The second part of our miRNA study, examined if hsa-mir-657 is detected in our TR 
patients. Due to a low level of mRNA expression, some of our TR samples, which 
we know from the SNP array study to carry this miRNA, did not detect any 
expression of hsa-mir-657 by qPCR. Although the qPCR validation was not 
significant between TR and the TS primary breast tissue samples, the trend for a 
higher level of hsa-mir-657 was found in the TR cohort. Interestingly, the protein 
expression for three proteins potentially regulated by hsa-mir-657, namely THRAP5, 
HOXB13 and KIAA1324L was decreased in the human primary tissue whole cell 
extract lysates (see Figure 4.16). Protein expression of p53 in the lysate of hsa-mir-
657 carriers was not consistently down-regulated as expected, but this could be due 
to the fact that a crucial master transcriptional controller like p53 is likely to be 
controlled by more that one miRNA as well as multiple other regulatory 
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mechanisms. MicroRNA-657 is also elevated in half of our TR cell lines (in a set of 
ten breast cell lines and their paired TR counterpart) by qPCR (see Figure 4.19). 
These results suggest that further in-vitro studies, such as knockdown study using 
antagomiR-657 in tamoxifen-resistant cells to see any the effect on the reversibility 
of sensitivity to tamoxifen, is warranted. 
Conclusions: 
 
MAGEA2 and EGLN3 study: 
 
1) From our microarray study of the tamoxifen-resistant ER-positive breast 
cancer cell lines, MCF-7, T47D and ZR75-1, MAGEA2 and EGLN3 is 
found to be 4.0 and 3.8 up-regulated. In my in-vitro study, I have made into 
stable MAGEA2 and EGLN3-expressing clones in MCF-7 and T47D cell 
lines and carried out functional studies. MAGEA2 and EGLN3-expressing 
clones (respectively) have proliferation advantage, and decrease apoptosis 
compared to their control, vector-alone. I have shown that MageA2 has a 
direct interaction with p53, sequestering p53, and decreasing acetylated-p53 
in the cytoplasm and the nucleus. 
 
2) In the immunohistochemistry validation study (n=196), MageA and Egln3 
are good sensitive and specific predictive biomarker for tamoxifen-resistant 
in primary breast cancer tumours, with MageA having a sensitivity of 38% in 
primary breast tumours, and 61% (even though this is only a set of 9 patients 
as relapsed specimen are rare), and Egln3 having a sensitivity of 42% and 
sensitivity of 66% for picking up tamoxifen-resistant cases.  
 
3) There is statistical significant p-value for the positively stained MageA cases 
in overall survival (OS); p=0.0455*. In addition, when the positive-MageA 
stained cases were analysed according to cytoplasmic versus nucleus 
staining, there was a statistical significance for the cytoplasmic MageA 
staining cohort to do worse than the nucleus-staining, p=0.0448*. 
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4)   Egln3 had no statistical difference between the positively-stained from the 
negatively stained cases in disease-free and overall survival. However it is 
interesting that the EGLN3-expressing clones had elevated levels of 
MAGEA2 mRNA expression. And survival analysis with the Kaplan-Meier 
curve showed a trend for the combined positive, i.e. the positive-MageA and 
positive-Egln3 to do worse in overall survival when compared with 
negatively stained MageA and negatively stained Egln3, but this did not 
reach a statistical significance (see Figure 3.28). 
Predictive signature from human breast cancer study: 
1) From the human breast primary cancer tissue study, combined integrated 
analysis of the Exon expression array and SNP6.0 genomic array was 
undertaken with the aim of finding a predictive signature which includes the 
3D-structure of breast cancer, which tissue array provides. 
 
2) Five biomarkers have been found and validated, OPCML, OR10G7, 
SNF1LK2, PALM2 and ZBTB-16. Individually they have moderately low 
specificity but high sensitivity. However 4 out of 5 have very high negative 
predictive value, which means if stained negative, they are highly likely to 
predict tamoxifen sensitivity. 
 
3) We are currently working in collaboration with the Wolfson Institute‟s 
statistical department to analyse if in combination, the 5 genes could give a 
reproducible predictive signature, which can predict accurately the 
probability of TR. This is very exciting as these genes are novel and have 
never been associated with the ER-related genes. 
 
4) Four out of the 5 genes/protein, OPCML (11q25), OR10G7 (11q24.1), 
SNF1LK2 (11q23.1), PALM2 (9q31.3) and ZBTB-16 (11q23.2) is within the 
most significant region of copy number changes in the SNP6.0 studies. I am 
currently analysing with the detailed exonal mRNA changes in this region, 
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11q23-25, and also the other region of interest 17q21-22, to ascertain if there 
is a trigger variant, or a direct association of these genes in conferring TR. 
 
miRNA study: 
1)   last but not least, the miRNA has shown promise as there is correlation with 
our human specimens and TR breast cancer cell lines with hsa-mir-221, and 
ERBB2 connection. We hope to expand this into a full in vitro study with our 
miRNA, hsa-mir-657 in the study of its role in tamoxifen tolerance. 
The exact mechanisms that predict an individual to be tamoxifen-resistant is 
unknown, but in the last decade, we have come closer to assemble the pathways 
which may be associated with the downstream targets rendering a cell „resistant‟, 
and also closer to the upstream genes activation which predispose an individual to 
TR. I believe in the near future, patients‟ care will include their inert inherited genes 
as part of their staging work-up, which will be an integrated factor in deciding the 
best possible treatment for that individual patient. 
 
In an ideal world, a predictive chip would consist of few clusters of genes which 
covers all of the essential network pathways, that predicts response to a treatment or, 
predict prognosis. These two chips should be designed separately with specific 
targets. The training sets in array studies should be clearly defined. 
 
If I were to design a chip predicting response to tamoxifen, I would like to include 
genes which are highly specific for TR, low false positive for tamoxifen sensitive, a 
reproducible high positive predictive value, and inclusive of all the known and the 
new novel genes (as comprehensive as any high-throughput genenic and genomic 
study vehicles can provide). The bearing of each gene will be calculated from a 
statistical formula, which should be validated on a large number of validation 
cohorts. Finally, all predictive genetic chips should be validated on a large 
independent cohort in phase 3 trials, with interim results available to the public.  
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